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Differential Sensing of Kinases 
 
Diana Paulina Zamora Olivares, Ph.D. 
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Supervisor:  Eric V. Anslyn 
 
During the last decade, organic and supramolecular chemistry in combination 
with analytical and fluorescent-based sensing methods have led to the development of 
chemical biology tools to study protein phosphorylation in vitro. However, further 
challenges remain present to develop better chemical approaches that can allow us to 
understand the activation/inhibition of specific kinase pathways. 
To avoid the tedious process of developing individual highly selective receptors, 
the use of differential sensing techniques has been growing in the supramolecular 
chemistry field. This sensing protocol exploits the interactions between target analytes 
and a library of cross-reactive receptors to create a response pattern that is unique for 
individual analytes or different mixtures thereof.  Using this approach, one obtains a 
distinct fingerprint of composite signals produced by the sensor elements allowing for 
discrimination of different kinases in vitro and in complex mixtures such as cell lysates.  
The main emphasis of this work sought to expand the current optical-based 
detection systems of phosphorylated proteins to include a new pattern-based recognition 
method for a new class of protein kinases. To this end, the synthesis of chemosensors and 
peptide-based biosensors was pursued to detect and differentiate relevant mitogen-
 viii 
activated protein (MAP) kinases which represent targets of pharmaceutical interest. 
Further, this research included the quantitative detection of MAP kinases and 
corresponding inhibitors using a combination of pattern recognition approaches with new 
chemometric tools.  
 ix 
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Chapter 1: Optical-Based Sensing Methods for the Detection of 
Phosphorylated Protein Kinases 
1.1 Introduction 
The coordinated activity of enzymes, substrates, ligand molecules and metal ions 
within cells follows a systematic network of modulated signals, producing the necessary 
metabolic processes for the appropriate balance of cellular functions. Among the diverse 
post-translational modifications implicated in cellular signaling pathways, the 
phosphorylation and dephosphorylation of proteins are two of the most important and 
prevalent processes in eukaryotic cells. Phosphorylation and dephosphorylation are 
regulated by protein kinases and protein phosphatases, respectively. Interestingly, it has 
been found that nearly 30% of all human proteins are phosphorylated at any time, while 
about 500 different protein kinases participate in this process.
1
 
Traditional methods have evolved into more efficient and versatile tools to study the 
dynamics of protein phosphorylation. Over the last decade, organic and supramolecular 
chemistry in combination with analytical and fluorescence-based sensing methods have 
led to the development of chemical biology tools to study protein phosphorylation in 
vitro. However, further challenges remain present to develop better chemical approaches 
that can allow us to understand the activation/inhibition of specific kinase pathways. 
Herein, we review on the progress toward the development of new chemical biology 
tools to sense phosphorylation events on peptides and proteins. The focus is placed on the 
synthesis of chemosensors in combination with the application of differential sensing 
2 
 
methods. Afterwards, we discuss the detection and differentiation of phosphorylated 
Mitogen-activated protein (MAP) kinases and their dynamic active/inactive states in 
complex mixtures such as cell lysates. 
1.1.1 Protein Phosphorylation 
Reversible phosphorylation of proteins is one of the most important regulatory 
processes in cell function. Chemically, it is considered a covalent modification reaction, 
where the γ-phosphoryl group of 5’-Adenosine TriPhosphate (ATP) is transferred to the 
hydroxyl group of the amino acids tyrosine, threonine and/or serine increasing the 
hydrophilic properties of the protein (Figure 1.1).
2
 This event acts as a “switch on”, 
leading to conformational changes in the protein, which are correlated with protein-
protein interactions following a cellular signaling pathway. Protein phosphorylation 
regulates a wide range of cellular processes involved in metabolic pathways such as cell 
growth, proliferation and differentiation, membrane transport, mitosis, and apoptosis.
3
 
Previous studies have shown that mutations and aberrant kinases can induce 
overexpression of the protein substrate, causing abnormalities in the cellular processes 
and leading to negative outcomes such as cancer, neurodegenerative and inflammatory 
diseases, diabetes mellitus, endocrinological disorders, and hematological malignances.
3-5
 
Most importantly, academic institutions and drug companies have made a substantial 
effort in order to understand the correlation between the dynamics of aberrant kinases and 
early cancer onset. Thus, developing new sensing methods that can establish a correlation 
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between kinase activity and a fluorescent substrate that modulates its signal upon 
phosphorylation remains a challenging task. The creation of such methods could 
potentially allow for the development of protein-kinase inhibitors that target a specific 
group of kinases for therapeutic purposes.
4
  
 
 
 
 
 
 
Figure 1.1: Protein phosphorylation reaction. Graphic representation of the 
phosphorylation event of a protein substrate where a kinase transfers the γ-phosphoryl 
group of ATP to the hydroxyl group of the amino acid tyrosine. 
 
 γ    β    α 
5’-Adenosin triphosphate (ATP) 
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1.1.2 History of Protein Kinases 
In the 1950s, kinase activity was first observed when Eugene Kennedy described a 
liver enzyme capable of catalyzing the phosphorylation of casein using radioactive ATP.
6
 
Afterwards, Edwin G. Krebs and Edmond H. Fisher discovered the dynamic reversible 
transformation of phosphorylase a to phosphorylase b in the presence of Mg-ATP. Krebs 
and Fisher gave the name phosphorylase kinase to the enzyme that was responsible to 
catalyze the transfer of the γ-phosphoryl group of ATP to a particular serine residue in 
phosphorylase b.
7
 Their pioneering discoveries earned Ed Fisher and Ed Krebs the Nobel 
Prize in 1992. 
 However, it took several decades for researchers to become aware of the 
importance of protein phosphorylation. At the end of the 1960s, protein phosphorylation 
was still thought of as a single and specialized mechanism to regulate glycogen 
metabolism. It was during the 1970s and 1980s that several kinases were discovered and 
correlated with other cellular functions such as glycolysis and lipolysis in liver, heart-
muscle relaxation and contractibility.
8
  Soon afterwards, some protein kinases such as 
epidermal growth factor (EGF) were discovered to be specific tyrosine kinases.
9
 
Additionally, most of the threonine/serine kinases and their regulatory mechanisms were 
discovered during the late 1970s.
8
 
The first connections between malfunctioning kinases and disease were made in the 
late 1970s. Castagna discovered tumor-activators that were analogous to the second 
messenger diacylglycerol responsible for the activation of protein kinase C.
10
 In the 
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twenty-first century, protein kinases have become one of the major target groups of 
enzymes in drug discovery after G-protein-coupled receptors.
4
 
1.2 Protein Kinase Classification 
More recently, Manning et al. categorized the human kinome to discover a total of 
518 human protein kinases. The human kinome is first classified in two major kinase 
groups. The first group is a single super-family that encompasses 478 eukaryotic protein 
kinases (ePKs), which are categorized based on the sequence similarity of their catalytic 
domain. These (ePKs) conventional protein kinases are divided into 388 protein-
serine/threonine kinases and 90 protein-tyrosine kinases. The second kinase group 
includes 40 atypical protein kinases (aPKs) which are found in thirteen families. These 
aPKs present biochemical kinase activity, but they lack sequence similarity to the ePK 
group. This new kinome database is encoded by 2% of all the human genome.
11
 
The 518 human kinases were also classified into nine major groups according to the 
sequence similarity of their catalytic domain and biological functions. Each group is 
divided into families and subfamilies. CMGC group 1 containing CDK, MAPK, GSK3, 
CLK families; AGC group 2 containing PKA, PKG, PKC families; TK Tyrosine kinase 
group 3; TKL Tyrosine kinase-like group 4; CAMK Calcium/calmodulin-dependent 
protein kinase group 5; CK1 Casein kinase 1 group 6; STE Homologs of yeast Sterile 7 
group 7, Sterile 11, Sterile 20 kinases. For instance, the following dendogram can quickly 
help to identify kinase groups whose members are only phosphorylated substrates with 
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tyrosine residues (TK or TKL), while enzymes in the other groups are phosphorylated 
serine and threonine residues (Figure 1.2).
11
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Major groups of human protein kinases. Kinome dendogram showing seven 
major groups of kinases, which are also divided in families and subfamilies. (Reproduced 
from Ref. 11. © Science, 2000) 
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1.3 Mitogen-Activated Protein Kinases (MAPK) 
In the late 1980s, a protein kinase identified as insulin-stimulated protein kinase was 
found to phosphorylate microtubule-associated protein-2 (MAP2). Later on, it was found 
that the activation of insulin-stimulated protein kinase required the presence of mitogens 
and growth factors, changing the name to mitogen-activated protein kinase (MAPK).  
The MAP kinase family is composed of serine/threonine kinases that are members of 
the CMGC kinase group, which were named according to the initials of some members of 
this group. The MAP kinase family is classified in subfamilies called extracellular signal-
regulated kinases ERK1 and ERK2; the c-Jun N-terminal kinases, JNK1, JNK2, JNK/3; 
and four p38 enzymes p38α, p38β, p38γ and p38δ.3 
External factors activate the cell-surface receptors which result in a cell signal 
cascade of events that promote activation of the MAP kinase module MAPKKK- 
MAPKK-MAPK (Figure 1.3). On this module, MAPKKK and MAPKK are known as 
upper kinases or upstream activating kinases that need to be active through the MAPK 
cascade, which in turn signal the activation or phosphorylation of MAPKs. ERK, c-Jun 
and p38 MAP kinases translate these signals into modulation of gene expression and 
regulation of cell function such as cell growth, proliferation, differentiation and 
apoptosis.
12
 
MAP kinases catalyze the phosphorylation of substrates that contain serine/threonine 
residues on the consensus PX(S/T)-P motif. Their downstream MAPK substrates 
constitute other protein kinases, transcription factors, phospholipases and cytoskeletal 
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proteins.
13
  In general, MAP kinases are responsible for key cellular functions such as 
gene expression, mitosis, regulation of apoptosis and the cell cycle, cytokine production 
and inflammatory responses.  
 
 
Figure 1.3: Mitogen-activated protein kinase module. Graphical representation of the 
conventional ERK, JNK and p38 upstream and downstream signaling cascades. 
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1.3.1 Activation of MAP Kinases 
The most essential requirement for MAP kinase activation is the dual 
phosphorylation of the threonine (Thr) and tyrosine (Tyr) residues present in a particular 
segment called the Thr-Xaa-Tyr (TXY) motif. This dual phosphorylation motif TXY is 
located on the activation loop of MAP kinases (Figure 1.4). The phosphorylation of both 
amino acids promotes conformational changes stabilized by electrostatic interactions 
within the loop. Conformational rearrangements of MAP kinase structure involved loop 
reorientation, lobe closure, αC helix orientation and C-terminal reorganization.
14
  The 
structural changes of the catalytic site and the ATP binding groups create the recognition 
site for the protein substrate.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Active protein structure of ERK2 (PBD ID: 2ERK). ERK1/2 presenting dual  
phosphorylation on the
183
T-E-Y
185
motif located on the activation loop. The electrostatic 
interactions between negatively charged phosphoryl groups and positively charged 
arginine residues induce conformational changes on activated MAP kinases. 
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1.3.2 ERK, JNK and p38 MAP Kinases 
1.3.2.1 Extracellular Signal-Regulated Kinases  
Extracellular signal regulated kinases ERK1 and ERK2 are 43 and 41 kDa 
respectively, and are considered isoforms because they share 83% of their amino acid 
sequence. The ERK pathway is mainly initiated by stimulation of growth factors, 
hormones, virus infection or carcinogens. Important functions of the ERK cascade 
involve the regulation of meiosis, mitosis, cell migration and antiapoptotic signals.
12
 
After extracellular stimuli signal through the cell surface plasma membrane, the ERK 
cascade (Ras, Raf-1, MEK1/2, ERK1/2) starts with the activation of GTP-bound Ras 
which in turn promotes Raf association with the plasma membrane (Figure 1.5). Then 
Raf phosphorylates MAP kinases MEK1 and MEK2. ERK1 and ERK2 are activated by 
dual phosphorylation of the TEY (
183
Thr-Glu-Tyr
185
) motif by dual-specificity upstream 
kinases MEK1 and MEK2.
15
After activation, Both ERK1 and ERK2 translocate from the 
cytosol to the nucleus, where they phosphorylate several important substrates, such as 
transcription factors Ets-1, Elk-1, c-Myc and more. ERKs also activate the ribosomal S6 
protein kinase (p90RSK), responsible for signal transduction and activation of other 
ribosomal proteins.
16
,
17
 
The structural differences between active and inactive ERK2 have been intensively 
studied in the past two decades. Dual phosphorylation of Thr-183 and Tyr-185 promotes 
conformational rearrangements stabilized by electrostatic interactions between the 
negatively charged phosphoryl groups and the positively charged arginine residues.
18
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There is an important association between the duration of ERK signaling and 
abnormal cell behavior. Unregulated ERK  cascade activation by growth factors and Ras 
oncogene can lead to sustained ERK1 and ERK2 activity, resulting in the suppression of 
signals that control the cell cycle and cell survival.
19
 
1.3.2.2 c-Jun N-Terminal Kinases and p38MAP Kinases 
JNK and p38 MAP kinases are also identified as stress-activated protein kinases 
(SAPK). In most cases, JNK and p38 cascades are simultaneously activated by cellular 
and environmental stress such as DNA damage, ischemia, UV irradiation, changes in 
osmolality, oxidative stress and heat shock. Likewise, different cytokines such as tumor 
necrosis factors (TFN) which are responsible for programmed cell death can cause 
activation of JNK and p38 kinases. Anomalies on JNK gene expression are involved in 
different diseases such as diabetes (Type 1 and 2), cardiovascular diseases, arthritis, 
Alzheimer’s and Parkinson’s diseases.20 
The JNK signaling pathway turns on different cellular functions, including 
differentiation, cell growth, transportation and apoptosis.
19
 There are three isoforms in the 
JNK subfamily (JNK1, JNK2 and JNK3) which are activated by dual phosphorylation of 
the TPY (Thr-Pro-Tyr) motif within the activation loop.
21
 The JNK cascade (MKK4/7, 
JNK, c-Jun) starts with activation of the upstream kinases MKK4 and MKK7 by 
upstream activators ASK, MLK, TAK, among others. MKK4 and MKK7 are dual-
specificity kinases that phosphorylate threonine and tyrosine residues on JNK isoforms, 
which in turn activate the transcription factor c-Jun (Figure 1.3).
22
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Due to its prevalent role in cell migration and apoptosis, JNK activation can trigger 
tumor proliferation or tumor suppression. C-Jun acts as a transcriptional repressor of the 
gene p53, which is responsible for tumor suppression. The oncogenic function of JNK 
cascade induces the sustained activation of c-Jun which promotes cell proliferation and 
cell cycle progression. In addition, the C-Jun oncogene has been highly expressed in most 
carcinoma cells.
23,24
 
Instead, the proapoptotic functions of the JNK cascade can restrict Ras-induced tumor 
progress by inhibition of proliferation, inhibition of angiogenesis or promotion of 
apoptosis. JNKs initiate apoptosis in response to many different types of stress such as γ-
irradiation, ischemia/reperfusion injury in heart attacks, protein synthesis inhibitors 
(anisomycin) and inflammatory cytokines. Particularly, chemotherapeutic agents require 
JNK participation to induce apoptosis.
25,26
 
Different isoforms have been identified in the p38-MAPK subfamily: p38α, β,  and 
δ, including ERK6 which was recently identified.27Analogous to the JNK cascade, 
MKK3 and MKK6 are also phosphorylated by upstream kinases ASK, MLK and TAK. 
Dual upstream kinases MKK3 and MKK6 phosphorylate p38-MAP kinases on the TGY 
(Thr-Gly-Tyr) motif. Different target proteins such as transcription factors, kinases or 
phosphatases (MEF2, ATF-2, MSK1/2) are activated by p38-MAPKs.
28
 
Similar to JNK signaling pathways, the p38-MAPK cascade is involved in several 
cellular functions such as differentiation, proliferation, cytokine secretion and gene 
expression. Likewise, p38-MAPK signaling presents antagonistic roles. It is required for 
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apoptosis and cell survival, depending on the cell type and associated environmental 
stress.
19
 
1.3.3 Ras Proteins and MAPK Signaling Pathway 
Unregulated MAPK signaling pathways can trigger the development of tumor 
initiation and progression, as well as the processes of invasion and metastasis.
19
 The 
following MAP kinases, ERKs, JNKs and p38s have been recognized to play an essential 
role in controlling cell migration through the regulation of the module Ras/Raf/MAPK 
(Figure 1.5), and migration is remarkably important in leading metastatic processes. 
Substantial experimental data has shown that aberrant activation of Ras proteins is 
responsible for the development of the malignant phenotype in a variety of cancer cells.
29
 
Extracellular ligands bind to the cell surface plasma membrane receptors. These 
interactions cause guanine nucleotide exchange factors (GEFs) to activate and regulate 
the cycle between inactive guanosine diphosphate GDP-bound and active guanosine 
triphosphate GTP-bound forms (Figure 1.6). Ras proteins are located in the inner face of 
the plasma membrane and their activity is regulated by the GDP-bound/GTP-bound 
nucleotide exchange.
30
 GTP-bound Ras binds to a broad variety of effector proteins (Raf 
serine/threonine kinases, PI3K lipid kinases) to stimulate different intracellular signaling 
pathways. Particularly, the ERK-MAPK protein kinase cascade has been associated to the 
development of Ras oncogenesis. Sustained signaling of mutationally activated Ras at 
residues 12, 13 and 16 is present in almost 30% of all known human cancers.
31
 The 
manner in which Ras is involved in the deregulation of the cell cycle process and 
14 
 
promotion of cell survival has been well documented; additionally, much emphasis has 
been placed in the understanding on how Ras promotes metastasis.
30
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Activation of Ras /Raf/MAPK signaling pathway. External stimuli cause the 
activation of guanine nucleotide exchange factors (GEFs), which in turn replace inactive 
Ras-GDP to active Ras-GTP. GTPase –activating proteins (GAPs) regulate the hydrolysis 
of Ras-GTP back to the inactive form. Active GTP-bound Ras stimulates intracellular 
Ras/Raf/MAPK signaling. 
15 
 
Traditional Methods Used to Study Kinase Activity 
1.3.4 Radioactivity-Based Assay 
Conventional methods to study the activation state of kinases are associated with 
some drawbacks such as time-consuming and expensive protein purification protocols for 
in vitro assays, which lack spatial-temporal resolution. The phosphotransfer of 
radioactive isotope 
32 
P-ATP to a substrate is monitored by scintillation counting.
32
 
Even though radioactive-based assays are efficient and sensitive, they present additional 
setbacks: 1) they require special handling for safety reasons, 2) this method generates 
radioactive waste, 3) these assays cannot be used for high-throughput analysis due to 
their inherent endpoint nature,4) these methods are not practical when working with cell 
lysates, and 5) sub-physiological concentrations of ATP (10-50 µM) are required for the 
assay to avoid dilution of
32
P-ATP.
33
 
1.3.5 Immunoblotting 
Alternatively, endogenous kinase activity can be detected by performing in-gel 
assays. Western blotting analysis is still a powerful semi-quantitative analytical technique 
to detect specific kinases in cells from cell cultures or tissues.
34
 After sample preparation, 
the first step separates the proteins from the sample using gel electrophoresis, where a 
small sample volume with the kinase protein is loaded into wells in a polyacrylamide gel 
membrane. (Figure 1.6) Then, the gel is introduced into a blotting tank that is filled up 
with detergent. After voltage is applied along the gel, proteins migrate through the gel at 
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different speeds. The proteins are separated based on their isoelectric point, molecular 
weight or electric charge.
35
 For the second step, the gel is placed on top of a 
nitrocellulose or polyvinylidene difluoride (PVDF) membrane which possesses a strong 
affinity for proteins inside another blotting tank. Usually an electrical current is applied to 
the blotting tank in order to transfer the proteins to the thin membrane (Figure 1.7).
35
 
After the transfer process, a blocking step is performed before the addition of an 
antibody. 
17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: Immunoblotting process. Schematic representation of Western blot method 
for the detection of phosphorylated protein kinases. 
 
Considering that the membrane has the same affinity for the antibody and the protein 
targets, the membrane is first incubated with a diluted solution of protein such as non-fat 
dry milk or bovine serum albumin (BSA) to avoid non-specific interactions between the 
antibody and the PVDF membrane. Then, a second diluted solution, which contains a 
primary antibody (0.5-5 µg/mL) for a specific kinase, with small percentage of detergent 
and powdered milk or BSA, is added to the membrane and incubated for 30 min to 
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overnight. A subsequent washing step is done to remove unbound primary antibodies. 
Then, the secondary antibody, which is directed at a specific portion of the primary 
antibody (known as anti-mouse or anti-goat, etc) is incubated with the membrane. These 
antibodies or monoclonal antibodies are produced by rabbits or mice, or in cells 
respectively. The secondary antibody is attached to biotin or to a reporter enzyme such as 
horseradish peroxidase.
36
 Finally, a substrate for the enzyme is added to the membrane 
producing luminescent light in proportion to the amount of phosphorylated or non-
phosphorylated kinases. A sheet of photographic film is placed on top of the membrane, 
and the film is passed through a photo developing machine. The film provides clear 
visualization and shows short bands that represent individual kinases on that sample. 
Even though immunoblotting is a non-radioactive labeling approach and can detect 
phosphorylation states of kinases using phospho-specific antibodies, several steps are 
necessary throughout the process, which makes it time-consuming and expensive. 
Another limitation is that several kinases have many phosphorylation sites to which 
specific antibodies are not available.
37
 In general, the major limitation of radio-labeling 
and immunoblotting assays is that they do not allow for real-time detection of kinase 
activity within cellular processes with normal or modified expression in cell extracts or 
living cells. 
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1.4 Fluorescence-Based Sensing Methods to Study Protein Phosphorylation 
1.4.1 Fluorescence Sensing 
The use of fluorescence spectroscopy as an analytical tool has seen greater spread in 
the last decade due to its versatility in fundamental research within different fields in 
medicine and biotechnology. In this context, fluorescence-based probes that can report 
fluorescence changes upon phosphorylation are rapidly increasing in number. 
Fluorescence is preferred over other spectroscopic methods such as absorbance due to its 
high sensitivity (1000-fold higher), selectivity, short detection times, and 
biocompatibility.
38
 Likewise, fluorescence-based chemosensors have become powerful 
tools to monitor phosphorylation events not only in purified kinases but also while in 
their native cellular environment, allowing for quantification of kinase activity with 
temporal and spatial resolution. 
Fluorescence is a photophysical process that takes place when a molecule is irradiated 
with UV/vis light, resulting in the emission of light from a singlet excited state. First, the 
exposure of a molecule to light at an appropriate wavelength promotes the absorption of a 
photon which in turn excites an electron from the ground state S0 (taking place from the 
highest occupied molecular orbital, HOMO), to a higher energy orbital. This electron is 
promoted to the lowest unoccupied molecular orbital (LUMO) in the molecule; this 
excited state is known as the singlet state S1 where the spin is conserved by light 
excitation (Figure 1.8). Then, energy is released as radiationless transitions when the 
electron relaxes from a higher to a lower vibrational level within the S1 electronic state. 
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Next, fluorescence emission occurs when the excited molecule relaxes from the excited 
singlet state to the ground state releasing excess energy in the form of photons.
39
 
 
Figure 1.7. One representation of a molecular orbital diagram. Promotion of an electron 
occurs from the HOMO to the LUMO after light excitation. 
 
Once in the ground state, the molecule can undergo repeating absorption-emission 
cycles giving continuous signaling photons, which is the origin for the high sensitivity of 
this technique. Nevertheless, excited molecules can follow different pathways to release 
the obtained energy; thermal deactivation, intersystem crossing followed 
phosphorescence, or interactions of the excited state molecule with other molecules 
resulting in electron transfer shown in the Jablonski diagram (Figure 1.8).
40
 
The intrinsic properties of fluorescence, including anisotropy, FRET, PET quenching, 
environment sensitivity and metal-ion enhancement have allowed for the design of a wide 
variety of kinase sensors.  
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Figure 1.8: One representation of a Jablonski diagram. Summary of the several 
electronic and vibrational states, and photophysical processes observed in the singlet and 
triplet excited states. 
 
1.4.2 FRET-Based Protein Biosensors 
Forster resonance energy transfer (FRET) is a distance dependent process wherein 
nonradioactive energy is transferred from a donor to an acceptor. Cyan fluorescent 
protein (CFP) and yellow fluorescent protein (YFP) were used as a donor-acceptor pair 
because of their photostability and sensitivity. Usually FRET sensors present a modular 
design including a peptide substrate to target a kinase, a flexible linker, a phosphopeptide 
binding domain (PBD), and two fluorescent proteins (FPs) attached to the N- and C- 
termini. Upon phosphorylation the PDB binds to the phosphorylated fragment, bringing 
both FPs together into close proximity, resulting in an intramolecular FRET event.
41
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Figure 1.9: Modular design of FRET-based biosensors. Schematic representation of the 
Reporter of Zap-70 activity, including the peptide substrate, a linker, FRET resporters: 
Cyan fluorescent protein (CFP) and yellow fluorescent protein (TFP). (Reproduced from 
Ref.46. © PloS ONE, 2008) 
 
As an example, Lellouchet al.
42
 designed a genetic encoded biosensor called ROZA 
(Reporter of Zap-70 activity) to detect phosphorylation events of tyrosine kinase ZAP-70 
in Jurkat T-cell membrane receptors. ROZA sensors were produced using peptide 
substrates for ZAP-70 that contained tyrosine residues Tyr132, Tyr175 and Tyr195. The 
peptide substrates were linked to the respective SH2 domain of mouse Grb2 for Y175 and 
Y195 (Figure 1.9). Several variants of ROZA were generated by varying the peptide 
substrate, the length of the linker, and the SH2 fragment. The sequence that resulted in 
the most significant FRET change due to efficient phosphorylation was incorporated to a 
peptide containing 13 N-terminal residues of mouse Lck to restrict its location to the 
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plasma membrane of Jurkat T- cells. Upon addition of a phosphatase inhibitor which 
reveals tyrosine kinase activity to the ROZA-expressing Jurkat cells, kinase activity was 
observed by a decrease of the 535 nm/470 nm ratio corresponding to the FRET signal. 
Jurkat T-cells expressing ROZA were examined by immunoblotting to prove that the 
observed FRET changes were due to ZAP-70 dependent phosphorylation. Additionally, 
treatment of the transfected T-cells with a kinase inhibitor for ZAP-70 resulted in the 
inhibition of ROZA phosphorylation. Remarkably, subcellular localization of ZAP-70 
clusters was observed in Jurkat cell conjugates due to probe localization in the plasma 
membrane.  
1.4.3 Environmentally-Sensitive Peptide Sensors 
Environment-sensitive biosensors present a fluorophore that exhibits different 
spectroscopic properties such as shifts in the emission wavelength, fluorescence lifetimes, 
and quantum yields in response to changes in solvent polarity of their immediate 
environment. Solvatochromic fluorophores usually present large excited-state dipole 
moments, displaying weak fluorescence emission and low quantum yields in aqueous 
media. In contrast, fluorophores display high fluorescence signals in non-polar solvents 
or when linked into hydrophobic pockets in proteins. Typical solvatochromic 
fluorophores include 4-dimethylamino phthalimide (4-DMAP, 1.1), PRODAN (1.2), 
DANSYL (1.3) or 7-nitrobenz-2-oxa-1,3-diazole (NBD, 1.4).
40,43
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Typical environment-sensitive kinase sensors contain a substrate recognition site and 
a fluorophore linked to amino acid side chains in close proximity to the phosphorylation 
site (one to five residues apart). As a result of kinase activity, the inserted phosphoryl 
group changes the local polarity of the fluorophore, altering its spectroscopic properties. 
 
 
Figure 1.10: General mechanism of environment-sensitive kinase sensors. The presence 
of the phosphoryl group modifies the local surroundings of the adjacent solvatochromic 
fluorophore.  The fluorophore is attached to the peptide chain which is one to five 
residues apart from the phosphorylation site, enhancing the fluorescent signal. 
 
 
 
1.1            1.2   1.3           1.4 
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This strategy led Lawrence et al.
44
 to build a library of peptides containing different 
environmentally-sensitive fluorophores (1.5, 1.6, 1.7) to study the phosphorylation 
reaction of  tyrosine peptide substrates with Src protein kinase in the presence of the Lck 
SH2 domain. The SH2 protein-binding domain has the ability to recognize 
phosphorylated serine and tyrosine residues; likewise, the presence of the SH2 domain is 
expected to cause polarity changes in the environment of phosphorylated peptides during 
recognition. Therefore, the phosphorylated peptides 1.9 were anticipated to present a 
selectively fluorescent enhancement compared to their nonphosphorylated counterparts 
1.8, when interacting with the Lck SH2 domain (Figure 1.11). The three fluorophores 
were first linked to (L)-2,3-diaminopropionic acid (Dap)1.10 and (L)-2,4-diaminobutyric 
acid (Dab)1.11 to give a total of six different fluorophore-Dap/Dab residues. 
Successively, these residues were coupled at four different sites along different Src 
peptide substrates, which in turn were assessed by their fluorescent response in the 
presence of Src protein kinase and Lck SH2 domain. Peptides with Dap-1.5 and Dab-1.5 
positioned at residues +3 and +4 sites produced the largest increase in fluorescent signal. 
The authors further assessed additional peptide substrates derived from Rink resin 
containing Dap-1.6 and Dab-1.5 positioned at +1 and +4 residues on the peptide 
sequence, respectively. A dissociation constant of 2.1 µM was found for peptide Dap-1.6. 
A concentration-dependent experiment was performed to assure that the fluorescent 
signal was only produced in the presence of the Lck SH2 domain after phosphorylation. 
The concentration of Lck SH2 domain was increased from 0 to 32 µM, where saturation 
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was achieved at 16 µM. Moreover, the addition of a phosphotyrosine phosphatase after 
completion of the phosphorylation reaction by Src kinase produced a decrease in the 
fluorescence intensity to the initial value.  This study highlights a new kinase sensing 
method wherein the fluorophore site attachment does not require a fixed spatial 
relationship with respect to the phosphorylated residue. 
27 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11: Kinase sensing approach using environmentally-sensitive fluorophores 
from Lawrence et al. Src protein kinase catalyzing the phosphorylation reaction of 
tyrosine peptide substrates containing fluorophores 1.5, 1.6, and 1.7, which become 
fluorescent in the presence of SH2 binding domain. (Reproduced from Ref.48. © Journal 
of American Chemistry Society, 2005) 
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1.4.4 Metal Ion-Based Fluorescence Sensing 
1.4.4.1 Zinc Chemosensors 
Research in supramolecular chemistry has led to the development of 
chemosensors capable of detecting with high selectivity and affinity phosphorylated 
peptides and proteins under physiological conditions. These phosphate ion chemosensors 
are designed on the bases of the model fluorophore-spacer-receptor, in which a covalent 
spacer separates the analyte-binding receptor and the fluorophore.
39
 The main binding 
force between host-guest interactions derives from metal-ligand coordination chemistry, 
producing emission signaling changes upon binding the target analyte. The turn-on 
strategy is based on the photoinduced electron transfer (PET) mechanism. Herein, the 
receptor unit works as an electron donor when the analyte is absent, quenching the 
fluorophore excited state. Upon formation of the phosphate anion–receptor complex, 
electron transfer is prevented and the fluorescence is restored.
45
 
Hamachi and co-workers have built a wide variety of chemosensors using 
zinc(II)dipicolylamine Zn(DPA) as a molecular recognition moiety for phosphate anions. 
The artificial receptors 1.12 and 1.13 contain an anthracene fluorophore core linked to 
two Zn(DPA) units.
46
 Binding studies showed that both chemosensors present high 
selectivity towards phosphate species in the presence of other anions such as sulfate, 
nitrate, acetate and carboxylates. The binding events were measured with fluorescence 
titrations. Apparent affinity constants on the order of 10
4
-10
5
 M
-1
 were obtained for 
receptors 1.12 and 1.13 with adenosine nucleotides, phosphate monoesters and phospho-
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L-tyrosine.
47
 Interestingly, the addition of dimethyl phosphate or cyclic AMP did not 
cause any fluorescence change in the emission spectra of the chemosensors. Furthermore, 
the mono substituted Zn(DPA) anthracene 1.14 did not present fluorescence changes in 
the presence of the previous phosphate species. 
1
H-NMR studies and X-ray 
crystallographic analysis of receptor 1.13 and phenyl phosphate revealed the cooperative 
participation of both Zn(DPA) units, with each metal cation coordinating with a 
phosphate oxygen atom. The authors found that fluorescence enhancement upon addition 
of phosphate species to these chemosensors arises from the second zinc cation complexed 
with the benzylic amine of the DPA unit. Hence, this increased metal-ligand interaction 
diminishes the intrinsic PET quenching of the anthracene fluorescence by the benzylic 
amine.
48
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Further studies by Hamachi and co-workers showed that the two Zn(DPA) 
moieties of 1.12 and 1.13 interact with various phosphorylated peptides but not with their 
non-phosphorylated counterparts in aqueous solution at neutral pH. Fluorescence 
spectroscopy was used to measure binding constants of 1.12 and 1.13 with peptide 
substrates 1.15a and 1.15d to find Ka values ranging from 10
4
 to 10
7 
M
-1
. On the other 
hand, no binding event was observed for non-phosphorylated peptide 1.15g. The 
receptors were found to preferentially bind to the negatively charged phosphorylated 
peptides compared to the positively charged one 1.15c containing arginine residues. The 
binding selectivity was ascribed to charge repulsion between the zinc cations and the 
arginine side chains. Additional binding studies with phosphorylated peptides 1.15a-f 
proved that the affinity of the receptors depends on the peptide sequence and the total 
charge of the peptide. The receptors bind more strongly to the phosphorylated peptides 
that contain increasing negative charge 1.15a and 1.15b with Ka values of 10
6
 to 10
7 
M
-
1
.
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a:  Glu-Glu-Glu-Ile-pTyr-Glu-Glu-Phe-Asp 
b:  Asp-Glu-Glu-Ile-pTyr-Gly-Glu-Phe-Phe 
c:  Arg-Arg-Phe-Gly-pSer-Ile-Arg-Arg-Phe 
d:  Lys-Ser-Gly-pTyr-Leu-Ser-Ser-Glu 
e:  Ala-Glu-Glu-Ile-pTyr-Gly-Val-Leu-Phe 
f:   Ala-Arg-Arg-Gly-pSer-Ile-Ala-Ala-Phe 
g:  Glu-Glu-Glu-Ile-Tyr-Glu-Glu-Phe-Asp 
                 1.15     
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In addition, the same group used receptor 1.13 to monitor the dephosphorylation 
reaction catalyzed by the protein tyrosine phosphatase 1B (PTP1B) and its correspondent 
phosphorylated peptide substrate AspAlaAspGlu-pTyr-LeuIleProAsnAsnGly. The kinetic 
assay showed that the fluorescence intensity of 1.13 decreased with the addition of 
PTP1B over time.
48
 Receptor 1.12 was also found to be a useful staining agent allowing 
for the selective identification of phospho-proteins in SDS-PAGE gel. Emission bands 
were observed only for phospho-ovalbumin and phospho-α-casein, but not for the non-
phosphorylated proteins β-galactosidase, bovine serum albumin, avidin and lysozyme.49  
Despite the high sensitivity and different applications reported by the previously 
described receptors; 1.12 and 1.13 are not useful to monitor kinase-catalyzed 
phosphorylation reactions. The strong binding affinity towards other phosphorylated 
entities such as ATP, which is required in a phosphorylation assay, interferes in the 
binding between the chemosensors and phosphorylated peptide substrates or proteins. 
To overcome this situation, Hamachi and co-workers designed a very highly 
selective hybrid biosensor, where a similar dinuclear zinc receptor was incorporated into 
the phosphoprotein binding site of the M15C-WW mutant protein, allowing them to 
monitor kinase-catalyzed phosphorylation.
50
 The Zn(DPA) chemosensor derivative 1.16 
was synthesized using a stilbazole linker to attach a maleimide group. The WW binding 
domain derived from protein Pin1 was used to covalently attach receptor 1.16 using the 
thiol group of the cysteine residue. Relevant bis-phosphorylated peptides enclosing 
sequences that are usually recognized by the Pin1 WW domain were titrated into the 
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hybrid biosensor. High affinity constants Ka˃10
6
 M
-1 
were measured for peptide 1.17a 
using fluorescence titrations under physiological conditions. Additionally, no binding was 
observed for mono-phosphorylated substrates 1.17b-d. Thus, two main requirements 
were needed to achieve high affinity and selectivity by the biosensor. Firstly, the 
consensus sequence of the peptide substrate needed to be originally recognized by the 
Pin1 WW domain. Secondly, one of the phospho-recognition sites was occupied by one 
of the phosphorylated residues, while the second phosphorylated amino acid residue 
needed to be located at a particular distance to be recognized by the chemosensor binding 
region.
51
 
 
 
 
 
 
 
 
 
 
a: His-Tyr-pSer-Pro-Tyr-pSer- Pro-Ser 
b: His-Tyr-Ser-Pro-Ser-Tyr-pSer-Pro-Tyr-pSer- Pro-Ser 
c: His-Tyr-Ser-Pro-Ser-Tyr-pSer-Pro-Tyr-Ser- Pro-Ser 
d: His-Tyr-Ser-Pro-Ser-Tyr-Ser-Pro-Tyr-pSer- Pro-Ser 
 
                 1.17   
  
  1.16  
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Figure 1.12: Sensing approach using hybrid biosensor from Hamachi et al. Pin1 WW 
domain biosensor recognizing bis-phosphorylated peptide. (Reproduced from Ref. 55. © 
Journal of American Chemistry Society, 2007.) 
 
More recently, a different strategy was followed by Hamachi et al. developing 
BODIPY-based chemosensor 1.18. The receptor contains a BODIPY fluorescence 
scaffold attached to two Zn(Dpa) units. Fluorescent titrations were used to measure 
dissociation constants. Chemosensor 1.18 was found to have high selectivity towards i+4 
bis-phosphorylated peptides 1.19a and 1.19c. Dissociation constants of 43 µM were 
found for peptide substrate 1.19a in the absence of ATP. Interestingly, the Kd changed to 
150 µM when 1.19a was added to the receptor in the presence of ATP. Moreover, no 
binding event was observed for mono-phosphorylated peptide 1.19b. The receptor bound 
preferentially to peptide 1.19c, whose sequence was bearing a negative net charge. An 
increase in the fluorescence intensity of up to 1.5 fold was found for 1.19c compared to 
1.19a. A binding affinity of 8.5 µM was found in the presence of ATP. Thus, chemosensor 
1.18 was used to monitor the kinase-catalyzed reaction with glycogen synthase kinase 3β 
(GSK3β), which is involved in insulin signaling and neurofibrillary tangles in brain 
tissue. A fluorescent enhancement of 2-fold was found for peptide 1.19b in the presence 
of GSK3β protein and the receptor after 60 min. In addition, an inhibitor assay was 
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carried out in the presence of GSK3β inhibitor 1.20. The formation of 1.19c was 
suppressed to 13%, showing a decrease in the fluorescence intensity of the receptor in the 
presence of 0.5 µM of 1.20 and GSK3β.52 In further biosensing applications, receptor 
1.18 was found useful as a fluorescent staining agent. Hyperphosphorylated proteins were 
selectively detected in hippocampus tissue after 10 min of incubation with 10 µM of 
1.18.
53
  
 
 
 
 
 
a: Tyr-Ala-Val-Val-Arg-pTyr-Pro-Pro-Lys-pSer-Pro-Ser-Ser 
b: Tyr-Ala-Val-Val-Glu-pTyr-Pro-Pro-Glu-pSer-Pro-Ser-Ser 
c: Tyr-Ala-Val-Val-Glu-Tyr-Pro-Pro-Glu-pSer-Pro-Ser-Ser 
                 1.19     
1.18          
 
 
  
1.20
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More recently, chemosensor 1.21 was studied by Gunning and co-workers.  This 
receptor contains a pyrene fluorophore covalently attached to a Zn-cyclen macrocycle. 
The turn-on fluorescence signal resulted from the π-π stacking of two receptor units 
forming an excimer reporter upon the binding to bis-phosphorylated peptides and 
proteins. Analogous to Hamachi’s receptor design, Zn(II) was used as coordination metal 
for the molecular recognition of phosphoryl groups. Fluorescent titrations showed that 
receptor 1.21 selectively binds to bis-phosphorylated peptides containing Ala-pTyr-pTyr-
Ala-Ala motifs, resulting in a 2:1 sensor-peptide stoichiometry. An affinity constant of 
Ka= 4.3 M
-1
 and limit of detection of 0.6 µM
 
were measured using fluorescence titrations 
under physiological conditions. The addition of mono-phosphorylated peptides did not 
cause significant changes in the emission spectra of the receptor. In further studies, 
excimer formation was induced by the incubation of the sensor with full-length proteins 
α- and β- casein containing bis-phosphorylated motifs. Sensor 1.21 was also used as a 
fluorescent staining agent in polyacrylamide gel, showing high selectivity towards 
proteins with bis-phosphorylated sequences.  
 
 
 
1.21
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1.4.4.2 Chelation-Sensitive Peptide Sensors 
Imperiali and co-workers have extensively developed peptide-based sensors that 
work based on the chelation-enhanced fluorescence process. The peptides are covalently 
attached to the sulfonamide-oxine (SOX) fluorophore which chelates Mg
2+ 
ions in the 
presence of a phosphoryl group. These SOX-peptide sensors have been widely used in a 
variety of kinase assays due to their high compatibility with non-physiological Mg
2+ 
levels. Additionally, this method is applicable for the detection of serine, threonine and 
tyrosine kinase activity.
38
 The non-phosphorylated SOX-peptides present low metal ion 
affinity, displaying low or no fluorescence. However, upon phosphorylation the peptide 
increases its affinity for Mg
2+ 
metal ion, resulting in chelation-enhanced fluorescence (λex 
= 360 nm, λem = 485 nm).
54
 
The first synthesized SOX-peptides were designed with three organized segments 
(Figure 1.13A) using a β-turn focused design (BTF). A) SOX-amino acid placed +/- 2 
residues apart from the phosphorylation site, 2) a kinase recognition unit including the 
amino acid to be phosphorylated, and 3) a β-turn peptide sequence between the SOX-
amino acid and the recognition unit, allowing preorganization of the binding site to 
interact with Mg
2+
.
54
 The peptide sensors were successfully used to assess kinase activity 
in vitro and in cell extracts. However, the β-turn requirement limits the application of this 
design to small peptide fragments rather than full peptide recognition sequences, due to 
the conformational constraint of the β-turn moiety. 
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To circumvent the β-turn limitation, a different strategy known as the recognition 
focused domain (RFD) approach was used (Figure 1.13B), where the SOX fluorophore 
was incorporated by alkylation of the cysteine residue to afford a C-SOX peptide sensor. 
The C-SOX design allowed for the insertion of extended substrate sequences to maximize 
the specificity by the target kinase. This RFD approach was used to monitor the 
phosphorylation of several relevant substrates of protein kinase C (PKC), protein kinase 
A (PKA), sarcoma kinase (Src), and insulin receptor kinase (IRK). The C-SOX peptides 
were used in 96 well plates, allowing for high-throughput measurements of multiple 
kinases and obtaining significant kinetic parameters.
55
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Figure 1.13: Kinase sensing approach using SOX-peptide sensors from Imperiali et al. 
A) β-turn focused (BTF) design. B) Recognition focused domain (RFD) design. The 
affinity for Mg
2+ 
is increased upon phosphorylation of Ser, Tyr or Thr residues, and the 
SOX-amino acid undergoes chelation-enhanced fluorescent. 
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1.4.5 Concluding Remarks for Fluorescent Chemosensors  
The main requirement for the correct performance of the aforementioned 
chemosensors and biosensor systems is the existence of high molecular complementarity 
to afford high affinity and specificity to target specific peptides or proteins. The design 
process of these fluorescence-based sensors has been inspired by the study of the binding 
sites of phosphate-recognition proteins. Additionally, computer modeling has been used 
to improve host-guest interactions by assuring that the structure of the receptors 
maximizes the expected interactions with the phosphoryl groups. However, these 
traditional lock-and-key based sensors have been designed to target one specific type of 
protein analyte, due to their inherent molecular complexity. Using the lock-and-key 
model, an individual chemosensor has to be developed and can only detect one analyte. 
In this context, detection of proteins remains a major task due to their composite nature 
and the required neutral aqueous conditions for their structural stability. Thereby, 
additional detection methods that can identify protein entities and the variation of their 
concentrations as biological markers can serve as powerful tools to assess cellular 
responses to external factors, pathological conditions, or as screening for kinase 
inhibitors. 
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1.4.6 The Pattern-Based Recognition Approach 
As an alternative to the highly specific chemosensors described above there is the 
approach of differential sensing which is inspired by the human olfactory and gustatory 
senses. These biological entities use an array of cross-reactive receptor proteins which 
interact with their analytes through differential binding or cross-reactive reactions, 
creating a unique response pattern that is recognized as a particular smell or taste. This 
biological model has encouraged supramolecular chemists to develop differential sensing 
arrays that mimic these sensory systems.
56
 Thereby, a sensing array is composed of a 
collective assembly of differential receptors. In the field of Supramolecular Analytical 
Chemistry, differential sensing is commonly used to describe the binding form of the 
receptor elements in the array. Herein, the individual sensors present moderate affinity 
and selectivity, binding differently to each analyte through non-specific interactions. 
Hence, each receptor can interact with several analytes, but each receptor binds the 
targets differently from the other receptors. Using this approach, one obtains a distinct 
fingerprint of composite optical signal produced by the sensor elements, allowing for 
detection and differentiation of different challenging biomolecules, including proteins.
57
 
This approach overcomes the tedious process of planning and developing highly selective 
binding recognition sites on the receptors. Less synthetic effort is needed to build 
receptors that can distinguish between structurally analogous analytes. In addition, less 
time is consumed synthesizing a new host for every analyte, considering the structural 
and dynamic complexity of proteins.
58
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1.4.6.1 Chemometric Analysis in Differential Sensing 
In practice, the fingerprint refers to the convoluted data consisting of absorbance 
or fluorescence signals, which can be difficult to analyze by the naked eye. Sensing 
arrays usually need a variety of receptors to obtain a good discriminatory response, thus 
the information that is acquired from these arrays becomes intrinsically multivariate. 
Thereby, the use of differential sensing arrays conveys the need of statistical tools to 
interpret and analyze multivariate datasets. Chemometric analytical methods have been 
implemented to resolve this task. Mathematical and statistical methods such as principal 
component analysis (PCA),
59
 linear discriminant analysis (LDA),
60
 and hierarchical 
cluster analysis (HCA)
59
 are typically used for the qualitative or semi-quantitative 
analysis of the data set. Likewise, artificial neural networks (ANN),
61
 and support vector 
machines (SVM)
62
 have been successfully employed for the quantitative analysis of the 
multivariate data, in addition to analyte identification.  
In general, PCA and LDA are considered statistical treatments, which through a 
combination of mathematical functions and correlation matrixes reinterpret the 
multivariate data from the array, and produce a different dataset with reduced 
dimensionality. In both cases, the variance contained in the original dataset is the major 
statistical characteristic that is preserved during the chemometric analysis. As a result, the 
observations (hosts and fluorescence dataset) are correlated with the variables (analytes), 
leading to the detection and visualization of the pattern responses in the data input. 
Mathematically, PCA creates a series of orthogonal axes that convert the original dataset 
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to a new coordinate system. The greatest extent of variance within the dataset is 
represented by the first coordinate, known as the first principal component. The second 
and third principal components represent the amount of decreasing variance. As a result, 
plots of lower dimensionality are obtained that usually show the first, second and third 
principal components, which separate out different clusters of analogous data. 
PCA is an unsupervised method or clustering analysis method, where the response 
patterns are obtained without additional information about the classes of analytes prior to 
the implementation of the PCA algorithm. On the other hand, supervised statistical 
approaches require prior identification of the analyte before operation of the chemometric 
algorithms. LDA is a supervised technique essentially used for analyte classification and 
dimensionality reduction. A different mathematical model is developed during LDA 
operation, where the discriminant functions maximize the variance between differing 
classes of analytes, while minimizing the variance within each analyte class. 
Analogously, LDA plots are obtained by discriminant factors, separating clusters of data 
with similar identity along the orthogonal axes. A validation process is required at the 
end of the analysis to evaluate the confidence of analyte discrimination by the 
implemented model. The leave-one-out or jack-knife analysis is the most common cross-
validation approach where one data point is left out at a time from the dataset, and the 
mathematical functions are recalculated in the absence of the removed point. The 
previously omitted data point is then used to assess the mathematical model by treating 
the point as an unknown, and predicting which analyte class it fits in. This operation is 
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repeated until every data point is removed and categorized, where the classification 
ability of the model is represented by the correct placement of all analytes. 
Analysis of multivariate data with nonlinear relationships between the values that 
are measured and the values that are known is achieved by using ANN, which is a more 
advanced computational model. This method was inspired by the central nervous system, 
where interconnected sets of neurons form a network. ANNs can establish relationships 
between known and observed data, conveying confidence levels to the experimental 
trends. The input data is first entered into a program and then computed by mathematical 
functions. An output value is generated by a different function in the same program. 
These functions transform and correlate the input information that is passed along the 
network to the derived output signals. Thus, an ANN is considered an adaptive model 
that generates a nonlinear mapping between input values and output data. 
Recently, SVMs have emerged as a powerful tool to process multivariate data 
analysis. This model is mainly applied to datasets with different classes that cannot be 
separated using linear planes. SVM is a supervised method used for analyte classification, 
where mathematical functions separate the classes by mapping the inputs into a different 
dimensional space. This method is capable of classifying any type of multivariate data 
due to the variety of functions that can be applied to obtain linear correlations between 
the variables. These functions are known as kernel, and can be linear, polynomial, 
Gaussian-based functions, and so on. These kernel functions are used to transform the 
input data in different categories using a different dimensional space that linearly 
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separates the classes. A different operator or hyperplane is created in this higher-
dimensional space, maximizing the separation or margin between the two classes. The 
maximum-margin hyperplane is the largest distance between the hyperplanes that 
separate the data points of the two categories. This gap should be as wide as possible to 
maximize the resolution between the two categories. New data points are then mapped 
into the training data with higher-dimensional space, and predicted to belong to a class 
according to which side of the margin they fit in.  
1.4.6.2 Differential Sensing of Proteins 
Different protein-detecting arrays have been developed in the last decade for the 
detection of different classes of proteins. These cross-reactive receptors are composed by 
large molecular scaffolds such as supramolecular structures, DNA base pairs or 
nanoparticles, containing different recognition motifs to enhance receptor-protein surface 
interactions.  Our group and others
63-65
 have traditionally generated differential receptors 
that incorporate two main structural features. Firstly, a core host structure is designed to 
contribute to the enhancement of the binding affinity between receptor and protein 
analyte. The host scaffold is additionally used to form a pre-organized binding site which 
can interact with different protein surfaces. Secondly, variable recognition moieties such 
as peptidic arms, metal centers, DNA strands or fluorophores are covalently or non-
covalently attached to the core unit, imparting the desirable differential binding. These 
libraries of receptors have been successfully elaborated using a rational design of 
molecular recognition units capable of interacting with protein surfaces through 
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hydrogen-bonding, hydrophobic effects and ion pairing. Hydrophilic groups have been 
introduced to increase the selectivity towards different proteins, and to assure the 
appropriate solubility of the receptors under physiological conditions. Additionally, host-
guest complementarity is generally achieved through electrostatic interactions by 
incorporation of peptide-based ligands. These sensing arrays have been able to detect 
structurally similar proteins which also presented different conformational characteristics 
in solution, and in the presence of complex mixtures.  
Anslyn and co-workers developed a combinatorial library of peptide-based 
receptors to differentiate proteins and glycoproteins. The library of receptors was built 
using a hexasubstituted benzene core with two appended peptidic arms (1.22). This 
pinwheel scaffold was used for the formation of a prearranged binding cavity. The 
tripeptide arms were diversified by incorporating all natural amino acids (except Cys) to 
provide differential binding, using the side chains for distinctive hydrogen-bonding, ion 
pairing and hydrophobic interactions. The receptors also contained boronic acids to give 
preferential binding towards glycoproteins. A combinatorial library of 19
3
 resin bound 
receptors was created, where 29 receptors were arbitrarily chosen, and incorporated into 
the array. The protein analytes were firstly added to the array, followed by the addition of 
bromopyrogallol red indicator (1.23).  
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Kinetic indicator-uptake studies were done to obtain the respective slopes of each 
of the 29 receptors. The slopes were converted to single data points, and analyzed using 
PCA. This sensing array successfully differentiated glycoproteins ovalbumin and fetuin 
and the other proteins elastin, bovine serum albumin and lysozyme at 355 µM 
concentration. Seven of the 29 receptors were sequenced by Edman degradation, and 
were found to have the greatest contribution in the discrimination of the proteins. This 
study established the use of differential peptide-based receptors to provide a wide range 
of binding modes, and successfully detect and differentiate large biomolecules.  
1.22
 
 
  
1.23 
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 Hamilton and co-workers developed a library of fluorescent tetraphenylporphyrin 
receptors (1.24) capable of differentiating metal and nonmetal-containing proteins.
64
 
Different peptidic arms with basic, acidic and aromatic residues were attached to the 
porphyrin receptors. The hydrophobic porphyrin scaffolds were used to impart good 
binding affinity, while the side chains of the amino acids were used to impart different 
selectivity by varying the total charge of the receptors. The combination of five different 
amino acid derivatives with the porphyrin cores resulted in the formation of 35 porphyrin 
sensors. Different protein targets such as basic cytochrome c, acidic ferredoxin, lysozyme 
and lactalbumin were studied using this array. The fluorescence of the porphyrin sensors 
was quenched upon addition of the proteins, which could be also observed by the naked 
eye. The metal-containing proteins, cytochrome c and ferredoxin gave the most 
representative differentiation due to their inherent charge and hydrophobic distribution on 
their respective surfaces. Furthermore, the iron metal incorporated in these paramagnetic 
proteins produced additional quenching of the fluorescence of the receptors. 
Alternatively, the fluorescent changes produced by neutral proteins lysozyme and 
lactalbumin were presumably derived from differential association with polar and 
nonpolar surfaces. The obtained fluorescent pattern responses lead to the identification of 
each of the four analytes. From the previous library receptor, eight porphyrin receptors 
were chosen to develop a second array to differentiate metal and nonmetal protein 
mixtures. Chemometric analysis was used to analyze the obtained fluorescence pattern, 
and showed good differentiation of the ten analyte mixtures.   
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A different strategy was followed by Hamilton et al.,
66
 developing an array of 
receptors based on fluorescent DNA G-quadruplexes with protein-binding fragments. The 
G-rich strands (1.25) were functionalized with three different fluorophores, pyrene (1.26), 
fluorescein (1.27) and tamra (1.28). Each fluorophore was chosen due to their convenient 
spectral overlap within them. Pyrene displayed excimer formation when forming π-π 
stacking (1.29), whose emission overlapped with the excitation spectra other two 
fluorophores. Four emission signatures were produced by direct excitation of each 
fluorophore, and by the induction of a FRET process from fluorescein and tamra which 
are a well-known donor-acceptor pair. Five protein analytes were studied using this array, 
including melittin, avidin, histone, heme and myelin basic protein. A distinctive 
fluorescence pattern was obtained upon addition of the protein targets to the G-
quadruplex ensemble. Several photophysical events such as fluorescence quenching, 
interruption of the π-π stacking formation, and differences in FRET were ascribed to 
1.24 
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produce the differential fluorescence pattern due to the effect of the peptide side chains 
on the protein surfaces. These fluorescent pattern responses allowed for the identification 
of the five protein analytes using PCA (Figure 1.14).   
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1.26
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1.29
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Figure 1.14: Discrimination of five proteins with DNA G-quadruplexe sensing array 
from Hamilton et al. PCA plot of hemoglobin, melittin, avidin, histone, and myelin basic 
proteins at 500 nM concentration. (Reproduced from Ref. 63. © WILEY-VCH, 2009.)  
 
 Rotello et al.
67
 developed a different type of sensing array using gold 
nanoparticles (AuNPs) functionalized with different chemical structures. An improved 
feature of this array is the use of both synthetic and biomolecular elements, which were 
introduced to mimic multivalent interactions of biomacromolecules. The incorporation of 
green fluorescent protein (GFP) as a fluorescent reporter for the binding event improved 
the biocompatibility of the system. The protein-protein surface interactions were 
improved using the nanoparticle-GFP receptor complex, allowing the system to reach low 
detection limits. Different sensor elements were synthesized using five AuNPs with 
ligand varying in hydrophobicity, hydrogen-bonding ability and aromaticity. The 
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nanoparticle-GFP receptor conjugates were formed due to the electrostatic 
complementarity between the cationic surface of the AuNPs and the negatively charged 
GFP, resulting in fluorescence quenching of the GFP. Five protein targets were used for 
this study, including fibrinogen, transferrin, IgG, human serum albumin and α-
antitrypsin. The addition of the protein analytes to the nanoparticle-GFP complex 
mixtures produced either a positive response where the fluorescence was restored when 
the GFP was displaced by the analytes; or a negative response as a consequence of 
protein-GFP aggregation. The five serum proteins were successfully discriminated at 25 
nM concentration using this sensing array. In further studies, the previous serum proteins 
were also differentiated at 500 nM physiological concentration when added to a complex 
mixture of human serum (Figure 1.15). 
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Figure 1.15: Discrimination of serum proteins with nanoparticle sensing array from 
Rotello et al. LDA plot of fibrinogen, transferrin, IgG, human serum albumin and α-
antitrypsin at 500 nM concentration. (Reproduced from Ref. 64. © Nature Publishing 
Group, 2009.)  
 
 More recently, Rotello and co-workers improved the previous nanoparticle-based 
sensing method.
65
 The surface of the cationic AuNPs was linked to different ligands with 
different physicochemical properties to impart differential binding toward protein 
surfaces. Additionally, different fluorescent conjugated polymers and GFP were used as 
reporters for the binding event upon addition of the protein targets. The anionic polymers 
(1.30, 1.31) were conjugated to oligo(ethylene glycol) chains to improve the solubility 
and to avoid aggregation problems. The sensing ensemble was formed using a 
combination of six different AuNPs, GFP and three fluorescent polymers. The receptor-
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reporter complexes were mainly bound due to strong charge complementarity. A 
remarkable range of 12 proteins were differentiated using this nanoparticle sensing 
ensemble. Upon addition of the protein analytes to the array, changes in fluorescence 
emission were obtained due to the displacement of the reporters from the AuNPs. The 
obtained fluorescence pattern was analyzed using LDA, showing good clustering and 
differentiation of the individual proteins.  
 
 
1.4.7 Concluding Remarks for Differential Sensing of Proteins 
In summary, the previous examples have shown that proteins can be successfully 
detected and differentiated under physiological conditions using a combination of 
differential sensing and chemometric tools. Each of the aforementioned array sensing 
systems distinguished different classes of proteins by including different receptor-
1.30 
 
  
1.31 
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indicator complexes in their respective arrays. Different receptor designs were developed 
to obtain the appropriate cross-reactive library of receptors for the arrays. These receptor 
varieties used a combination of specific interactions and differential binding to classify 
protein analytes. The pattern-based recognition approach has proven to be effective for 
protein sensing, extending its differential sensing power to the discrimination of protein 
mixtures.           
1.5 SUMMARY AND OUTLOOK 
Protein phosphorylation is one of the most remarkable events for the correct 
performance of cellular activity. MAP Kinases are one of the most important families of 
proteins in cancer research. X-ray crystallography and computational models have 
revealed the notable similarity and complexity of MAPK conformational structure. 
Traditionally, radioactive-based assays with ATP and antibodies have functioned with 
inherently high selectivity to detect the phosphorylation state of MAP kinases. In the last 
decade, a variety of fluorescence-based sensing methods have been developed to study 
protein phosphorylation. Each researcher had a different approach for developing an 
appropriate biosensor or chemosensor for different types of phosphorylated peptides or 
proteins. The lock-and-key model relied on biosensors or chemosensors with high 
selectivity and specificity. Some examples used a peptide or protein substrate which was 
functionalized with a fluorophore located in close proximity to the phosphorylation site, 
reporting the binding event. Other examples developed small artificial chemosensors that 
contain recognition moieties towards phosphoryl groups on peptides/proteins. Using this 
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approach only one receptor can be used to target one particular protein. The synthesis of 
this type of receptors has been evidently challenging for chemists. The introduction of the 
pattern recognition approach which combines differential sensing and chemometrics has 
shown that single highly selective receptors may not be required for certain studies. 
Instead, differential receptor arrays with low selectivity can be used which mimic the 
mammalian senses of taste and smell through cross-reactive interactions. The above-
mentioned arrays encompassed receptors that incorporate different binding modes within 
each receptor. A general large scaffold was first incorporated into the receptor, targeting 
the general properties of the protein surface such as hydrophobicity, charge, and 
aromaticity; and enhancing the binding affinity. Then, different binding moieties were 
added to the scaffold to impart differential binding. The cross-reactive interactions 
between the library of receptors and analytes, allowed the detection and differentiation of 
different proteins with the same array. Finally, the power of differential sensing arrays 
has enabled the detection of proteins in complex mixtures.  
To the best of our knowledge, phosphorylated proteins and particularly MAP kinases 
have not been yet detected using the pattern-based recognition approach. Our group and 
others have established the basis to use this method to study the activity of MAP kinases 
in vitro and in cell lysates. In the following chapters, the development of new differential 
sensing methods and their application for protein phosphorylation and MAPKs will be 
discussed.  
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Chapter 2: In-Situ Generation of Differential Sensors that Fingerprint 
Kinases and the Cellular Response to their Expression 
 
2.1 ABSTRACT 
Mitogen activated protein (MAP) kinases are responsible for many cellular functions, 
and their malfunction manifests itself in several human diseases. Usually, monitoring the 
phosphorylation states of MAP kinases in-vitro requires the preparation and purification 
of the proteins or western blotting. Herein, we report an array sensing approach for the 
differentiation of MAP kinases and their phosphorylated counterparts in-vitro. This 
technique utilizes a library of differential receptors created in-situ containing peptides 
known for affinity to MAP kinases, and a Zn(II)–dipicolylamine complex that binds 
phosphate groups on proteins.  An indicator-displacement assay signals the binding of the 
individual receptors to the kinases, while chemometrics is used to create a fingerprint for 
the kinases and their state of activity. For example, linear discriminant analysis correctly 
identified kinase activity with a classification accuracy of 97.5% in-vitro, while the 
cellular response to kinase expression was classified with 100% accuracy. 
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2.2 INTRODUCTION 
 Protein phosphorylation is a pivotal post-translational modification that regulates 
intracellular signaling networks, gene transcription, and cell growth in eukaryotic cells.
11
 
The specific phosphorylation of serine, threonine, and tyrosine residues controls the 
enzymatic activity of a diverse range of kinases. For example, the mitogen-activated 
protein (MAP) family of kinases triggers key cell-signaling pathways, thus regulating a 
variety of cellular responses, such as mitosis, cell differentiation, the cell cycle, and 
apoptosis.
13,68
 Aberrant MAP kinase activity is associated with human diseases, such as 
inflammatory response, hematologic malignancies, and cancer.
5,69 
Of the MAP kinases, 
several are associated with these disease states, including extracellular signal regulated 
kinases (ERK1/2), the c-Jun N-terminal kinases (JNK1/2/3), and p38 MAPK α, β, γ, and 
δ.70  
Simple and efficient protein phosphorylation detection methods, as well as 
techniques to qualitatively assess cellular changes in response to the phosphorylation, 
could serve as tools to monitor cell status, kinase activity, and as screens for potential 
inhibitors.
5,13,68-70
 While many approaches involve antibodies and radioactivity-based 
assays,
71
 optical-based sensing methods to detect phosphorylation events are advancing 
rapidly.
72-74
 Efforts in this area have focused on the development of receptors whose 
responses are sensitive, as well as being functional in physiological environments.
75,76
 
For instance, the chelation-enhanced fluorescence strategy popularized by Imperiali using 
a sulfonamido oxime (SOX) fluorophore is a leading approach.
77
 Phosphorylation of 
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Ser/Thr residues enhances the affinity of SOX with magnesium, and as a result increases 
the fluorescence of SOX.
78
  
Other groups are working to create supramolecular receptors as kinase 
chemosensors.
79,80
 Hamachi and co-workers studied chemosensor 2.1, which contains 
two units of zinc-dipicolylamine Zn(DPA).
81
 In aqueous solution at neutral pH, the two 
Zn(Dpa) moieties of 2.1 interact with various phosphopeptides (Ka values ranging from 
10
4
 to 10
7 
M
-1
),
82
 but not with their nonphosphorylated counterparts. Additionally, the 
same group designed a highly selective hybrid biosensor,
50
 where a similar dinuclear zinc 
receptor was incorporated into the phosphoprotein binding site of M15C-WW mutant 
protein, allowing them to monitor kinase-catalyzed phosphorylation.  
While the Hamachi and Imperiali detection systems selectively bind to and signal 
phosphorylation, it is necessary to synthesize a different receptor to be selective for each 
phosphorylated target. Further, in some cases it may be desirable to characterize an 
overall change in cell signaling pathways and the detection of a specific phosphorylation 
event is not necessarily indicative of other cellular changes. To avoid the tedious process 
of developing individual highly selective receptors, the use of differential sensing 
techniques has been growing in the supramolecular chemistry field. This sensing protocol 
exploits the interactions between target analytes and a library of cross-reactive receptors 
to create a response pattern that is unique for individual analytes, or different mixtures 
thereof.
83,84
  Using this approach, one obtains a distinct fingerprint of composite signals 
produced by the sensor elements, allowing for discrimination of different challenging 
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analytes.
57
 Our group,
85
 and others,
64-67
 have used differential sensing for the analysis of 
various pure peptides and proteins. For example, we recently reported a pattern-based 
approach to discriminate phosphorylated tripeptides. A library of cross-reactive receptors 
was derived from a tris(2-pyridylmethyl)amine unit conjugated to guanidinium ligands 
and random tripeptides (2.2). Five different tripeptides, three metals, and three indicators 
led to 45 receptors, imparting cross-reactivity to the array, allowing chemometric-based 
differentiation of the targets.
86
 Hence, as the next step in extending differential sensing to 
the detection of post-translational modifications, we envisioned that differential sensing 
could also be used to pattern protein phosphorylation events, and thereby fingerprint 
kinases in vitro. Furthermore, we also sought to challenge the methodology with a real-
life test and examine its utility in complex mixtures, specifically cell extracts. In cell 
extracts, the technique would necessarily be responding to changes in distributions of 
protein modifications that result from activating a kinase pathway. 
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2.3 RESULTS AND DISCUSSION   
2.3.1 Design Criteria 
To pattern kinases and cellular responses to their activation we first considered 
the use of library 2.2. However, the synthetic complexity of 2.2 is daunting, and hence we 
set another goal, that of creating a general method by which a suite of receptors could be 
generated simply by mixing components in-situ. The conjugate addition reaction of thiols 
to different conjugate acceptors caught our attention because of its recent use for drug 
discovery.
87
 
 
The reaction involves the 1,4-addition of sulfhydryl groups to an enone, 
which takes place rapidly in water at room temperature.
88,89
 For our purposes the 
differential receptor library was based on the functionalization of 1,3,5-
2.1 2.2 
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triacryloylhexahydro-1,3,5-triazine (2.3) which has been shown by Son (Scheme 2.1), to 
be an attractive conjugate acceptor scaffold for creating tripodal systems.
90
  
 
Scheme 2.1: Thiol-ene 1,4-addition of sulfhydryl groups to a conjugate acceptor.  
 
To pursue our objectives, specific components of the tripodal receptor library 
were chosen. First, we created component 2.4 (Figure 2.1). This compound carries a 
nucleophilic thiol for use in Scheme 2.1, as well as Hamachi’s proven phosphate binding 
bis-Zn(DPA) unit (the synthesis of 2.4 is described in detail in the Supporting 
Information). Second, because our group has previously shown that peptides provide 
differential binding towards different analytes,
91
 we synthesized by SPPS techniques two 
peptides with known affinities to the MAP kinases. For example, ERK-2 phosphorylates 
the transcription factor Ets-1 at Thr-38 with high specificity.
92
 Residues 31-35 (PVDAC) 
are in close proximity to the phosphorylation site of Ets-1.
93
 Hence, the PVDAC 
sequence (2.5), when incorporated into a receptor library, was expected to impart cross-
reactivity between ERK-2 and other kinases. In addition, continuing with this design 
strategy, we followed the lead of Dalby, who reported the modular peptide substrate Sub-
F, which is phosphorylated by ERK-2 when docking with the F-recruitment site (FRS) of 
2.3 
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this enzyme.
94
 The KALIC peptide (2.6) derives from a linker that separates the C-
terminal WXWP binding motif from the MAP kinase phosphorylation site of sub-F 
peptide. Therefore, such a linker is expected to bind but have low specificity. Lastly, 
dithiothreitol (2.7) was envisioned as a linker that would add to two different scaffolds 
(2.3), resulting in oligomerization, such as dimers, trimers or even larger receptors.  
When mixtures of three equivalents of these four components are added to 2.3, a mixture 
of receptors is created.  By varying which components are combined together in the 
individual wells of a multi-well plate, each well contains a unique set of receptors, 
thereby creating the diversity and cross-reactivity needed in a differential sensing scheme 
simply by mixing the components. 
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Figure 2.1: Structure of the receptor library components. Bis-Zn(DPA) receptor (2.4), 
DTT (2.7), and designed peptides 2.5 and 2.6 with cysteine residues used to generate our 
in-situ created cross-reactive array for the discrimination of MAP kinases.  
 
2.3.2 Determination of the Optimal Ratio of Fluorophore to Receptor 
 For the creation of an optical-signaling protocol that reports the binding of the 
suite of receptors to the kinases, we turned to indicator displacement assays (IDAs). In an 
IDA, the receptor interacts with the indicator through non-covalent interactions, and the 
indicator is displaced from the receptor when it is replaced by the analyte, inducing a 
signal modulation.
95
 IDAs have several advantages when using differential sensing: 1) 
fluorescent indicators can be easily incorporated to impart optical signal changes, 2) they 
2.4 
2.7 
2.5 2.6 
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are modular, meaning that different combinations of receptors and indicators are created 
simply by mixing, 3) the receptor-indicator stoichiometries can be adjusted to optimize 
the optical response and the threshold concentration for signaling,
96
 and 4), one avoids 
the synthesis of several indicator-linked receptors.
97
 To signal peptide and protein 
binding events to our receptors, the coumarin-based indicator 2.8 was chosen due to its 
high solubility under physiological conditions, and previous binding studies with zinc 
coordination compounds.
98,99
  
 
 
 
Figure 2.2: Chemical structures of components in the sensing ensemble. Coumarin-based 
indicator (2.8) and bis-Zn(DPA) chemosensors ZnR-9 (2.9), ZnR-10 (2.10), and ZnR-11 
(2.11). 
2.8 
2.9 2.10 2.11 
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 To test our IDA strategy, and to probe for any differential interactions of our 
general receptor design with phosphoproteins, receptor ZnR-10 (2.10) was synthesized. 
This receptor was used to model the behavior of all receptors in the array; it carries two 
of the bis-Zn(DPA) units and one underivatized site. First, fluorescence titrations in 
HEPES buffer were performed to optimize the correct receptor to indicator ratio. To 
study the binding of indicator 2.8 to ZnR-10, 750 µL of 100 µM 2.8  in HEPES buffer in 
a septum-capped glass cuvette (Starna cells) was titrated with aliquots of at least 5 µL, 
using 100 µL Hamilton microsyringe, of a solution of 250 µM ZnR-10 and 100 µM 2.8 
in HEPES buffer. The spectra at 357 to 644 nm were recorded after each addition with an 
excitation wavelength of 347 nm. The fluorescence values at the maximum wavelength 
(475 nm) were obtained after each aliquot.  The addition of receptor ZnR-10 into a 
solution of 2.8 resulted in a concentration-dependent quenching of the fluorescence 
emission of 2.8 (Figure 2.3A), and a 1:2 receptor-indicator binding stoichiometry was 
found.  The change in fluorescent intensity at 475 nm was plotted against increasing 
concentration of host (Figure 2.3B) which determined the ratio of ZnR-10 to indicator to 
be used in the following binding assays with peptides and proteins.  
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Figure 2.3: Binding of coumarin-based indicator to receptor ZnR-10. (A) Addition of 
ZnR-10 (0 - 82 µM) to Indicator (100 µM) in 50 mM HEPES, 10 mM NaCl Buffer, 
pH=7.4, ex 347 nm. (B) Binding isotherm for the binding of indicator to ZnR-10 of the 
data in Figure 2.3A, fitting 2:1 binding ratio at em = 475 nm. 
 
 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
67 
 
2.3.3 Indicator Displacement Assay Using a Phosphorylated Peptide 
To prove our principle for sensing protein phosphorylation, we first targeted a 
specific phosphorylated peptide. We synthesized Sub-F peptide 
(YAEPLTPRILAKWEWPA), which is a substrate for ERK-2. Phosphorylation 
conditions and characterization of sub-F peptide is described in the Supporting 
Information. In our first IDA, we prepared a 1:2 receptor-indicator complex (ZnR-10: 
2.8) in aqueous solution at pH=7.4 (50 mM HEPES, 10 mM NaCl). Then, in separated 
experiments fluorescent titrations between peptides with ZnR-10-indicator complex were 
done. Individual solutions of 36.6 µM ZnR-10 and 100 µM 2.8  in HEPES buffer were 
titrated with aliquots of 1.92 mM phosphorylated peptide solution and 1.92 mM non-
phosphorylated peptide solution, which also contained the receptor-indicator complex. 
Only the phosphorylated peptide (Figure 2.4A) was able to displace the indicator, which 
resulted in the restoration of the emission intensity at the λmax of 2.8 (Figure 2.4B). 
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Figure 2.4: Addition of phosphorylated peptide to indicator-ZnR-10 complex. Increase in 
the fluorescence intensity due to displacement of the coumarin indicator. (A) Addition of 
phosphorylated Sub-F peptide (PO4-peptide) (0 – 1.37 mM) to ZnR-10 (36.6 µM), 2.8 
(100 µM) in 50 mM HEPES, 10 mM NaCl pH=7.4, ex 347 nm. (B) Binding curve of 
data in Figure 2.4A measured at em = 475 nm.  
 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
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Figure 2.5: Addition of nonphosphorylated peptide to indicator-ZnR-10 complex. 
Increase in the fluorescence intensity due to displacement of the coumarin indicator. (A) 
Addition of nonphosphorylated Sub-F peptide (0 - 1.42 mM) to ZnR-10 (36.6 µM) and 
2.8 (100 µM) ) in 50 mM HEPES, 10 mM NaCl pH=7.4, ex 347 nm. (B) Binding curve 
of data in Figure 2.5A measured at em = 475 nm. 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
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2.3.4 In Vitro Differentiation of Active and Inactive MAP Isoform Kinases  
Because it was found that chemosensor ZnR-10 can differentiate between 
phosphorylated and non-phosphorylated peptides, we anticipated a similar distinction 
between active and inactive kinases. In separate experiments, phosphorylated ERK-1 and 
its inactive form were titrated into a 1:2 receptor-indicator complex solution. A 
significant increase in the fluorescence intensity was observed upon the addition of active 
ERK-1 (Figure 2.6A), compared with the non-phosphorylated analog. Despite an 
increase in the fluorescence intensity observed in both cases (Figure 2.6C), there was a 
large enough and reproducible difference to encourage us to continue.  
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Figure 2.6: Addition of active and inactive ERK-1 to indicator-ZnR-10 complex. Increase 
in the fluorescence intensity due to displacement of the coumarin indicator. (A) Addition 
of phosphorylated ERK-1 (0 – 3.8 µM p-ERK-1) to ZnR-10 (36.6 µM) and 2.8 (100 µM) 
in 50 mM HEPES Buffer, 10 mM NaCl pH=7.4, ex 347 nm. (B) Addition of non-
phosphorylated ERK-1 (0 – 3.8 µM ERK-1) to ZnR-10 (36.6 µM) and 2.8 (100 µM) in 
HEPES Buffer, 10 mM NaCl pH=7.4, ex 347 nm. (C) Binding curves of data in Figures 
2.6A and 2.6B measured at em = 475 nm, respectively. 
A B 
C 
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Hence, our third and final test prior to creating the array was to analyze the 
response to a different MAP kinase. Starting with ERK-2, an isoform of ERK-1 with 84% 
identity at the amino acid level,
100 
we found that the inactive ERK-2 induces a 
fluorescence response similar to that of active ERK-2 (Figure 2.7C). Although the 
response of this single receptor to active and inactive ERK-2 are similar, the isotherms 
are different from those of ERK-1, and potentially other receptors that result from our in-
situ generated array would be able to differentiate these two ERK-2 species. Hence, these 
preliminary results showed that this single receptor-indicator system is not only capable 
of distinguishing active and inactive kinases, but it can also differentiate between close 
isoforms, and it led credence to the notion that a series of such receptors may lead to a 
reliable method to classify kinases and their active/inactive forms.  
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Figure 2.7: Addition of active and inactive ERK-2 to indicator-ZnR-10 complex.          
(A) Addition of phosphorylated ERK-2 (0 – 3.8 µM p-ERK-2) to ZnR-10 (36.6 µM) and 
2.8 (100 µM) in 50 mM HEPES buffer, 10 mM NaCl pH=7.4, ex 347 nm. (B) Addition 
of non-phosphorylated ERK-2 (0 – 3.8 µM ERK-2) to ZnR-10 (36.6 µM) and 2.8 (100 
µM) in 50 mM HEPES, 10 mM NaCl pH=7.4, ex 347 nm.  (C) Binding curves of data in 
Figures 2.7A and 2.6B measured at em = 475 nm, respectively. 
 
 
A 
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2.3.5 Detection Limit Determination 
The standardized analytical method to calculate the limit of detection (LOD), 
detection limit (DL), limit of quantitation (LOQ) and lower limit of quantitation (LLOQ) 
requires seven replicates of a blank to calculate the signal noise.
101,102
 Part of the 
background signal will arise from the fluorescence of host-indicator complex without the 
analyte. Thus, the average of the fluorescence intensity at 475 nm (Figure 2.8) was 
obtained from seven blank replicates in the presence of the host-indicator complex, and 
the standard deviation was used to substitute in Equations 2.1 to 2.4.   
 
     (Eq. 2.1) 
 
     (Eq. 2.2) 
  
      (Eq. 2.3) 
 
      (Eq. 2.4) 
 
The parameters used in the equations are described as follows: , blank average; 
, the standard deviation; and m, slope value of a calibration curve. Equation 2.1 has 
been used to find the limit of detection of the signal. The 3  method introduced by Kaiser 
defines the limit of detection which refers to the concentration that will give a signal 
75 
 
three times the standard deviation of the noise.
1 
The LOQ is at least ten times the LOD.
102  
In addition, Equation 2.3 has been used to calculate the actual DL which is the minimal 
concentration of analyte that can be detected, and Equation 2.4 has been used to find the 
LLOQ which gives a more accurate value of the minimal amount of phosphorylated 
ERK-1 that can be measured. The slope (m) in Equation 2.3 and Equation 2.4 is 
equivalent to the extinction coefficient ( ) of the fluorophore. Thus, the binding isotherm 
acquired from the addition of phosphorylated ERK-1 to host-indicator complex (Figure 
2.6A) was used to obtain the slope value applying the following mathematical method. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8: Control experiment with indicator-ZnR-10 complex. Seven blank 
measurements of ZnR-10 (36.6 µM) and 2.8 (100 µM) in 50 mM HEPES Buffer, 10 mM 
NaCl pH=7.4, ex 347 nm. 
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Igor Pro 6.04 software was used to fit the exponential curve and obtain the 
corresponding coefficients (Figure 2.9) to substitute in Equation 2.5. The slope of the fit 
at x = 0 corresponds to the linear portion of the curve, and so it can be used to find the 
extinction coefficient. To find this value we simply took the derivative of the fit 
(Equation 2.6) and solved at x = 0. 
 
 
 
 
Figure 2.9: Curve fitting of the binding isotherm of ERK1 to host-indicator complex 
using Igor Pro. The red solid line corresponds to the obtained binding isotherm for the 
binding of phosphorylated ERK-1 to host-indicator complex at em = 475 nm from the 
data in Figure 2.6A. The red dot line corresponds to the curve fitting. 
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     (Eq. 2.5) 
 
       (Eq. 2.6) 
 
If  where it is the most linear then: 
 
 
 
 
The value of the slope was found to be m = 51077 8320 . Equation 2.7 
was used to find the error propagation
4
 of the slope, DL and LLOQ: 
 
    (Eq. 2.7) 
 
The parameters used in the Equation 2.7 are described as follows: δa, 
uncertainties of quantities a; and δb, uncertainties of quantities b.103 After substituting the 
values for A and  and their corresponding uncertainties (from Figure 2.9) into Equation 
2.7, the uncertainty value of the slope was 8320. 
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Finally, after substituting the slope value into Equation 2.3 and Equation 2.4, the 
detection limit and the lower limit of detection were 14 2.3 nM and 46 7.5 nM of 
phosphorylated ERK-1, respectively. 
Blank repetitions Fluorescence at 475 nm 
1 23722.7 
2 23905 
3 23981 
4 23439.2 
5 23874.6 
6 24224 
7 23656.9 
AVERAGE 23829.05 
STDEV 232.94 
   
Signal detection limit 24527.89 
Limit of Quantitation 26158.51 
  
Slope m = 51077 8320 
Detection limit 0.0136  0.0022 µM 
Lower limit of quantitation 0.0456  0.0074 µM 
 
Table 2.1: Summary chart showing blank measurements. SDL, LOQ, DL and LLOQ 
values of phosphorylated ERK-1. 
 
2.3.6 Sensing Ensemble Construction and Fingerprint of MAPK  
To evaluate the ability of the in-situ generated cross-reactive receptors to 
discriminate ERK-1/2, JNK-3 and p38γ kinases, we prepared a 384-well plate with 
receptor-indicator combinations. To generate the sensing ensemble, bis-(DPA) receptors 
R-9, R-10 and R-11 were synthesized (see Supporting Information), and used to create 
seven different combinations of hosts (Table 2.2). Host H1 contains R-9 (57 µM); Hosts 
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H2 and H3 contain receptor R-9 (57 µM) which was stirred separately with one 
equivalent (per free vinyl group) of the correspondent peptide PVDAC or KALIC (57 
µM), and DTT (57 µM). Hosts H4 and H5 contain receptor R-10 (39 µM) and Host H6 
contains receptor R-10 (39 µM) and DTT (39 µM). Host H7 contains receptor R-11 (35 
µM).  
 
Host 
 
1 2 3 4 5 6 7 
Type of 
bis-
Zn(DPA) 
receptor 
ZnR-9 ZnR-9 ZnR-9 ZnR-10 ZnR-10 ZnR-10 ZnR-11 
Type of 
Host  
R-9 
Zn(NO3)
2 
Indicator 
R-9 
PVDAC 
DTT 
Zn(NO3)2 
Indicator 
R-9 
KALIC 
DTT 
Zn(NO3)2 
Indicator 
R-10 
Zn(NO3)2 
Indicator 
R-10  
Zn(NO3)2 
Indicator 
R-10 
 DTT 
Zn(NO3)2 
Indicator 
R-11 
 Zn(NO3)
 
Indicator 
 
Receptor 
(µM) 
57 57 57 39 39 39 35 
 
DTT 
(µM) 
- 57 57 - - 39 - 
 
PVDAC 
(µM) 
- 57  - - - - 
 
KALIC 
(µM) 
- - 57 - - - - 
 
Zn(NO3)2 
(µM) 
114 114 114 155 155 155 213 
 
Indicator 
(µM) 
57 57 57 57 100 100 124 
 
Equiv. 
 
1:2:1 1:1:1:2:1 1:1:1:2:1 1:4:1.5 1:4:2.5 1:1:4:2.5 1:6:3.5 
 
Table 2.2: Host concentrations used in the sensing ensemble. 
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The order of addition of each of the reagents was important due to the known 
coordination interactions between sulfhydryl groups and Zn
2+
 metal ions.
104
 Therefore, 
zinc nitrate was the last reagent added in appropriate equivalents according to the number 
of DPA moieties present in each receptor where the final concentration was 114 µM, 155 
µM and 213 µM according to each host (Table 2.2). Aliquots of each host solution were 
loaded into a 384-well plate (32 µL Costar black polystyrene microplate), followed by 
indicator aliquots according to the number of bis-Zn(DPA) moieties present in each 
receptor. The final concentrations of indicator were 57 µM of 2.8 to hosts H1-4, 100 µM 
of 2.8 to hosts H5 and H6, and 124 µM of 2.8 to host H7 in HEPES buffer. Finally, 
respective aliquots of phosphorylated and non-phosphorylated kinases ERK-1, ERK-2, 
JNK-3 and p38γ were added to each set of host-indicator solutions, so that the final 
protein concentrations were 4 µM (four replicates each). 
Changes in the emission data at the λmax of 8 at pH = 7.4 (475 nm) for each 
ensemble of the sensor array upon addition of each kinase were recorded using a 
microplate reader (Biotek Synergy 2). The data generated (4 replicates x 7 host x 8 
kinases) were analyzed with the program XLSTAT using linear discriminant analysis 
(LDA). This chemometric analytical technique simplifies the data set obtained from the 
sensing array, allowing for differentiation and classification of the response pattern. LDA 
maximizes the distance between analyte groups while minimizing the distance within an 
analyte group.
105
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A series of LDA tests were set up with purified and single proteins. First, using 
the four phosphorylated kinases (ERK-1, ERK-2, JNK-3 and p38γ), the resulting score 
plot (Figure 2.10A) shows excellent differentiation along the F1 and F2 axes, and good 
clustering of the experimental replicates at the given concentration. The active kinases 
are organized along the F1 axes by emission modulation of the sensing ensemble, where 
isoform ERK-2 is located into the left quadrant and ERK-1 into the right one. The kinases 
are classified into respective sets with 100% accuracy according to a jackknife 
analysis.
106
 Next, using the same conditions we sought to test the capability of our 
sensing ensemble to discriminate phosphorylated and non-phosphorylated kinases (ERK-
1, ERK-2, JNK-3 and p38γ). Similar to the previous study, each active and inactive 
kinase produced a distinctive fluorescence pattern, but with a lower accuracy, 93.5% via 
a jackknife (Figure 2.11A). Although inactive p38γ overlaps with active ERK-2, we can 
clearly distinguish that the active/inactive p38γ and ERK-2 proteins are located on 
opposite sides of the left quadrant. It is also observed that ERK-1/ERK-2 kinases, which 
have very similar structures, are classified in opposite areas along F1. Furthermore, the 
phosphorylated isoforms are significantly differentiated from the non-phosphorylated 
ones, and within themselves, along both F1 and F2 axes. Finally, active and inactive 
JNK-3 kinases are clearly classified and located on the top right quadrant. A general 
trend was found, where the active kinases are located on the right side and the inactive 
ones are located on the left side, except the ERK-2 isoform. 
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It was found that the protein kinases located on the right side of the score plot 
displaced indicator 2.8 in the array to a higher extent than those kinases located on the 
left side of the score plot (Figure 2.10A and 2.11A). A loading plot can be generated 
along with the LDA score plot, and it gives vectors that represent the host contribution to 
the differentiation of the kinases (Figure 2.10B and 2.11B). 
According to both loading plots, hosts H-1, H-5, H-6 and H-7 which contain 
single receptors ZnR-9, ZnR-10, ZnR-10 with DTT and ZnR-11 vary significantly in 
response to both active and inactive kinases, whereas hosts H-2, H-3 and H-4 which 
contain ZnR-9 with peptides and DTT did not contribute significantly. This result 
suggests that different extents of bis-Zn(DPA) moieties on the receptors are responsible 
to maximize the differential binding between active and inactive kinases. 
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Figure 2.10: LDA score plot and loading plot of the response from the sensing array 
showing in-vitro differentiation of active MAP kinases. (A) LDA score plot and (B) 
loading plot of the fluorescence response pattern of phosphorylated MAP kinases (ERK-
1, ERK-2, JNK-3 and p38ϒ) at 4µM concentration with 100% jack knife analysis. 
Vectors on the loading plots represent individual host contribution on the array 
represented by host number. 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
84 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11: LDA score plot and loading plot of the response from the sensing array 
showing in-vitro differentiation of active and inactive MAP kinases. (a) LDA score plot 
and (B) loading plot of the fluorescence response pattern of phosphorylate (○) and non-
phosphorylated (△) kinases (ERK-1, ERK-2, JNK-3 and p38ϒ) at 4µM concentration 
with 93.5% jack knife analysis. Vectors on the loading plots represent individual host 
contribution on the array represented by host number. 
 
A 
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2.3.7 Fingerprint of Cell Lysates with Different Cellular Response 
After the successful in-vitro differentiation of purified active and inactive kinases 
using LDA of the signals from our array, we explored whether the system could be used 
to differentiate kinase activity in a complex mixture. To prove the discriminatory 
properties of our system, we assessed whether the differential receptor library could 
differentiate HEK293T cells that have differing kinase expression and activity. Because 
our approach necessarily responds to all phosphorylated proteins, the pattern that arises is 
a qualitative differentiation of distributions of proteins that change due to a specific 
profile of kinase activity. For example, differences in the cell line generated by 
stimulation with anisomycin, epidermal growth factor (EGF), and/or overexpression of 
ERK-1, would all be reflective of changes resulting from activation of specific pathways. 
Anisomycin has been reported to activate both JNK and p38 MAPK pathways,
107
 and 
EGF was reported to induce ERK and to a lesser extent the JNK pathway.
108
 
Before array analysis, western blot (WB) on lysates was performed to confirm the 
anticipated changes in these kinases (Figure 2.12). The WBs showed an increased 
activation/phosphorylation of JNK and p38 in the cells that were stimulated with 
anisomycin if compared to the untreated ones (control cells). Further, the ERK 
activation/phosphorylation pathway was confirmed to be increased in cells stimulated 
with EGF when compared to the control. Two other sets of lysates contained HEK293T 
cells that have ERK1-WT overexpressed, while one of them was also stimulated with 
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EGF. WB analysis showed that overexpressed ERK-1 was partially phosphorylated. 
However, induction of the cells with EGF significantly increased its phosphorylation. 
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Figure 2.12: Western Blot analysis of different HEK293 cell lysates. The JNK pathway 
was induced by the addition of anisomycin (100 nM) for 5-10 minutes (Aniso) or the 
ERK pathway was induced by the addition of 100 ng/mL EGF (EGF) for 30 minutes 
before lysing the cells. Cells that were transfected with pcDNA-ERK construct to 
overexpress WT-ERK1, were either induced with 100 ng/mL EGF for 30 minutes before 
lysis (ERK+) or lysed without induction (ERK-). Lysates containing 60 µg of total 
protein were fractionated by SDS PAGE (10% gel) and subjected to western blot analysis 
in order to detect the phosphorylated forms of each MAP kinases. (The results were 
similar in two different experiments) 
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Cell lysate expression, purification, and activation, are described in the supporting 
information. HEK293T cell lysates were prepared in CytoBuster™ Protein Extraction 
Reagent (EMD-Biosciences) after washing in PBS (Invitrogen). The lysates were cleared 
by centrifugation, and ATP was washed away using Amicon Ultra-0.5 mL Centrifugal 
Filters. Bradford analysis (Bio-Rad) was used to measure the protein concentration. 
Discrimination of cell lysates was obtained at total protein concentration according to 
Table 2.3. For the detection, 6 µL of cell lysate was added to the same sensing ensemble 
and same data analysis was followed.  
Cell Lysates CL Aniso EGF ERK- ERK+ 
Total 
[Protein] 
mg/mL 
3.6 6.0 4.1 1.5 6.2 
 
Table 2.3: Total protein concentration of each cell lysate. 
The LDA score plot (Figure 2.13A) of the fluorescence data showed excellent 
differentiation between the cells overexpressing ERK-1 (ERK-), cells over-expressing 
ERK-1 and induced by EGF (ERK+), and control cells along the F1 and F2 axes, and 
good clustering of the replicates. This result suggests that the variation of the responses is 
dependent on protein and phospho-protein identity. Furthermore, the LDA score plot 
(Figure 2.14A) of the fluorescence data also showed excellent discrimination of the cells 
that have ERK induced by EGF (EGF), which are separated along the second principal 
component (F2) from the cells that have JNK/p38 induced by anisomycin, and separated 
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from the control cells along the first principal component (F1). This differentiation 
suggests that the sensing array is able to detect subtle changes in phosphoproteins when 
cells are stimulated with different activators. These cell extracts are classified into 
respective sets with 100% accuracy according to a jackknife analysis. Another general 
trend was found (Figure 6A and 6C), where the induced and/or over-expressed cell 
lysates are located on the right side of the score plot and the control lysates are located on 
the left side. 
The loading plots (Figure 2.13B and 2.14B) from the analysis showed a broad 
cross-reactivity from the hosts. In this case, hosts H-1, H-2 and H-3 correspond to the 
receptors with single ZnR-9, and ZnR-9 with peptides and DTT, which produced a 
completely different response from hosts H-4 and H-5,  which correspond to receptor 
ZnR-10; and host H-6 and H-7 which encompass receptors ZnR-10 with DTT and ZnR-
11, respectively.  
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Figure 2.13: LDA score plot and loading plot of the response from the sensing array 
showing differentiation of HEK293T cell lysates with differing kinase expression. (A) 
LDA score plot and (B) loading plot of the fluorescence response pattern of different sets 
of stimulated and untreated HEK293T cell lysates with 100% jack knife analysis: control 
lysate (CL), induced/over-expressed (ERK+), and over-expressed (ERK-). 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
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Figure 2.14: LDA score plot and loading plot of the response from the sensing array 
showing differentiation of HEK293T cell lysates with differing kinase expression. (A) 
LDA score plot and (B) loading plot of the fluorescence response pattern of different sets 
of stimulated and untreated HEK293T cell lysates with 100% jack knife analysis: control 
lysate (CL), JNK induced with anisomycin (Ansio), and ERK induction with EGF (EGF). 
 
A 
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2.4 CONCLUDING REMARKS 
In summary, we have shown that an array of self-assembled synthetic and peptidic 
elements in combination with an IDA protocol provides cross-reactivity for the 
differentiation of phosphorylation states on kinases. Significantly, this sensing system is 
capable of fingerprinting different classes of MAP kinases and cell lysates in-vitro at 
neutral aqueous conditions using chemometric analysis. In this manner, a new pattern 
recognition approach was derived to target this class of analyte. The ability of this 
sensing ensemble to differentiate cells that have been induced with different stimulants 
increases our expectation for the ability of this array to differentiate between different 
types of cells, such as cells from diseased and non-diseased tissues or even cells from 
different organs. 
2.5 ADDITIONAL AND EXPERIMENTAL INFORMATION 
This research has been published as a paper in the Journal of the American 
Chemistry Society.
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2.5.1 Materials and General Procedures 
Starting materials were purchased from Aldrich Chemical Co., Acros Organics, EM, 
or TCI, and used without further purification.  All solvents were of reagent grade quality 
and purchased commercially.  Compounds 2.13, 2.14 and 2.15 were prepared according 
to previous literature procedure.
110 
Coumarin-based indicator 2.8 was prepared according 
to Smith et al.
111
 All reactions were performed in standard glassware. Evaporation was 
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done by rotatory evaporation using a standard rotovap equipped with dry ice condenser. 
TLC analyses were carried out using Silica TLC Plates Aluminum Backing 20 by 20 cm 
sheet UV active.  Column chromatography (CC) was performed using silica gel 60 (230 
± 400 mesh, 0.040 ± 0.063 mm) from Dynamic Adsorbents. Reverse phase purification 
was done using a Teledyne CombiFlash Companion with C18 RediSep reverse phase 
columns. Analytical HPLC data was obtained with a Shimadzu HPLC equipped with 
Gemini C18 column (250 X 10 mm, 5 µm). Solvent A: H2O with 0.1% v/v TFA; solvent 
B: CH3CN with 0.1% v/v TFA.  Rate flow: 4 mL/min with an increase gradient 5 to 90% 
B over 20 min at 254 and 300 nm. 
1
H and 
13
C spectra were recorded on Varian DirectDrive or Varian INOVA NMR 
spectrometers.  The NMR spectra were referenced to solvent and the spectroscopic 
solvents were purchased from Cambridge Isotope Laboratories. Finnigan MAT-VSQ 700 
and DSQ spectrometers were used to obtain mass spectra. HR electrospray ionization 
(ESI) mass spectra were recorded using either Agilent 6530 Accurate-Mass Q-TOF 
LC/MS or MALDI-TOF (Vogayer, PerSeptive Biosystem). 
 
 
 
 
 
 
C 
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2.5.2 Synthesis of Dipicolylamine Chemosensor 
 
 
Diethyl 5-hydroxyisophthalate (2.13). Product 2.13 was prepared according to 
previous literature. White solid, mp: 95-98 °C; 
1
H NMR (300 MHz, CDCl3): δ 8.18 (s, 
1H), 7.80 (s, 2H), 7.36 (s, 1H), 4.37 (q, J = 7.1 Hz, 4H), 1.37 (t, J = 7.1 Hz, 6H); 
13
C 
NMR (300 MHz, CDCl3): δ 166.7, 156.37, 132.00, 122.61, 120.86, 61.67, 14.23; LRMS 
(m/z): [M-H]
-
 calcd. for C12H14O5, 237.08; found, 237.08. 
 
 
3,5-Di(hydroxymethyl)phenol (2.14). Product 3 was prepared according to 
previous literature. Clear yellow oil.  
1
H NMR (300 MHz, [D6] Acetone ): δ 6.78 (s, 1H), 
6.72 (s, 2H), 4.51 (s, 4H); 
13
C NMR (300 MHz, [D6] Acetone): δ 158.08, 144.29, 116.81, 
112.89, 64.52; LRMS (m/z): [M-H]
-
 calcd. for C8H10O3, 153.06; found, 152.92; 
[M+Formate]
-
 calcd. for C9H11O5 199.06; found, 198.92. 
 
2.12 2.13 
2.13 2.14 
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3,5-bis(bromomethyl)phenol (2.15). Product 2.15 was prepared according to 
previous literature. Brown solid, mp: 75-78 °C; TLC (hexane:ethylacetate, 4:1 v/v): Rf = 
0.27; 
1
H NMR (400 MHz, [D6] acetone): δ 7.00 (s, 1H), 6.88 (s, 2H), 4.54 (s, 4H); 
13
C 
NMR (400 MHz, acetone): δ 158.55, 140.92, 121.83, 116.96, 33.83; LRMS (m/z): 
[M+H]
+
 calcd. for C8H8Br2O, 279.96; found, 281. 
 
3,5-bis((bis(pyridin-2-ylmethyl)amino)methyl)phenol (2.16). A solution of 2.15 
(0.67 g, 2.40 mmol, 1.0 eq), 2,2'-dipicolylamine (1.08 mL, 6.02 mmol, 2.5 eq) and 
K2CO3 (0.39 g, 2.82 mmol, 1.2 eq) in dried DMF (6 mL) was stirred at room temperature 
during 3 h under nitrogen, monitored by TLC (hexane:ethylacetate, 2:1 v/v). The reaction 
mixture was neutralized with 20% acetic acid, and the product extracted with DCM (30 
mL). The organic layer was washed with NaHCO3, brine and dried over Na2SO4, filtered 
and the solvent evaporated and dried overnight under vacuum. Product 2.16 (0.77 g, 1.50 
2.15 2.14 
2.15 
2.16 
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mmol, 62%) was obtained as a yellow oil; TLC (EtOAc:MeCN:MeOH:H2O, 6:2:2:2 v/v): 
Rf = 0.48; Analytical HPLC: Reverse phase C18 column. r.t. = 9.58 min;  
1
H NMR (400 
MHz,CDCl3) δ 8.45 – 8.38 (m, 4H), 7.54 (ddd, J = 10.1, 9.6, 4.7 Hz, 8H), 7.06 (ddd, J = 
6.8, 4.9, 1.5 Hz, 4H), 6.99 (s, 1H), 6.76 (s, 2H), 3.74 (s, 8H), 3.52 (s, 4H); 
13
C NMR (400 
MHz, CDCl3) δ 159.65, 157.63, 148.46, 140.54, 136.59, 122.71, 121.96, 119.65, 114.63, 
59.76, 58.55. LRMS (m/z): [M+H]
+
 calcd. for C32H32N6O, 517.26; found, 517.50; 
[M+Na]
+
 calcd. for C32H32N6NaO 539.25; found, 539.50. 
 
 
Tert-butyl 2-(3,5-bis((bis(pyridin-2-ylmethyl)amino)methyl)phenoxy)acetate (2.17). Tert-
butylbromoacetate (0.087 mL, 0.595 mmol, 1.2 eq), K2CO3 (0.41 g, 2.971 mmol, 6.0 eq), 
NaI (0.037 g, 0.248 mmol, 0.5 eq), tetrabutylammonium iodide (0.091 g, 0.248 mmol, 0.5 
eq) and compound 2.16 (0.256 g, 0.495 mmol, 1.0 eq) were reflux in dry DMF (10 mL) 
at 110 °C for 24 h under nitrogen atmosphere. The reaction mixture was poured into H2O, 
extracted with ethylacetate and washed with NaHCO3 and brine. The crude product after 
evaporation was purified by reverse phase to yield compound 2.17 (0.156 g, 0.248 mmol, 
50%) as a transparent oil. Analytical HPLC: Reverse phase C18 column. r.t. = 11.24 min; 
2.16 2.17 
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1
H NMR (400 MHz, CD3CN) δ 8.78 (ddd, J = 5.7, 1.5, 0.6 Hz, 4H), 8.27 (td, J = 7.9, 1.6 
Hz, 4H), 7.77 (dd, J = 7.7, 5.9 Hz, 4H), 7.70 (d, J = 7.9 Hz, 4H), 6.67 (s, 1H), 6.53 (s, 
2H), 4.39 (s, 2H), 4.13 (s, 8H), 3.56 (s, 4H), 1.44 (s, 9H); 
13
C NMR (400 MHz, CD3CN) 
δ 168.60, 158.88, 154.21, 146.53, 143.75, 138.37, 127.76, 126.83, 125.31, 116.52, 82.81, 
65.99, 60.11, 57.69, 28.21; HRMS (m/z): [M+H]
+
 calcd. for C38H42N6O3, 631.33912; 
found, 631.33964; [M+Na]
+ 
calcd. for C38H42N6NaO3 653.32106; found 653.32136.  
 
 
2-(3,5-bis((bis(pyridin-2-ylmethyl)amino)methyl)phenoxy)acetic acid (2.18). A 
mixture of 20 mL of TFA/ H2O/TIS (95/2.5/2.5 % v/v) was added to compound 6 (0.100 
g, 0.174 mmol). The reaction mixture was stirred for 1 h at room temperature. The 
solvent was evaporated with high vacuum. The crude product was lyophilized to yield 
compound 7 (0.085 g, 0.149 mmol, 94%) as brown oil. Analytical HPLC: Reverse phase 
C18 column. r.t. = 9.78 min; 
1
H NMR (400 MHz, CD3CN) δ 8.77 (dd, J = 5.6, 1.2 Hz, 
4H), 8.34 (td, J = 7.9, 1.6 Hz, 4H), 7.85 – 7.79 (m, 4H), 7.76 (d, J = 8.0 Hz, 4H), 6.58 (s, 
1H), 6.46 (s, 2H), 4.49 (s, 2H), 4.14 (s, 8H), 3.48 (s, 4H); 
13
C NMR (400 MHz, CD3CN): 
2.17 2.18 
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δ 170.72, 158.71, 154.00, 147.62, 143.08, 138.49, 128.24, 127.17, 125.45, 116.46, 65.35, 
60.18, 57.83. HRMS (m/z): [M+H]
+
 calcd. for C34H34N6O3, 575.2765; found, 575.2763.  
 
2-(3,5-bis((bis(pyridin-2-ylmethyl)amino)methyl)phenoxy)-N-
2mercaptoethyl)acetamide (2.19). Cysteamine 2-chlorotrityl Novabiochem resin (0.106 g, 
0.096 mmol, 1.0 eq) was swelled with DMF (5mL) in a solid phase synthesis reactor for 
40 min and the solvent was discarded. The mixture containing 7 (0.165 g, 0.287 mmol, 
3.0 eq), HOAt (0.039 g, 0.287 mmol, 3.0 eq), HCTU (0.119 g, 0.287 mmol, 3.0 eq), 
NMM (0.063 mL, 0.574 mmol, 6.0 eq) in DMF (5 mL) was added to the resin. After 72 h 
of shaking under argon at room temperature, the excess reagents were drained and 
discarded. The resin was then washed with DMF, DCM and MeOH (5X) and dried under 
vacuum. The product was cleaved by exposing the resin to TFA/H2O/TIS (95/2.5/2.5 % 
v/v) for 20 min. The crude was purified by reverse phase to yield compound 2.19 (0.054 
g, 0.085 mmol, 30%) as a pale yellow oil. Analytical HPLC: Reverse phase C18 column. 
r.t. = 10.34 min; 
1
HNMR (400 MHz, D2O): δ  8.50 (dd, J = 6.1, 1.2 Hz, 4H), 8.29 (td, J = 
7.9, 1.6 Hz, 4H), 7.81 (d, J = 8.0 Hz, 4H), 7.73 (ddd, J = 7.5, 5.9, 1.2 Hz, 4H), 6.59 (s, 
2.18 2.19 
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1H), 6.52 (s, 2H), 4.37 (s, 2H), 4.13 (s, 8H), 3.57 (s, 4H), 3.31 (t, J = 6.3 Hz, 2H), 2.50 (t, 
J = 6.3 Hz, 2H); 
13
C NMR (400 MHz, D2O): δ 171.10, 157.40, 153.13, 145.97, 142.21, 
138.17, 126.92, 125.97, 125.05, 115.79, 66.67, 59.61, 57.11, 41.84, 23.47;  HRMS (m/z): 
[M+H]
+
 calcd. for C36H39N7O2S, 634.29587; found, 634.29633. 
 
 
Coumarin-based indicator 2.8 was prepared according to previous literature. 
1
H 
NMR (400 MHz, D2O) δ 7.20 (s, 1H), 6.82 (s, 1H), 6.28 (s, 1H), 4.27 (s, 2H). Analytical 
HPLC: Reverse phase C18 column. Increase gradient 5 to 70% B over 15 min at 347 nm. 
r.t. = 7.68 min. 
Synthesis of receptors R-9 (2.22), R-10 (2.23) and R-11 (2.24). Thiol-ene 
conjugate addition reactions of compound 2.19 to 1,3,5-triacryloylhexahydro-1,3,5-
triazine (2.3). 
 
 
 
2.20 2.21 2.8 
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Synthesis of compounds R-9 (2.22) and R-10 (2.23). 1,3,5-triacryloylhexahydro-
1,3,5-triazine 2.3 (6 mg, 0.0242 mmol, 1.0 eq) was dissolved in 500 µL of CH3CN, and 
then added to a vial containing 2.19 (23 mg, 0.0363 mmol, 1.5 eq). To this mixture, 500 
µL of H2O was added and few beads of K2CO3 were added to the reaction mixture to 
increase pH = 8. The reaction was stirred under nitrogen for 1 h. The reaction mixture 
was lyophilized. The products were purified using reverse phase chromatography to give 
R-9 and R-10. Preparative HPLC: Reverse phase C18 column. Flow rate 4 mL/min. 
Solvent A: H2O with 0.1% v/v TFA; solvent B: CH3CN with 0.1% v/v TFA. Increase 
gradient 5% B for 5 min, 5 to 25% B over 35 min, 25 to 90% B over 7 min. 
Compound R-9 (12.45 mg, 0.0141 mmol, 59%) was obtained as transparent oil. 
Analytical HPLC: Reverse phase C18 column.  r.t. = 10.88 min; 
1
H NMR (500 MHz, 
CD3CN) δ 8.78 (dd, J = 5.5, 1.2 Hz, 4H), 8.24 (td, J = 7.8, 1.6 Hz, 4H), 7.76 – 7.73 (m, 
4H), 7.69 (d, J = 8.0 Hz, 4H), 7.27 (t, J = 6.0 Hz, 1H), 6.71 (s, 3H), 6.66 (s, 2H), 6.20 (d, 
J = 16.7 Hz, 2H), 5.75 (s, 2H), 5.33 (d, J = 32.6 Hz, 6H), 4.30 (s, 2H), 4.15 (s, 8H), 3.63 
(s, 4H), 3.41 (dd, J = 13.0, 6.6 Hz, 2H), 2.80 – 2.67 (m, 4H), 2.64 (t, J = 6.8 Hz, 2H). 13C 
NMR (500 MHz CD3CN) δ 168.69, 158.61, 154.40, 146.07, 144.18, 138.54, 129.85, 
2.3 2.19 2.22 2.23
3 
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128.20, 127.57, 126.73, 125.43, 116.75, 67.97, 60.08, 57.72, 39.14, 34.20, 32.10, 27.13. 
HRMS (m/z): [M+2H]
+2
 calcd. for C48H56N10O5S, 442.20724; found, 442.20670.  
Compound R-10 (10.16 mg, 0.0067 mmol, 28%) was obtained as transparent oil. 
Analytical HPLC: Reverse phase C18 column.  r.t. = 10.85 min; 
1
H NMR (600 MHz, 
D2O, 30% CD3CN). Water peak was suppressed and compound peaks were referenced to 
CD3CN. δ 8.51 (ddd, J = 5.6, 1.6, 0.7 Hz, 8H), 8.15 (td, J = 7.9, 1.6 Hz, 8H), 7.68 (d, J = 
8.0 Hz, 8H), 7.65 – 7.61 (m, 8H), 6.74 (s, 2H), 6.66 (s, 5H), 6.11 (d, J = 17.0 Hz, 1H), 
5.77 (d, J = 10.6 Hz, 1H), 5.23 (d, J = 30.5 Hz, 6H), 4.36 (s, 2H), 4.10 (s, 16H), 3.68 (s, 
8H), 3.35 (t, J = 6.6 Hz, 4H), 2.62 (ddd, J = 29.6, 22.7, 6.2 Hz, 13H). 
13
C NMR (500 
MHz, CD3CN) δ 168.73, 158.67, 154.61, 145.24, 144.70, 138.52, 128.11, 127.23, 126.45, 
125.34, 116.73, 67.99, 59.99, 57.71, 39.19, 34.20, 32.06, 27.17. HRMS (m/z): 
[M+2H]
+2
 calcd. for C84H97N17O7S2, 760.36083; found, 760.35934. 
Preparation of compound ZnR-10. A solution of MeOH:H2O (1:1 v/v) was used 
to dissolve R-10 (0.0046 mmol) and zinc nitrate (0.0185 mmol). The reaction mixture 
was stirred for 0.5 h. Methanol was removed and the product lyophilized to afford Zn-
R10 in quantitative yield. MALDI-TOF: [M]
+
 calcd. for C84H93N23O25S2Zn4, 2150.47; 
found, 2151.09. 
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Synthesis of compound R-11 (2.24). 1,3,5-triacryloylhexahydro-1,3,5-triazine 2.3 
(1 mg, 0.0040 mmol, 1.0 eq) was dissolved in 500  µL of CD3CN, and then added to a 
vial containing 2.19 (5 mg, 0.0079 mmol, 1.98 eq). To this mixture, 500 µL of D2O was 
added and few beads of K2CO3 were added to the reaction mixture to increase pH = 8. 
The reaction was stirred under nitrogen for 1 h. The reaction mixture was lyophilized. 
The product was purified using reverse phase chromatography. Preparative HPLC: 
Reverse phase C18 column. Flow rate 4 mL/min. Solvent A: H2O with 0.1% v/v TFA; 
solvent B: CH3CN with 0.1% v/v TFA. Increase gradient 5% B for 5 min, 5 to 25% B 
over 35 min, 25 to 90% B over 7 min to give R-11 (5 mg, 0.0023 mmol, 58%) as light 
yellow oil. Analytical HPLC: Reverse phase C18 column. r.t. = 10.93 min; 
1
H NMR (500 
MHz, CDCl3) δ 8.50 – 8.46 (m, 12H), 7.61 (td, J = 7.7, 1.7 Hz, 12H), 7.53 (d, J = 7.8 Hz, 
12H), 7.12 – 7.09 (m, 12H), 7.08 (s, 3H), 6.88 (s, 6H), 5.20 (s, 6H), 4.48 (s, 6H), 3.76 (s, 
24H), 3.63 (s, 12H), 3.49 (dd, J = 12.8, 6.4 Hz, 6H), 2.76 (d, J = 10.9 Hz, 9H), 2.66 (t, J 
= 6.7 Hz, 6H); HRMS (m/z): [M+3H]
+3
 calcd. for C120H135N24O9S3, 717.66730; found 
717.66860; [M+3Na]
+3
 calcd. for C120H132N24Na3O9S3, 739.64924; found, 739.65048; 
2.3 2.19 2.24
5 
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[M+2H]
+2
 calcd. for C120H134N24O9S3, 1075.99731; found, 1075.99680; 
[M+2Na]
+2
 calcd. for C120H132N24Na2O9S3, 1097.97925; found, 1097.97953.   
2.5.3 Peptide Synthesis  
Peptides were synthesized using standard SPPS protocol. Peptide sub-F was 
synthesized on rink resin (NovaSyn TGR resin) using a peptide synthesizer (CEM 
Liberty Automated Microwave). Peptides KALIC (2.5) and PVDAC (2.6) were 
synthesized with Fmoc-Cys(Trt) Wang resin with a different peptide synthesizer (Prelude 
by Protein Technology, Inc). Coupling reactions used Fmoc-L-amino acid/ 
HBTU/DIPEA (5:5:10 eq) relative to 1 eq. of pre-loaded resin. Peptides were analyzed 
by analytical HPLC (Shimadzu HPLC) equipped with Gemini C18 column (250 X 10 
mm, 5 µm). Solvent A: H2O with 0.1% v/v TFA; solvent B: CH3CN with 0.1% v/v TFA. 
Rate flow: 4 mL/min with an increase gradient 5 to 95% B over 20 min at 220 nm. 
Purified peptides were characterized by mass spectrometry using a either MALDI-TOF 
(Vogayer, PerSeptive Biosystem) or ESI (LCQ, Thermo Finnigan).  
104 
 
 
Peptide Peptide Sequence Mol. Formula 
HPLC 
ret. time 
(min) 
ESI 
[M+H]
+
 
Calcd. 
ESI 
[M+H]
+
 
found 
6 KALIC C24H46N6O6S 12.03 547.3 
 
547.4 
 
7 PVDAC C20H33N5O8S 11.65 504.2 
 
504.2 
 
    
MALDI-
TOF [M]
+
 
Calcd. 
MALDI-
TOF [M]
+
 
found 
Sub-F 
YAEPLTPR 
ILAKWEWPA 
C101H147N23O25 14.20 2082.0938 
 
2082.9874 
 
 
Table 2.4:  HPLC retention time and MS analysis. 
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Figure 2.15: HPLC of peptides. (A) HPLC chromatogram of PVDAC, r.t.=11.65 min (B) 
HPLC chromatogram of KALIC, r.t.= 12.03 min. 
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B 
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Figure 2.16: HPLC and MS analysis of Sub-F peptide. (A) HPLC chromatogram of Sub-
F peptide, r.t.=14.20 min (B) MALDI-TOF of Sub-F peptide obsd m/z= 2159.57, calcd 
2159.34. 
 
 
 
 
 
A 
 
 
 
 
 
 
 
B 
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2.5.4 Phosphorylation of Sub-F Peptide 
Sub-F peptide (166 µM) was phosphorylated using ERK-1 (100 nM), BSA (10 
µg/mL), MgCl2 (12 µM), ATP (2mM), DTT (2 mM) in 30 mL Buffer solution (25mM 
HEPES, 50 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA pH = 7.4) and left overnight at 
37°C. The solution was lyophilized and preparative HPLC was performed using a rate 
flow: 10 mL/min, (A: 0.1% TFA in water; B: 0.1% TFA in acetonitrile). The run started 
at 5% B (over 10 min), increase to 15% B (over 10 min) and followed by a linear 
gradient to 45% B (over 20 min). Analytical results: r.t.=13.56 min and MALDI-TOF 
obsd m/z= 2159.57, calculated 2159.34. 
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Figure 2.17: HPLC and MS analysis of phosphorylated Sub-F peptide. (A) HPLC 
showing retention rime of  r.t. = 13.56 min. (B) MALDI-TOF showing obsd m/z= 
2159.57, calculated 2159.34. 
A 
 
 
 
 
 
 
 
 
 
 
B 
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2.5.5 Experimental Information 
Fluorimeter measurements for all the cuvette assays were done on a PTI fluorimeter 
with an 814 photomultiplier detection system using a 75W xenon short arc lamp at 25°C 
in 50 mM HEPES, 10 mM NaCl buffer, pH=7.4. For all the following titrations, the 
fluorescence spectra were recorded after each addition using the following parameters: 
Temperature: 25 C. Excitation wavelength: 347 nm. Excitation and emission slit width: 4 
nm. Integration time: 0.2 s. Acquisition range: 357-644 nm.  
Indicator displacement assays – Fluorescent titrations between ZnR-10, indicator 2.8, 
and peptides or proteins were done prior to the optimization of the sensing ensemble. A 
solution of 50 mM HEPES, 10 mM NaCl buffer pH = 7.4 was prepared using deionized 
water. The solution was filtered and degassed. Several stock solutions were prepared for 
the following titrations. Receptor R-10 and Zn(NO3)2 were first dissolved  in 1:1 MeOH-
H2O (v/v) and stir for 30 min to give a 583 µM solution of ZnR-10. The receptor solution 
was freeze dried, lyophilized and re-dissolved in HEPES buffer. Indicator stock solution. 
Indicator 2.8was dissolved in HEPES buffer to achieve a concentration of 5 mM.  Peptide 
stock solutions. Sub-F phosphorylated (2.96 mM) and Sub-F non-phosphorylated (2.78 
mM) peptides were dissolved in HEPES buffer, respectively. All stock solutions were 
refrigerated at -20 C. Receptor ZnR-10, indicator 2.8 and peptides were individually 
diluted in HEPES buffer to the correspondent final concentration according to each type 
of titration.  
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Uptake indicator titration – Cuvette assay to study the binding of coumarin indicator 
2.8 to receptor ZnR-10 was performed by successively adding a solution of receptor 
ZnR-10 (250 µM) into 750 µL solution of indicator 2.8 (100 µM) in HEPES Buffer 
using 100 µL Hamilton microsyringe.  
IDA titration of phosphorylated and non- phosphorylated Sub-F peptide – Cuvette 
assays to study peptide interaction with the previous sensing ensemble were performed 
by successively adding concentrated phosphorylated and non- phosphorylated peptide 
solution (1.92 mM p-peptide; 1.92 mM peptide, respectively)  into 160 µL solution of 
ZnR-10 (36.6 µM) and 2.8 (100 µM), in HEPES Buffer using 100 µL Hamilton 
microsyringe. 
IDA titration of phosphorylated and non-phosphorylated kinases – Fluorescent 
titrations between kinases with ZnR-10-indicator in different ratios were done separately 
as follows: 160 µL solution of 36.6 µM ZnR-10 and 50 µM indicator 2.8, or a solution of 
36.6 µM ZnR-10 and 100 µM 2.8 in HEPES buffer, were titrated with a correspondent 
solution of 5 µM phosphorylated or non-phosphorylated kinase p-ERK-1, ERK-1, p-
ERK-2, ERK-2, JNK-1 (which also contained the receptor-indicator complex in HEPES 
buffer) using a 50 µL Hamilton microsyringe. For each ZnR-10-indicator ratio at 
maximum saturation point was chosen as the optimal concentration for the ensemble.  
Sensing ensemble – The fluorescence measurements were taken with a Biotek 
Synergy 2 Multi-Mode Microplate Reader at 25°C in 50 mM HEPES, 10 mM NaCl 
Buffer, pH=7.4. Costar 384-well black polystyrene plates with flat bottom were used for 
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all array experiments. To generate the sensing ensemble, receptors R-9, R-10 and R-11 
were used to create the seven different hosts. The following stock solutions were 
prepared as follow: Individual receptors solutions R-9 (283 µM), R-10 (309 µM), R-11 
(308 µM) were dissolved in 1:1 MeOH/H2O (v/v). Peptides PVDAC (365 µM) and 
KALIC (365 µM), DTT (365 µM) and Zn(NO3)2 (727 µM) were also dissolved in 1:1 
MeOH/H2O (v/v). Indicator 2.8 (365 µM) was dissolved in HEPES buffer. Aliquots of 
receptor, peptide and DTT for a 120X volume were mixed for 1 h at pH=7.6 according to 
Table 2.2. Then, Zn(NO3)2 solution was added according to the number of DPA moieties 
present in each receptor and stirred for 30 min; the final Zn(NO3)2 concentrations were 
114 µM, 155 µM and 213 µM according to each host. Each host solution was freeze 
dried, lyophilized, and reconstituted by addition of HEPES buffer when used for the 
construction of the sensing ensemble.  
Indicator aliquots were added according to the number of bis-Zn(DPA) moieties 
present in each receptor, the final indicator concentrations were 57 µM, 100 µM, and 124 
µM according to each host. Finally, separated aliquots of phosphorylated and non-
phosphorylated kinases ERK-1, ERK-2, JNK-3 and p38γ (4 µM) were added to each set 
of host-indicator solutions (four replicates each).  
The same sensing ensemble shown in Table 2.2 was used for the discrimination of 
HEK293T cell lysates.  Aliquots of cell lysate (6 µL) were added to each set of host-
indicator solutions (four replicates each). Discrimination of cell lysates was obtained at 
total protein concentration according to Table 2.3. The solutions were brought to a 32 µL 
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final volume with HEPES buffer. The well plate reader was blanked with HEPES buffer. 
The 384-well plate were read with a ex filter of 360  10 nm and em filter of 485  10 
nm, using a top 400 mirror. Data collected were analyzed by linear discriminant analysis 
using XLSTAT 2011 software package. 
2.5.6 MAP Kinases and Cell Lysate Expression, Purification and Activation 
Expression, Purification and Activation of Tagless MAP Kinases – Tagless N-
terminal truncated human JNK3α2 (amino acids 39-422 with alanine inserted between 
amino acids 39 and 40, GenBank accession number NM_138982) was expressed, 
purified and activated as described previously.
112,113
 Activated tagless ERK2 (Rattus 
norvegicus mitogen activated protein kinase 1, GenBank accession number NM_053842) 
was expressed, purified and activated as described in Kaoud et al.
114
 Activated ERK1 
were expressed, purified and activated as described in Callaway et al.
115
 p38MAPKγ was 
expressed, purified and activated as described previously.
116,117
 The activated kinases 
were all stored in buffer S [25 mM HEPES (pH 7.5), 50 mM KCl, 0.1 mM EDTA, 0.1 
mM EGTA, 2 mM DTT and 10-20% (v/v) glycerol] at -80 ºC. 
Cell culture – HEK293T cells were maintained in DMEM (Invitrogen) supplemented 
with 10% (v/v) Fetal Bovine Serum (FBS)-US grade (Invitrogen), 2 mM L-glutamine 
(Invitrogen), 100 UmL
-1
 penicillin (Sigma), and 100 gmL
-1
 streptomycin (Sigma).  Cells 
were cultured in a humidified 5% CO2 incubator at 37 °C. Cells were seeded in 10 cm 
plates and incubated till 80-90% confluent and were then treated with anisomycin (50-
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100 nM) (MP Biomedicals) for 30 minutes or 100 ng/ml EGF (MP Biomedicals) for 30 
minutes. For experiments requiring ERK-1 overexpression, the pcDNA3 vector 
containing DNA encoding for WT-ERK1 was transfected into HEK293T cells by 
lipofectamine 2000 (Invitrogen, California, USA) according to the manufacturer’s 
protocol. After 48 hours of transfection, cells were either induced with 100 ng/mL EGF 
for 30 minutes before lysis or lysed without induction. 
Cell lysate preparation and Western blot analysis – HEK293T cell lysates were 
prepared in CytoBuster™ Protein Extraction Reagent (EMD-Biosciences) after washing 
in PBS (Invitrogen).  The lysates were cleared by centrifugation, and ATP was removed 
using an Amicon Ultra-0.5 mL Centrifugal Filter. Bradford analysis (Bio-Rad) was used 
to measure the protein concentration. Lysates containing 60 µg of total protein were 
fractionated by 10% SDS PAGE (Bio-Rad) and transferred to Hybond-P PVDF 
Membrane (GE Healthcare).  Primary antibodies were incubated overnight at 4 ºC using 
the following dilutions; 1:2000 anti-phospho-SAPK/JNK (Thr183/Tyr185) (G9) mouse 
mAb (Cell Signaling Technology); 1:2000 anti-phospho-p44/42 MAPK (ERK1/2) 
(Thr202/Tyr204) (E10) mouse mAb (Cell Signaling Technology); 1:10,000 anti-
phospho-p38α (Thr180/Tyr182), clone 8.78.8 rabbit mAb (Millipore); 1:1000 anti-p44/42 
MAPK (Erk1/2) (137F5) rabbit mAb (Cell Signaling Technology); 1:200 anti JNK (D2) 
mouse mAb (Santa Cruz Biotechnology); and 1:5000 anti-actin, clone 4 mouse mAb 
(Millipore). Either anti-rabbit (Bio-Rad) or anti-mouse (Bio-Rad) horseradish peroxidase-
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conjugated secondary antibodies and Pierce
®
 ECL Western Blotting Reagents (Pierce) 
were used to develop the blots. 
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2.5.7 Supplementary Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.18: Addition of active and inactive ERK-1 to indicator-ZnR-10 complex. 
Increase in the fluorescence intensity due to displacement of the coumarin indicator. (A) 
Addition of phosphorylated ERK-1 (0 – 3.8 µM p-ERK-1) to ZnR-10 (36.6 µM) and 2.8 
(50 µM) in 50 mM HEPES Buffer, 10 mM NaCl pH=7.4, ex 347 nm. (B) Addition of 
non-phosphorylated ERK-1 (0 – 3.8 µM ERK-1) to ZnR-10 (36.6 µM) and 2.8 (50 µM) 
in HEPES Buffer, 10 mM NaCl pH=7.4, ex 347 nm. (C) Binding curves of data in 
Figures 2.15A and 2.15B measured at em = 475 nm, respectively. 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
C 
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Figure 2.19: Addition of active and inactive ERK-2 to indicator-ZnR-10 complex. 
Increase in the fluorescence intensity due to displacement of the coumarin indicator. (A) 
Addition of phosphorylated ERK-1 (0 – 3.8 µM p-ERK-2) to ZnR-10 (36.6 µM) and 2.8 
(50 µM) in 50 mM HEPES Buffer, 10 mM NaCl pH=7.4, ex 347 nm. (B) Addition of 
non-phosphorylated ERK-2 (0 – 3.8 µM ERK-1) to ZnR-10 (36.6 µM) and 2.8 (50 µM) 
in HEPES Buffer, 10 mM NaCl pH=7.4, ex 347 nm. (C) Binding curves of data in 
Figures 2.16A and 2.16B measured at em = 475 nm, respectively. 
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B 
C 
117 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.20: Addition of JNK-3 to indicator-ZnR-10 complex. Addition of non-
phosphorylated JNK-3  (0 – 3.8 µM p-ERK-2) to ZnR-10 (36.6 µM) and 2.8 (100 µM) in 
50 mM HEPES Buffer, 10 mM NaCl pH=7.4, ex 347 nm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.21: Control experiment. Addition of HEPES buffer to ZnR-10 (36.6 µM) and 
2.8 (100 µM) in 50 mM HEPES Buffer, 10 mM NaCl pH=7.4, ex 347 nm. 
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Chapter 3: Peptide-Based Sensors for the Differential Sensing and 
Quantification of MAP Kinases 
3.1 INTRODUCTION 
The MAPK family that was described in Chapter 1 showed a high degree of similarity 
in their genome sequence. Interestingly, some members of this family such as ERK2, 
JNK1 and p38α share about 40 to 50% of sequence identity at the amino acid level.118 
The same protein surface of cognate MAPKs interacts with upstream activators and 
downstream substrates previously described in Chapter 1. These MAPK activators and 
protein substrates are recognized by either the catalytic site or by recruitment sites. These 
additional protein sites convey critical specificity for protein interactions, defining 
signaling events of MAPK pathways. Recently, researchers have mainly focused on the 
utility of these recruitment sites to develop new biosensors and detection methods to 
assess kinase activity. These methods can potentially be used to regulate cellular 
signaling pathways in MAPKs by developing new small molecule inhibitors targeting 
these sites. A kinase sensing system which can selectively target a variety of MAPKs 
with a low limit of detection under physiological conditions is quite challenging to 
design. The system must be capable of distinguishing from MAPKs from other kinases. 
Herein, we report a new sensing system which will present differential binding for 
MAPK sub-families and isoforms under physiological conditions, where the recruitment 
sites of these proteins are exploited for MAPK detection in solution. 
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3.2 DOCKING DOMAINS IN MAP KINASES 
Members of the MAPK cascade share linear motifs that are responsible for the 
specificity between MAP kinases, upstream kinases and downstream substrates. This type 
of interaction is referred to as docking for kinases and phosphatases. Thus, the docking 
interactions of MAPKs with substrates or ligands occur between modular docking 
sequences in the substrate and complementary recruitment sites of the kinase. The 
binding surface of the recruitment sites is separated and distal to the phosphorylation site. 
The docking interaction refers to the complementarity of the electrostatic or hydrophobic 
interactions between a protein kinase and its corresponding partner. Substrates contain 
docking motifs that are recognized as small peptide sequences with few charged and 
hydrophobic residues.
119
  
3.2.1 MAPK Substrates 
MAPK substrates present two binding sites in their sequence: a consensus 
phosphorylation motif and a docking site which is mainly responsible for the wide-
ranging selectivity and affinity towards MAPK sub-families (Figure 3.1). MAPKs 
catalyze the phosphorylation of substrates that contain serine/threonine residues that are 
directly linked to the proline on the carboxyl terminus. This consensus PX(S/T)-P motif 
is essential for the substrate in order to be phosphorylated by the catalytic site of MAPKs. 
In addition, MAPKs recognize substrates that contain modular peptide sequences called 
docking sites which are known as D-site and F-site. The D-sites are the most studied 
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docking domains, which are also referred as D-motifs, D-domains, DEJL motifs or kinase 
interaction motifs (KIM). The D-motifs are located in the N-terminus to the conserved 
Ser/Thr-Pro phosphorylation site. The D-site consists of a cluster of basic residues, a 
small peptide sequence that acts as a linker followed by a second nearby cluster of 
hydrophobic residues.
119
 The second docking domain also known as DEF domain or F-
site presents a characteristic Ψ(X/Ψ)P sequence, where Ψ is an aromatic residue. The F-
site has been found in transcription factors (ERK and p38α substrates) and phosphatases. 
This docking sequence can access and interact with its corresponding kinase pocket only 
when conformational changes have taken place upon phosphorylation.
120
 
 
 
 
Figure 3.1: MAPK substrates. Graphic representation of the different types of MAPK 
substrates presenting two different binding sites, a phosphorylation site and a distal 
docking site. (A) The D-site is positioned on the N-terminus of the peptide. (B) The F-
site is found on the C-terminus of the peptide substrate. 
 
A 
 
 
 
 
 
 
 
B 
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3.2.2 MAPK Recruitment Sites 
Most MAP kinases present two recruitment sites in their structure (Figure 3.2). 
The first one is called the D-motif or D-recruitment site (DRS). It is established that the 
DRS is an evolutionarily conserved domain among all MAP kinases of different species. 
This site is the main source of specificity that distinguishes the different subfamilies of 
MAP kinases. This domain is found on the rear face of the protein, and it is located in the 
C-terminal region. This region is formed by the common docking domain (CD domain), 
and the docking groove (ED site) which are constituted by hydrophobic residues. The CD 
domain resides in a cluster of negatively charged residues (Asp-316 and Asp-319) to 
which hydrophobic and basic residues bind. The ED site has been considered as a 
potential hydrophobic pocket for drug discovery since this site is considerably different 
among MAP kinases.
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The second recruitment site in MAPKS is called the F-recruitment site (FRS) or 
FXFP binding site. The FRS is located near the MAP kinase active site and helix G. This 
site is constituted of hydrophobic residues such as Leu-198, Tyr-231, Leu-232, Leu-235, 
Ala-258 and Tyr-261, forming a hydrophobic pocket with a preference for hydrophobic 
residues. Zhang and co-workers have shown that inactive ERK2 has the FRS occupied 
with residues Phe-181 and Leu-182 which are situated in the activation loop. Upon 
phosphorylation of ERK2, conformational changes cause activation loop reorientation 
and its exit from FRS; thereby, the FXFP motif is exposed and F-site substrates can 
interact with the active ERK2.
122
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Most ERKs, JNKs and p38 substrates present the D-site. Thus, drug discovery on 
MAP kinase has focused on the development of non-ATP competitive inhibitors since the 
goal is to target binding sites that exploit the differences on the docking domains instead 
of targeting the ATP binding site by traditional inhibitors. More recently, computational 
biology studies and screening of substrate peptide libraries have been implemented based 
on the modifications of these docking domains to find more non-ATP competitive 
inhibitors.
123
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Figure 3.2: Structure of ERK2 (PDB: 2ERK) showing binding sites. Helices are shown in 
light blue, β-strands are shown in magenta and loops are shown in pink. The D-
recruitment site encompasses the common-docking domain (green) and two hydrophobic 
surface areas. The F-recruitment site (orange) is a hydrophobic pocket with a preference 
for aromatic residues. The ATP binding site is specified in red. The binding site for 
substrate with Ser/Thr-Pro motif is indicated in black. 
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3.3 PREVIOUS STUDIES OF MAPK DOCKING SITES 
3.3.1 Modular-Peptide MAPK Substrates  
Recently, the docking sites of MAPKs and their mechanism of binding have been 
the subject of medicinal chemists. Dalby and co-workers used ERK2 as a MAPK model 
to evaluate the docking interactions of peptide ligands.
124
 The interactions between 
modular docking sequences and the recruitments sites of ERK2 were evaluated using 
both computational modeling and experimental studies with designed peptides. Two 
different peptide ligands, Lig-D and Lig-F were synthesized using standard Fmoc-peptide 
synthesis. Lig-D (FQRKTLQRRNLKGLNLNL) was found to bind the DRS of ERK2. 
Kinetic studies were performed to study the mechanism of inhibition by Lig-D. The 
activity of ERK2 was partially inhibited in the presence of Lig-D, decreasing the ability 
of ERK2 to phosphorylate Ets-1 (residues 1-138) which is an endogenous protein 
substrate. Lig-F (YAPRAPAKLAFQFPSR) was found to bind to the hydrophobic pocket 
of FRS. In contrast, Ets-1 was not phosphorylated by ERK2 in the presence of Lig-F, 
showing a mechanism of competitive inhibition.  
In further studies, different modular peptides to target ERK2 were developed 
based on the previous design, improving the binding interactions of the peptide ligands.
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The Sub-D peptide (QRKTLQRRNLKGLNLNL-XXX-TGPLSPGPF) was modified by 
adding a linker and a phosphorylation site to the previous peptide ligand. Sub-D peptide 
was generated by attaching the C-terminus of the original Lig-D sequence to a flexible 
linker (X = 6-amino-hexanoic acid), which was also connected to the TGPLSPGPF 
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sequence (Figure 3.3). The consensus phosphorylation site of Sub-F peptide 
(YAEPLTPRILAKWEWPA) derived from Lig-F, where the conventional FSFG 
sequence was changed to the WEWP modular docking site.  
 
 
 
Figure 3.3: General mechanism of substrate recognition by ERK2 reported by Dalby et 
al. Schematic representation of the binding interactions between ERK2 and peptide 
substrates with different docking sites. (A) Sub-D peptide is recognized by the DRS of 
ERK2, catalyzing the phosphorylation reaction of the amino acid Ser. Sub-F is 
recognized by the FRS in ERK, catalyzing the phosphorylation reaction of Thr residue. 
(B) Sub-D and Sub-F peptide sequences showing the consensus phosphorylation site, and 
the D-site and F-site, respectively.  
 
A 
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Peptide sequences Sub-D and Sub-F were studied using computational modeling. 
The peptide sequences were virtually constructed and modeled on the surface of ERK2 
(Figure 3.4). The D-site of the Sub-D peptide presented good docking interactions with 
the DRS of ERK2. A hydrophobic surface pathway was also found along the surface of 
ERK2 where the flexible linker can properly interact. The WXWP motif of Sub-F peptide 
was effectively recognized by the characteristic hydrophobic pocket of the FRS of ERK2. 
In further application-based studies, kinetic analysis was performed by measuring initial 
rates of the phosphorylation reaction of sub-D and sub-F substrates with ERK2, using a 
radioactive assay. Kinetic parameters kcat/Km 6 x 10
6
 M
-1 
s
-1 
and 2 x 10
6
 M
-1 
s
-1 
were 
calculated for Sub-D and Sub-F, respectively. Both peptides were found to be 
phosphorylated with the same efficiency (6 x 10
6
 M
-1 
s
-1
) compared to the Ets-1 substrate. 
In addition, the Lig-F was tested as a competitive substrate in the presence of either Sub-
D or Sub-F to study allosteric mechanisms. Sub-D was completely phosphorylated by 
ERK2 in the presence of Lig-F. In contrast, Sub-F peptide was inhibited by the presence 
of Lig-F. Presumably, the FRS can be used as a drug discovery target for substrate-
selective inhibition, where Sub-F peptide could be used for the evaluation of non-ATP 
competitive inhibitors. These kinetic studies demonstrated that the catalytic activity of 
ERK2 is not affected by docking peptides that interact with either the FRS or the DRS.  
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Figure 3.4: Molecular models of Sub-D and Sub-F peptides bound to ERK2 from Dalby 
et al. (A) Sub-D is interacting with the D-recruitment site of ERK2. (B) Sub-F is bound 
to the F-recruitment site. (Reproduced from Ref. 8. © American Chemical Society, 
2011.)  
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3.3.2 Highly Selective Peptide Sensor 
A highly selective SOX-peptide sensor was synthesized by Imperiali and co-
workers
125
 to study the kinase activity of p38α. Peptide MEF2A-CSox (3.1) was designed 
based on the docking sites of the p38 sub-family. The peptide sensor contained two 
different modules; the first one had a peptide sequence that was highly selective for the 
docking sites on p38α. A PEG-linker was used to attach the second module which 
contained a small sequence including a cysteine residue functionalized with the SOX 
fluorophore to target the phosphorylation site. The SOX fluorophore was correctly placed 
in close proximity to the phosphorylation site, enhancing the fluorescence signal upon 
phosphorylation in the presence of Mg
2+ 
ions.  The initial rate of phosphorylation of 3.1 
was measured in the presence of p38α and other MAP kinases, showing high selectivity 
for p38α over p38 isoforms and the remaining kinases. Further studies by the same group 
relied on the use of 3.1 in an assay with HeLa cell lysates. These studies used the broad 
spectrum staurosporine inhibitor to reduce the background signal from other kinases, 
increasing the fluorescent signal of p38α activity. Inhibitors of p38α were subsequently 
added to the cell lysates, reducing the rate of phosphorylation of 3.1. In additional 
application-based studies by this group, peptide 3.1 was found to report kinase activity of 
p38α in different cell lines. The activity of each cell line was corroborated with Western 
blot analysis, assessing for p38α levels in different cellular environments. These studies 
demonstrated the ability of peptide sensor 3.1 to measure p38α kinase activity using a 
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CHEF mechanism upon phosphorylation, detecting changes in the rate of 
phosphorylation in vitro and in cell lysates. 
 
 
3.4 MAPK DETECTION WITH A PEPTIDE-BASED SENSING ARRAY 
The development of biosensors with high specificity is one of the major challenges in 
the field of kinase analysis. In nature, closely related substrates will be phosphorylated by 
several kinases. Experimental assays where the radioactive γ-phosphoryl unit from ATP 
is transferred to a substrate have been applied to study kinase activity. Western blot 
analysis with highly specific antibodies is still the primary technique used to quantify 
kinases. However, these methods can be time-consuming and expensive. This lock-and-
key model has been difficult to follow in the case of peptide-based sensors which lack the 
specificity of docking sites of protein substrates. An additional challenge is the 
implementation of high-throughput screening to measure altered kinase activity. To 
overcome this problem, the differential sensing method can enable the detection and 
differentiation of closely related MAP kinases. Herein, a cross-reactive library of 
 3.1 
130 
 
fluorescent peptides was used to detect and differentiate a wide variety of MAPK 
isoforms; including ERK1/2, JNK1/2/3 and p38α/β/δ/γ. Changes of kinase concentrations 
were also semi quantitatively detected using this array sensing approach which 
discriminating characteristics originated from the recruitment sites of these peptides.  
3.4.1 Choosing Peptide Substrates for an Array 
Protein substrates are generally difficult to produce in large scale. Thus, peptides 
can be used as surrogates, simplifying the synthesis and assay assembly. At the structural 
level, most MAPK substrates incorporate a consensus phosphorylation motif and a 
docking site in their sequence to be recognized by a variety of MAPKs. Therefore, we 
followed the leading approach of Dalby by synthesizing modular peptides that contain 
docking sites. A variety of peptides with distinctive docking sites that presented different 
affinities and selectivity were thoroughly chosen to develop a library of peptide 
biosensors (Figure 3.5). The following five MAPK peptide substrates Sub-D (3.2), 
MEF2A (3.3), NFAT4 (3.4), Sub-F (3.5) and p38 (3.6) presented cross-reactive 
characteristics to target a wide range of nine different MAPKs. The differential binding 
strategy consisted of selecting two peptides (Sub-D, MEF2A) with high degrees of 
affinity towards most MAPK sub-families, including isoforms. Peptide sub-F showed 
moderate affinity and selectivity for most MAPKs. The remaining two peptides NFAT4 
and p38 exhibited higher selectivity towards JNK and p38 sub-families, respectively. 
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Figure 3.5: Schematic representation of five MAPK peptide substrates. Sub-D, MEF2A 
and NFAT4 peptides contain the D-site which is highlighted in red, and consensus 
phosphorylation motif with a serine residue. The D-site and phosphorylation site are 
attached by three 6-aminohexanoic acid groups in Sub-D and MEF2A peptides. Sub-F 
and p38 peptides contain the F-site which is highlighted in red, and consensus 
phosphorylation motif with a threonine residue. 
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3.4.1.1 Sub-D and Sub-F peptides  
 
In the aforementioned study by Dalby and co-workers, ERK2 was recognized by 
Sub-D and Sub-F peptides with high specificity. Therefore, the modular peptides Sub-D 
(3.2) and Sub-F (3.5) reported were chosen due to their ability of recognizing the D-
recruitment site and the F-recruitment site, respectively. The D-recruitment site has been 
recognized in ERK, JNK and p38 kinases, thus it is expected that peptide Sub-D will be 
phosphorylated by most MAPKs in this study. Furthermore, the F- site has been mainly 
identified in ERK substrates. Moderate affinity is then expected towards JNK and p38 
sub-families.   
3.4.1.2 MEF2A and NFAT4 peptides 
Recently, Albrecht and co-workers synthesized several docking peptides to study 
the specificity of linear motifs in known MAPK peptide substrates.
126
 These peptides 
were diversified by varying the region lengths and structural sequence, enhancing the 
specificity of the D-motif. Particularly, peptides MEF2A (myocyte enhancer factor 2A) 
and NFAT4 (nuclear factor of activated T cells 4) were included in this study to monitor 
the binding to ERK2, p38α and JNK1 using fluorescence polarization studies. Both 
peptides were divided in two different categories according to their binding affinities. 
MEF2A peptide was first categorized as a peptide with certain selectivity for ERK and 
p38. Presumably, signaling activation in cells occurs upon phosphorylation of Thr312 
and Thr319 residues by ERK2 and p38α. Interestingly, the D-motif of MEF2A peptide 
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was recognized by both MAPKs. SDS-polyacrylamide gel electrophoresis analysis 
showed modest discrimination in the binding affinity of MEF2A towards ERK and p38 
(Figure 3.6).  
The second category was formed by peptides with high specificity for JNK. 
NFAT4 docking peptide was derived from a JNK substrate. Residues Ser163 and Ser165 
located in the target site of NFAT4 peptide were only phosphorylated by JNK1 (Figure 
3.6). Computational models and X-ray crystallography analysis supported charge 
distribution and structural differences between the surface of JNK docking-site and 
ERK/p38 surfaces. Interestingly, a charge inversion was found in the D-recruitment site 
of JNK where a positively charged Lys83 residue is located, whereas both ERK2 and 
p38α DRS contained a negatively charged Glu residue in the corresponding position. 
Additionally, the linkage region of NFAT4 is shorter compared to that on MEF2A. Thus, 
the interactions of long peptide substrates were less compatible with the narrower D-
docking site on JNK.        
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Figure 3.6: SDS-polyacrylamide gel electrophoresis analysis by Albrecht et al. (A) 
MEF2A docking peptide showing the D-motif and target site which are connected by a 
long sequence of 31 residues. (B) NFAT4 docking peptide presenting the D-motif in 
close proximity to the phosphorylation site. (C) Gel analysis showing dual selectivity of 
p38α and ERK2 for MEF2A peptide. NFAT4 is phosphorylated only JNK1, showing 
high specificity. (Reproduced from Ref. 10. © Science, 2012.)  
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According to the aforementioned studies, MEF2A peptide was chosen to be part 
of the differential array of peptides, where MEF2A was expected to bind to ERK and p38 
sub-families. The full peptide sequence of MEF2A is shown in Figure 3.7, where the 
target site and the D-motif are connected by a large linkage region of 31 residues, which 
mainly present negative charge and hydrophilic characteristics. However, this peptide 
required a difficult synthesis procedure due to the long peptide sequence. To alleviate this 
synthetic effort, the D-motif was the only docking site that was retained from the original 
MEF2A peptide, whereas the consensus motif and linkage region were modified for this 
study. The phosphorylation site (TPVVSVTTPS) of the original sequence of MEF2A was 
substituted with the same target site used by Sub-D (TGPLSPGPF) which was 
successfully recognized by ERK2.
124
 This target site contained the Thr-Pro motif, which 
was incorporated in the docking peptides modeled by Dalby et al.
94
 The flexible linker 6-
amino-hexanoic acid was included (previously used for Sub-D), substituting the original 
31 residues of the connection region. Thus the new MEF2A peptide (3.3) was expected to 
be recognized by the catalytic site and the D-recruitment sites of ERK and p38 MAPKs.   
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Figure 3.7: Schematic representation of original MEF2A peptide sequence and MEF2A-
modified peptide. (A) MEF2A docking peptide showing the D-motif and phosphorylation 
site which are connected by a long sequence of 31 residues reported by Albrecht et al. 
(B) New MEF2A docking peptide (3.3) presenting the D-motif from the original 
sequence. The phosphorylation site (TGPLSPGPF) and the linker were incorporated from 
the Sub-D peptide model reported by Dalby et al. 
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Additionally, NFAT4 peptide (3.4) was chosen as a very selective member of the 
library of peptide sensors. The linkage region of NFAT4 peptide was only composed of 7 
residues. Therefore, NFAT4 peptide was synthesized using the original peptide sequence 
reported by the Albrecht group. This NFAT4 peptide sequence contains a different D-
motif, and a different consensus phosphorylation site compared to Sub-D and MEF2A 
binding sites. Thus, NFAT4 (3.4) was expected to be recognized by the catalytic site and 
the D-recruitment site of JNK isoforms. 
3.4.1.3 p38 Peptide 
Pazhanisamy and co-workers studied the activity of p38α with modified peptide 
substrates that contain a different consensus motif.
127
 A peptidic fragment of EGF 
(endothelial growth factor) protein 3.7a was chosen as an endogenous substrate to study 
the kinetic mechanism of p38α-catalyzed reaction in the presence of other competitive 
peptides. The kinase reaction was measured by HPLC analysis or using spectrometric 
coupled-enzyme experiments. A set of synthetic substrates 3.7b-e were designed with 
different PX(S/T) consensus motifs. Each synthetic peptide contained either a threonine, 
serine, or tyrosine residue located in a different position and linked to proline. The EGF 
peptide was phosphorylated on Thr669, reporting a Km of 840 µM and a kcat of 22.6 s
-1
. 
Peptide 3.7b was found to have a similar kcat compared to 3.7a, and a Km value 8-fold 
lower than that for 3.7a. The Ser residue next to Pro in 3.7a was replaced with Thr and 
Tyr residues in peptides 3.7c and 3.7d, respectively. Interestingly, peptides 3.7b and 3.7c 
which contained Ser and Thr at position -1 to Pro were equally phosphorylated, while no 
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phosphorylation event was observed for 3.7d which contained Tyr. Additionally, peptide 
3.7c was found to present a Km value 17-fold lower than that for 3.7a and a kcat of 8.4 s
-1
. 
The Pro residue in peptide 3.7b was substituted with Ala in peptide 3.7e, reducing the 
specific activity although the Km was not signficantly altered.   
 
 
 
 
 
 
 
This study highlighted two important characteristics for kinase reactions catalyzed 
by p38α. (1) Peptides with Ser and Thr residues next to Pro were specifically 
phosphorylated while no phosphorylation of Tyr was observed in these substrates. (2) 
The phosphorylation of substrates was not affected by replacing Pro for another 
hydrophobic residue next to the phosphorylation site. From these studies, peptide 3.7c 
was chosen as a very selective member for the library of cross-reactive peptide sensors. 
a:  Lys-Arg-Glu-Leu-Val-Glu-Pro-Leu-pThr-Pro-Ser-Gly-Glu-Ala-Pro 
     Asn-Gln-Ala-Leu-Leu-Arg 
b:  Ile-Pro-Thr-pSer-Pro-Ile-Thr-Thr-Thr-Tyr-Phe-Phe-Phe-Lys-Lys-Lys 
c:  Ile-Pro-Thr-pThr-Pro-Ile-Thr-Thr-Thr-Tyr-Phe-Phe-Phe-Lys-Lys-Lys 
d:  Ile-Pro-Thr-Tyr-Pro-Ile-Thr-Thr-Thr-Tyr-Phe-Phe-Phe-Lys-Lys-Lys  
e:  Ile-Ala-Thr-pSer-Pro-Ile-Thr-Thr-Thr-Tyr-Phe-Phe-Phe-Lys-Lys-Lys  
                  3.7 
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3.4.2 Design of Fluorescent Peptides 
Fluorescent peptide-based biosensors are rapidly developing as powerful 
biological tools to measure kinase activity, as described in Chapter 1. These biosensors 
display fluorescence changes upon phosphorylation, allowing for a continuous readout in 
real time. Fluorescent kinase assays can be designed in a high-throughput mode to 
concomitantly measure kinetic parameters of several protein targets in vitro. Thereby, the 
approach of the Imperiali group was followed by synthesizing SOX-Br 3.14. 
Additionally, the Cys residue was incorporated in close proximity to the phosphorylation 
site. Finally, the Cys residue was then functionalized by attaching the SOX fluorophore 
through an alkylation reaction, creating the new docking peptides SOX-Sub-D (3.15), 
SOX-MEF2A (3.16), SOX-NFAT4 (3.17), SOX-Sub-F (3.18) and SOX-p38 (3.19).  
 
3.4.2.1 Synthesis of Sulfonamido-Oxine (SOX) Fluorophore 
The fluorophore SOX-Br 3.14 was synthesized through literature procedure with 
some modifications (Scheme 3.1).
128,129
 To begin, 2-methylquinolin-8-ol (3.8) was 
obtained commercially. Sulfonation of 3.8 with chlorosulfonic acid yielded compound 
3.9, which was used as a crude material for the subsequent reaction. Sulfonamide 3.10 
was obtained by treatment of 3.9 and dimethylamine as reported. Compound 3.10 was 
allowed to react with tert-butyldiphenylsilyl chloride to protect the phenolic hydroxyl 
group on sulfonamide 3.11. The yield of this reaction was improved by purification of the 
product through recrystallization with a mixture of methanol and dichloromethane rather 
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than flash chromatography which produced product decomposition according to previous 
reports. The following two steps which included oxidation to the aldehyde with selenium 
dioxide and reduction of the aldehyde to alcohol with sodium borohydride were 
performed without purification of the intermediate product. The resulting crude material 
3.13 was allowed to react with carbon tetrabromide and triphenylphosphine to yield 
product SOX-Br 3.14. 
 
 
 
Scheme 3.1: Synthesis of 3.14 
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3.4.2.2 Peptide Functionalization with SOX Fluorophore 
The selected modular peptides Sub-D (3.2), MEF2A (3.3), NFAT4 (3.4), Sub-F 
(3.5) and p38 (3.6) were synthesized using standard Fmoc-based solid phase peptide 
synthesis (SPPS). In the aforementioned studies, Imperiali et al. showed that a Cys 
residue on peptide MEF2A can be easily modified by alkylation with the SOX 
fluorophore.
125
 This method was used to install a Cys(Mmt) residue at the P+2 or P-2 
position to the phosphorylation site of each peptide as shown in Scheme 3.2.   
 
 
 
Scheme 3.2: Deprotection reaction of Mmt group and alkylation of cysteine residue with 
3.14. 
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A selective deprotection of the Cys residue was achieved by cleaving the p-
methoxytrityl (Mmt) protecting group with a diluted solution of trifluoroacetic acid 
(TFA) in the presence of triisopropylsilane (TIPS) which was used as a scavenger for 
Mmt cations. The tert-butyl protecting groups on hydroxyl groups were stable under 
these mild acidic conditions. The alkylation reaction of the Cys residue with SOX-Br 
3.14 yielded the desired resin-bound SOX-peptides. The remaining side chains were 
deprotected using standard cleaving conditions. The SOX-peptides were cleaved from the 
resin and purified with preparative HPLC, resulting in the modular SOX peptides Sub-D 
(3.15), MEF2A (3.16), NFAT4 (3.17), Sub-F (3.18) and p38 (3.19) shown in Scheme 
3.3. 
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Scheme 3.3: Schematic representation of modular SOX-peptides. 
3.15 
3.16 
3.17 
3.18 
 
3.19 
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3.4.3 Rate Equations for First-Order Phosphorylation Reactions 
Continuous fluorescent changes of modular peptides Sub-D (3.15), MEF2A (3.16), 
NFAT4 (3.17), Sub-F (3.18) and p38 (3.19) were detected upon phosphorylation with in 
vitro kinases at nanomolar concentrations. Nine isoforms of MAP kinase groups ERK1/2, 
JNK1/2/3 and p38α/β/γ/δ were added in vitro to each SOX-peptide substrate. The 
phosphorylation reaction was carried out in the presence of ATP and Mg
2+ 
to allow for 
the chelation enhanced fluorescence mechanism. First-order rates of fluorescence 
increase of SOX-peptide versus time were measured using the method of pre-steady state 
kinetics. The rate constants were initially analyzed by software curve fitting Igor Pro 
6.04.  The rate law equations for the first-order phosphorylation reaction of each SOX-
peptide in the presence of individual MAPKs are described in Scheme 3.4. The 
concentration of B at time t or  is related to the final concentration of B,  by 
Equation 3.1. The fluorescence of the product ( ) or phosphorylated SOX-peptide 
is directly proportional to [B]. In addition, the fluorescence of the product is also defined 
by the total fluorescence at time t ( ) and the initial fluorescence of the substrate ). 
Thus, the fluorescence of the product at any time is defined by Equation 3.3 which is 
obtained by substitution of Equation 3.2 into [B] of Equation 3.1. Finally, fluorescence 
as a function of time can be plotted using Equation 3.4 which was derived from 
Equation 3.3, reducing the number of variables. The parameters used in the final 
Equation 3.4 are described as follows: , fluorescence as a function of time; , 
fluorescence of the product; , initial fluorescence of the peptide substrate; , observed 
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rate constant; t, time. Thereby, the rate constant was obtained using Equation 3.4 in the 
curve fitting program.  
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Scheme 3.4: Schematic representation of fluorescence changes upon phosphorylation of 
SOX-peptides. Parameters in Equation 3.4:  , fluorescence as a function of time; , 
fluorescence of the product; , initial fluorescence of the peptide substrate; , observed 
rate constant; t, time. 
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3.5 PRELIMINARY SENSING ARRAY 
3.5.1 Sensing Ensemble 
A preliminary fluorescence kinase assay was performed to investigate whether an 
increase of the fluorescent signal would be measurable at 2 µM SOX-peptide 
concentration. A 96-well plate was prepared using the five SOX-peptides as 
discriminating variables. The nine MAPK analytes were added to the corresponding well 
to obtain the following final concentrations ERK1/2 (2 nM), JNK1/2/3 (20 nM) and 
p38α/β/γ/δ (10 nM). The general layout of the sensing ensemble for all SOX-peptides is 
shown in Figure 3.8, presenting the different volumes (µL) of kinase stock solutions, 
peptide stock solution and ATP added to each well. The kinase solution contained the 
corresponding MAP kinase in the presence of DTT (2 mM) and BSA (2.5 µg/mL) for 
kinase stabilization. The fluorescence intensity of the SOX-peptide was enhanced in the 
presence of MgCl2 (5 mM) in HEPES buffer. The ATP solution (5 mM) was the last 
aliquot added to each well, triggering the phosphorylation reaction. Five SOX-peptides, 
nine MAP kinases and four repetitions were included in this preliminary sensing array.  
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Figure 3.8: Schematic representation of the sensing ensemble. Sensing array for the 
detection of nine MAP kinases: ERK1/2 (2 nM); JNK1/2/3 (20 nM); p38α/β/γ/δ (10 nM) 
with SOX-Sub-D peptide (2 µM). 
 
3.5.2 Analyzing Rates of Phosphorylation 
 
A continuous increase in the fluorescence intensity over 10 min was observed 
upon phosphorylation of the SOX-peptides. Changes in the emission data at 485  10 nm 
of each SOX-peptide at pH = 7.4 upon addition of each MAP kinase were recorded using 
a microplate reader (Biotek Synergy 2). The observed fluorescence intensity against time 
was plotted for each MAP kinase and its corresponding SOX-peptide, including four 
repetitions for each kinase as shown in Figure 3.9 for SOX-Sub-D and Figure 3.10 for 
SOX-NFAT4. The fluorescence increase from the phosphorylated SOX-peptides was 
sensitive enough to be detected at the given concentrations. The resulting kinetic 
experiments showed that SOX-Sub-D peptide was efficiently phosphorylated by all the 
different MAPKs groups. In addition, SOX-MEF2A peptide was phosphorylated by most 
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MAPK sub-families to different extents (see supplementary material Figure 3.38 and 
3.39), showing a notable preference from ERK1/2 and the p38 isoforms. Remarkably, 
ERK1 was found to phosphorylate SOX-Sub-F with higher efficiency compared to ERK2 
(supplementary information Figure 3.40 and 3.41). Furthermore, isoforms p38α/γ/δ 
were also found to phosphorylate SOX-Sub-F. However, no fluorescence increase of 
SOX-Sub-F was observed in the presence of the JNK sub-family. As estimated from the 
substrate specificity of NFAT4, the SOX-NFAT4 peptide showed remarkably selectivity 
towards the JNK group. Interestingly, SOX-NFAT4 peptide was also phosphorylated by 
p38β, showing a higher phosphorylation efficiency compared to JNK1 and JNK3.  
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Figure 3.9: Fit curves of the fluorescence changes of SOX-Sub-D peptide upon 
phosphorylation with six different MAPKs. Data collected with 96-well plate half volume, 
plate reader with ex filter of 360  10 nm and em filter of 485  10 nm, using a top 400 
mirror. Kinase concentrations: ERK1/2 (2 nM), JNK1/2/3 (20 nM) and p38α/β/γ/δ (10 
nM) with SOX-peptide (2 µM). Assay buffer:  (25mM HEPES, 50mM KCl, 0.1 mM 
EDTA, 0.1 mM EGTA pH 7.4) with 2 mM DTT, 2.5 µg/mL BSA, 5mM MgCl2, 500 µM 
ATP at 25 . 
JNK3 
p38δ 
ERK1 
p38γ 
JNK1 
ERK2 
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Figure 3.10: Fit curves of the fluorescence changes of SOX-NFAT4 peptide upon 
phosphorylation with six different MAPKs. Data collected with 96-well plate half area, 
plate reader with ex filter of 360  10 nm and em filter of 485  10 nm, using a top 400 
mirror. Kinase concentrations: ERK1/2 (2 nM), JNK1/2/3 (20 nM) and p38α/β/γ/δ (10 
nM) with SOX-peptide (2 µM). Assay buffer:  (25mM HEPES, 50mM KCl, 0.1 mM 
EDTA, 0.1 mM EGTA pH 7.4) with 2 mM DTT, 2.5 µg/mL BSA, 5mM MgCl2, 500 µM 
ATP at 25 . 
JNK3 
ERK2 ERK1 
JNK2 
p38β 
JNK1 
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3.5.3 Fingerprint of Nine MAPKs 
 
From these results, it was clearly observed that the rate of phosphorylation is 
different for each SOX-peptide depending on the MAPK that was used. A total of 180 
rate constants were obtained from the phosphorylation of each SOX-peptide using the 
curve fitting program. The rate constants were used as input data to perform linear 
discriminant analysis (LDA) using the program XLSTAT. The SOX-peptides were used 
as discriminatory variables against MAPK analytes. The following LDA plot (Figure 
3.11A) was obtained using this sensing ensemble. The discriminatory properties of the 
SOX-peptides showed excellent differentiation of the nine MAPK kinase groups with 
62.2% of the variance along the F1 axes, and 28.17% of the variance along the F2 axes. 
The nine MAPK groups were correctly classified into respective sets with 100% accuracy 
according to the jack-knife analysis. Each of the MAPK isoforms was classified into their 
corresponding sub-family group. The JNK group is located on the right side of the LDA 
plot, whereas the ERK and p38 subfamilies are located on the left side. In addition, ERK1 
and ERK2 are distinctly located in the top left quadrant along with p38α and p38δ, while 
the other isoforms p38β and p38γ are located in the bottom left quadrant. The 
corresponding loading plot (Figure 3.11B) was generated along with the LDA plot, 
showing the contribution of each SOX-peptide to the differentiation of the nine MAP 
kinases.  
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Figure 3.11: LDA score plots of the response from the SOX-peptides showing in vitro 
differentiation of nine MAP kinases. (A) LDA score plot and (B) loading plot of the 
fluorescence response pattern of phosphorylated MAP kinases. 100% jack knife analysis.  
Kinase concentrations: ERK1/2 (2 nM), JNK1/2/3 (20 nM) and p38α/β/γ/δ (10 nM) with 
SOX-peptide (2 µM). Data collected with 96-well plate half area, plate reader with ex 
filter of 360  10 nm and em filter of 485  10 nm, using a top 400 mirror. Assay buffer:  
(25mM HEPES, 50mM KCl, 0.1 mM EDTA, 0.1 mM EGTA pH 7.4) with 2 mM DTT, 
2.5 µg/mL BSA, 5mM MgCl2, 500 µM ATP at 25 . 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
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3.5.4 Analyzing Experimental  Kinetic Parameters 
The previous kinase sensing array allowed for the detection and differentiation of 
nine MAP kinase groups which were recognized using only five different SOX-peptide 
substrates. However, some approximations were made which may need to be more 
precisely calculated for the accurate implementation of this sensing array system in future 
experiments. (1) The addition of each of the solutions was manually executed, including 
the addition of ATP solution. The overall time of ATP addition in the entire plate may be 
completed within 2 to 3 minutes. This last addition immediately triggers the 
phosphorylation reaction. Thus, the rate of phosphorylation may not be correctly 
measured by the time that the plate is introduced into the plate reader. (2) The time range 
(10 min) may not be long enough to acquire the appropriate exponential curves, and to 
obtain the rate constants using the curve fitting program. (3) Saturation kinetics have 
previously been required to obtain correct final fluorescence points which can cause 
errors in the derived rate constant.
130
 The endpoint or final fluorescence ( ) is 
considered an important kinetic parameter that requires experimental determination. In 
the previous kinase assay, the final fluorescence was automatically calculated by the 
software program, producing diverse rate constants according to each final fluorescence 
point within experimental replicates. Consequently, Equation 3.5 was considered to 
theoretically determine when the actual reaction time starts, and to estimate the 
fluorescence endpoint. The endpoint of SOX-Sub-D-peptide was calculated from the 
corresponding plot that showed the highest fluorescence point, obtaining an average of 
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the four replicates. This maximal fluorescence value was then constrained in the 
equation. The parameters used in Equation 3.5 are described as follows: , highest 
fluorescence point; , initial fluorescence of the peptide substrate; , 2-3 min time 
range. The equation was then applied to two experimental runs of SOX-Sub-D peptide, 
including JNK3 and p38δ. (Figure 3.12). The fitting curves (dotted lines) obtained by the 
software were plotted along with the experimental exponential curves (solid lines), 
showing the initial reaction time. As shown in the graphs, the phosphorylation reaction 
took place during the first 2-3 min range after the addition of ATP, displaying an 
important portion of the kinetic data during this time. Furthermore, the plot of SOX-Sub-
D with JNK3 (Figure 3.12A) showed that saturation was not achieved during this overall 
time range (10 min), suggesting that the endpoint was not properly calculated. This result 
suggested that the maximal average values could be miscalculated for SOX-peptides with 
no saturation kinetics in further experiments. As a result, the experimental rate constants 
from this sensing array may be unreliable for the acquired MAPK fingerprint.  
 
 
   (Eq. 3.5) 
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Figure 3.12: Experimental exponential curves (solid lines) and fitting curves (dotted 
lines) showing a fluorescence increase of SOX-Sub-D vs time using Igor Pro 6.04. (A) 
Fluorescent increase of SOX-sub-D peptide with JNK3. (B) Fluorescent increase of 
SOX-sub-D peptide with p38δ. 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
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3.6 OPTIMIZING SENSING ARRAY 
3.6.1 Sensing Ensemble 
To improve the reliability of this peptide-based sensing array, a different microplate 
reader (Tecan Infinite 500) with an automatic internal injector was used to perform the 
following kinase assay. The general layout of the sensing ensemble for the five SOX-
peptides is shown in Figure 3.13.  Changes in the emission data at 485  10 nm of each 
SOX-peptide were measured upon addition of ATP in HEPES buffer at pH = 7.4. 
Alternatively, three MAPK analytes were chosen for this preliminary experiment, 
including ERK-1, JNK3 and p38γ. The concentration of these kinases was changed to 
lower the limit of detection using 1/4 of the previous concentrations to obtain the 
following final concentrations ERK1 (0.5 nM), JNK3 (5 nM) and p38γ (2.5 nM) in the 
sensing ensemble. The volumes (µL) of kinase solution, and peptide solution were 
manually added. The 5 µL ATP aliquot was dispensed by the internal injector to each 
well using a speed of 300µL/sec. The time range was changed to 20 min to allow for 
saturation kinetics. Equation 3.4 was again used to fit the exponential curves, where the 
fluorescence endpoint at 20 min was calculated from the average of the four experimental 
replicates. The resulting kinetic data was analyzed with OriginPro curve fitting program 
to obtain the rate constants. 
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Figure 3.13: Schematic representation of the sensing ensemble. Sensing array for the 
detection of three MAP kinases: ERK1 (0.5 nM), JNK3 (5 nM) and p38γ (2.5 nM) with 
five SOX-peptides (2 µM). 
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3.6.2 Analyzing Rates of Phosphorylation 
As expected the same rates of phosphorylation of the five SOX-peptides were 
observed in the presence of each MAPK upon addition of ATP. Four experimental 
replicates of the fluorescence intensity versus time were plotted for individual MAP 
kinase with each SOX-peptide as shown in Figure 3.14. Interestingly, saturation kinetics 
were nearly achieved for each peptide in the presence of ERK1, JNK3 or p38γ over 20 
minutes. In addition, the SOX-peptides were efficiently phosphorylated using lower 
kinase concentrations. The same fluorescence increase pattern (Supplementary 
information Figures 3.40, 3.41 and 3.42) was observed within each MAPK sub-family, 
where SOX-sub-D was phosphorylated by the three groups. ERK1 efficiently 
phosphorylated SOX-MEF2A with respect to JNK3 and p38γ. In contrast, SOX-Sub-F 
was efficiently phosphorylated by p38γ, while no phosphorylation event was observed by 
JNK3. In addition, SOX-NFAT4 was only phosphorylated by JNK3. However, no 
phosphorylation of SOX-p38 peptide was observed using the three MAPKs.  
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Figure 3.14: Fluorescence changes of SOX-peptides upon phosphorylation with MAPKs. 
(A) SOX-Sub-D with ERK1 (0.5 nM). (B) SOX-Sub-F with p38γ (2.5 nM). (C) SOX-p38 
peptide with p38γ (2.5 nM). (D) SOX-MEF2A with ERK1 (0.5 nM). (E) SOX-NFAT4 
with JNK3 (5 nM). Kinase concentrations: ERK1 (0.5 nM), JNK3 (5 nM) and p38γ (2.5 
nM) with five SOX-peptides (2 µM). Data collected with 96-well plate half area, plate 
reader with ex filter of 340  35 nm and em filter of 485  20 nm. Assay buffer:  (25mM 
HEPES, 50mM KCl, 0.1 mM EDTA, 0.1 mM EGTA pH 7.4) with 2 mM DTT, 2.5 
µg/mL BSA, 5mM MgCl2, 500 µM ATP at 25 . 
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3.6.3 Fingerprint of MAPK Groups 
 
As expected, the following LDA plot in Figure 3.15 was acquired from this sensing 
array, showing excellent differentiation between the MAPK groups. In this LDA plot 
80.9% of the data was discriminated along the F1 axes and 19% of differentiation was 
found along the F2 axes. This LDA plot presented 100% jack-knife analysis, signifying 
satisfactory clustering of the replicates. Interestingly, the same MAPK group pattern was 
obtained with respect to the previous LDA plot for the nine kinases. JNK3 was again 
placed on the right quadrant of the LDA plot. However, the y-axis in the LDA plot was 
inverted for this optimized experiment. ERK1 was clearly distinguished on the bottom 
left quadrant of the plot, while p38γ was placed on the top left quadrant.  
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Figure 3.15: LDA score plots of the response from the SOX-peptides showing in vitro 
differentiation of MAPK sub-families. (A) LDA score plot and (B) loading plot of the 
fluorescence response pattern of three MAP kinases with 100% jack knife analysis. 
Kinase concentrations: ERK1 (0.5 nM), JNK3 (5 nM) and p38γ (2.5 nM) with five SOX-
peptides (2 µM). Data collected with 96-well plate half area, plate reader with ex filter of 
340  35 nm and em filter of 485  20 nm. Assay buffer:  (25mM HEPES, 50mM KCl, 
0.1 mM EDTA, 0.1 mM EGTA pH 7.4) with 2 mM DTT, 2.5 µg/mL BSA, 5mM MgCl2, 
500 µM ATP at 25 . 
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3.7 ARRAY REPRODUCIBILITY OF NINE MAPKS 
 
The previous results demonstrated that the methodology was improved by using the 
new plate reader which had the capability of dispensing the ATP aliquots to the entire 
plate in less than 20 seconds. In addition, the fixed fluorescence endpoints in the equation 
and the extension of the time range further improved the kinetic data, increasing the 
reliability of the obtained rate constants. After showing the successful differentiation of 
MAPK groups using the previous sensing array, the rest of the MAPK isoforms were 
subjected to the same sensing ensemble to investigate the reproducibility of the optimized 
kinase assay.  
3.7.1 Optimizing SOX-p38 Peptide Concentration 
In this assay the concentration of SOX-p38 peptide was increased to improve the 
fluorescence signal. The optimal SOX-p38 peptide concentration for the sensing 
ensemble was found by increasing the concentration of peptide in the presence of p38γ 
MAPK at a fixed concentration of 8 nM. Fluorescent changes of SOX-p38 were detected 
using a well-plate reader under the same buffer conditions for 60 minutes. The graph in 
Figure 3.16 showed that the peptide is efficiently phosphorylated by p38γ using a 
concentration close to 10 µM. Higher concentrations were not considered due to the 
possible overflow of the fluorescence signal which was observed at 50 µM concentration. 
From this experiment, a final concentration of 8 µM of SOX-p38 peptide was chosen for 
the following sensing ensemble.  
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Figure 3.16: Fluorescent increase of SOX-p38 peptide upon phosphorylation. Plots 
showed emission changes at different SOX-p38 concentrations in the presence of p38γ 
MAPK at a fixed concentration of 8 nM. Data collected with 96-well plate half area, plate 
reader with ex filter of 340  35 nm and em filter of 485  20 nm. Assay buffer:  (25mM 
HEPES, 50mM KCl, 0.1 mM EDTA, 0.1 mM EGTA pH 7.4) with 2 mM DTT, 2.5 
µg/mL BSA, 5mM MgCl2, 500 µM ATP at 25 . 
 
3.7.2 Reproducible Fingerprint of Nine MAPKs 
The experiment with the nine MAPK analytes was replicated in its entirety using the 
previous low concentrations of ERK1/2 (0.5 nM), JNK1/2/3 (5 nM) and p38α/β/γ/δ (2.5 
nM) in the sensing ensemble. A final concentration of SOX-peptide (2 µM) was also used 
in this sensing array, with the exception of SOX-p38 peptide (8 µM) concentration. The 
resulting kinetic plots showed comparable rates of phosphorylation of SOX-peptides with 
respect to the preliminary experiment (Supplementary information Figures 3.43, 3.44, 
3.45 and 3.46).  SOX-p38 peptide was phosphorylated by all p38 isoforms at the given 
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concentrations ((Supplementary information Figures 3.47), while lower fluorescence 
increase was detected in the presence of the ERK and JNK groups. The LDA plot in 
Figure 3.17 was acquired from this array, showing a similar pattern response with 
respect to the previous LDA plot with nine MAPKs. The data presented 62.99% 
differentiation along the F1 axes and 33.24% separation along the F2 axes, showing a 
jack-knife analysis of 86.11%. The JNK sub-family was found on the right side of the 
plot. The y-axis was also inverted in this LDA plot where the ERK isoforms were found 
on the bottom left quadrant along with p38α. The isoforms p38δ and p38γ were placed on 
the top left quadrant. Interestingly, p38β was located on the right side of the LDA plot, 
along with the JNK group. Despite most of the MAPKs being differentiated along the F1 
axes some overlap was observed between JNK2 and p38β on the right side of the plot. In 
addition, the ERK isoforms showed close approximation between each other. In contrast 
to the formerly obtained LDA plot (Figure 3.11) with nine MAPKs, this sensing 
ensemble presented a slight decrease of discriminatory power. From these results, it was 
hypothesized that the addition of more discriminatory variables to the array may improve 
the differentiation of the MAPK isoforms.  
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Figure 3.17: LDA score plots of the response from the SOX-peptides showing in vitro 
differentiation of nine MAP kinases. (A) LDA score plot and (B) loading plot of the 
fluorescence response pattern of phosphorylated MAP kinases with of 86.11% jack-knife 
analysis. Kinase concentrations: ERK1/2 (0.5 nM), JNK1/2/3 (5 nM) and p38α/β/γ/δ (2.5 
nM) with Sox-peptides (2 µM) and SOX-p38 peptide (8 µM). Data collected with 96-
well plate half area, plate reader with ex filter of 340  35 nm and em filter of 485  20 
nm. Assay buffer:  (25mM HEPES, 50mM KCl, 0.1 mM EDTA, 0.1 mM EGTA pH 7.4) 
with 2 mM DTT, 2.5 µg/mL BSA, 5mM MgCl2, 500 µM ATP at 25 . 
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3.7.3 Additional Discriminatory Variables  
Our group has previously shown that spectrophotometric changes at different 
wavelengths for a given sensor can be used to increase the number of discriminatory 
variables in a sensing array.
131
 In the case of kinetic assays more variables could be added 
to the array by using additional kinetic parameters from the previously obtained data. The 
additional kinetic parameters considered were the initial and final fluorescence of the 
product. However, the initial and final fluorescence values were fixed in the equation for 
a particular SOX-peptide to obtain the rate constants. Thereby, it was investigated 
whether a randomly chosen fluorescence value could be used to improve the 
differentiation of this sensing array. From the previously acquired kinetic data in the 
sensing array for nine MAPKs, the fluorescence values at 20 minutes were chosen to be 
included in the input data in combination with the rate constants (supplementary 
information Table 3.9). The LDA plot in Figure 3.18 was obtained using the same 
sensing ensemble with additional fluorescence variables. The nine MAPK kinases were 
differentiated with 55.13% of the variance along the F1 axes, and 26.09% of the variance 
along the F2 axes. In this LDA plot, eight analyte groups were classified into respective 
sets with 94.44% accuracy according to the jack-knife analysis. The analyte clustering 
was improved in comparison to the previously discussed LDA plot in Figure 3.17. In 
addition, each of the MAPK isoforms was classified into their corresponding sub-family 
group with the exception of p38β which was found in close proximity to the JNK group. 
The JNK group was placed on the left side of the LDA plot, whereas the ERK and p38 
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sub-families were found on the right side. ERK isoforms were found in the top right 
quadrant, presenting further separation along both axes. The isoforms p38δ and p38γ are 
located on the bottom right quadrant. Finally the discriminating variables (rate constants 
and fluorescence values) obtained from each SOX-peptide showed the contribution to the 
differentiation of the enzymes in the loading plot (Figure 3.18B). The peptide-based 
sensors presented excellent cross-reactivity properties, allowing for further separation of 
the enzymes. A three-dimensional plot was also obtained from this data (Figure 3.19), 
carrying an additional 14.19% of differentiation in the third axis. This sensing array was 
reproduced and demonstrated to be effective to assess for the detection and differentiation 
of MAPK groups and isoforms. 
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Figure 3.18: LDA score plot of the response from the SOX-peptides showing in vitro 
differentiation of nine MAP kinases. (A) LDA score plot and (B) loading plot obtained 
with 94.44% jack knife analysis. Kinase concentrations: ERK1/2 (0.5 nM), JNK1/2/3 (5 
nM) and p38α/β/γ/δ (2.5 nM). Sox-Sub-D, SOX-MEF2A, SOX-NFAT4 and SOX-Sub-F 
(2 µM) and SOX-p38 peptide (8 µM). Data collected with 96-well plate half area, plate 
reader with ex filter of 340  35 nm and em filter of 485  20 nm. Assay buffer:  (25mM 
HEPES, 50mM KCl, 0.1 mM EDTA, 0.1 mM EGTA pH 7.4) with 2 mM DTT, 2.5 
µg/mL BSA, 5mM MgCl2, 500 µM ATP at 25 . 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
170 
 
 
 
 
 
Figure 3.19: Three-dimensional LDA plot score plot showing in vitro differentiation of 
nine MAP kinases. Fluorescence response pattern of SOX-peptides in the presence of nine 
active MAP kinases obtained from Figure 3.18.  
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3.8 SEMIQUANTITATIVE ANALYSIS OF MAPKS 
After it was corroborated that a sensing array composed of five SOX-peptides was 
capable of qualitatively recognizing the studied MAPKs, the semiquantitative 
determination of mixtures of MAPK groups was explored. MAPKs are intrinsically found 
in different concentrations in complex mixtures such as cell lysates. In addition, 
uncontrolled activity of upper kinases can lead to overexpression of aberrant MAPKs, 
causing altered kinase concentrations. A semiquantitative assay with structurally related 
MAPK groups was investigated in vitro by using a mixture of three MAPKs at different 
nanomolar concentrations.  
3.8.1 Detecting Increasing ERK1 Concentrations 
The aforementioned peptide-based sensing ensemble was used to detect increasing 
concentrations of ERK1 in the presence of fixed concentrations of JNK3 and p38γ. The 
plate layout of the sensing ensemble for each SOX-peptide and the mixture of ERK1, 
JNK3 and p38γ analytes is shown in Figure 3.20. For this kinase assay, eight kinase 
solutions were prepared using the following fixed concentration of JNK3 (10 nM) and 
p38γ (5 nM). Each kinase stock was prepared with increasing concentrations of ERK1 as 
described in the supplementary information. The following final concentrations of ERK1 
were estimated in each well as follows 0 nM, 0.05 nM, 0.1 nM, 0.2 nM, 0.4 nM, 0.8 nM, 
1.6 nM and 3.2 nM ERK1 in the presence of JNK3 (5 nM) and p38γ (2.5 nM). The SOX-
peptide concentrations were correspondingly used for this assay as previously described.  
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Figure 3.20: Schematic representation of the sensing ensemble. Sensing array for the 
semi-quantitatively detection of increasing ERK1 concentration in the presence of JNK3 
and p38γ with SOX-Sub-F peptide. 
 
3.8.1.1 Analyzing Kinetic Data 
An average of the four experimental replicates was obtained for each ERK1-
catalyzed reaction at each different concentration to clearly visualize the kinetic trend 
with each SOX-peptide. In contrast, the rate constants were individually obtained from 
each replicate using the same equation. The fluorescence endpoint ( ) was obtained as 
an average value from the highest ERK-1 concentration (3.2 nM) for each SOX-peptide 
and this  value was considered a constrained variable. The resulting kinetic data in 
Figure 3.21 was obtained from this array, showing emission changes that were dependent 
on increasing ERK1 concentration for three SOX-peptides. SOX-Sub-D peptide was 
initially phosphorylated by JNK3 and p38γ, showing an initial fluorescence increase at 0 
nM of ERK1 concentration (Figure 3.21A). The rate of phosphorylation was clearly 
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enhanced after the addition of 0.2 nM ERK1, reaching saturation after 0.4 nM 
concentration. SOX-MEF2A was also firstly phosphorylated by JNK3 and p38γ. A 
slower fluorescence increase was observed upon addition of increasing ERK1 
concentration with respect to SOX-Sub-D (Figure 3.21B). Saturation kinetics were 
achieved in the presence of 1.6 nM ERK1 concentration. These results were consistent 
with the previously obtained kinetic data where the five SOX-peptides were 
phosphorylated by individual MAPK groups. SOX-Sub-F presented a similar kinetic 
trend with respect to SOX-Sub-D and MEF2A peptides, showing a continuous 
enhancement of the fluorescence signal (Figure 3.21C). However, the initial 
fluorescence of SOX-Sub-F was higher at 0 nM ERK concentration, suggesting that the 
peptide was efficiently phosphorylated by p38γ. In contrast, SOX-NFAT4 and SOX-p38 
peptides showed high specificity for JNK3 and p38γ, respectively. Thus, no change in the 
rate of phosphorylation was observed for these peptides (supplementary information 
Figure 3.57).  
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Figure 3.21:  Kinetic plots showing emission changes as a function of phosphorylated 
SOX-Sub-D, SOX-MEF2A and SOX-Sub-F peptides at different ERK1 concentrations in 
the presence of fixed JNK3 and p38γ concentrations. (A) Fluorescence increase of SOX-
Sub-D peptide. (B) Fluorescence increase of SOX-MEF2A peptide. (C) Fluorescence 
increase of SOX-Sub-F peptide. Final ERK1 concentrations:  0 nM, 0.05 nM, 0.1 nM, 0.2 
nM, 0.4 nM, 0.8 nM, 1.6 nM and 3.2 nM. Final fixed concentrations of JNK3 (5 nM) and 
p38γ (2.5 nM). Sox-Sub-D, SOX-MEF2A, and SOX-Sub-F (2 µM). Data collected with 
96-well plate half area, plate reader with ex filter of 340  35 nm and em filter of 485  
20 nm. Assay buffer:  (25mM HEPES, 50mM KCl, 0.1 mM EDTA, 0.1 mM EGTA pH 
7.4) with 2 mM DTT, 2.5 µg/mL BSA, 5mM MgCl2, 500 µM ATP at 25 . 
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3.8.1.2 Semiquantitative Analysis Using Pattern Recognition 
From the aforementioned kinetic data, rate constants and fluorescence values at 20 
minutes were obtained. This sensing array enabled the semiquantitative detection of a 
mixture of kinases at different concentrations. The LDA plot in Figure 3.22A was 
acquired from this sensing ensemble, showing a progression of the concentration changes 
in the array response. Interestingly, the LDA plot showed a strong dependence of the 
kinetic response on the increasing concentrations of ERK1. This LDA plot presumably 
showed the amount of ERK1 concentration in the presence of other MAPKs, displaying 
82.09% of differentiation along the F1 axes, and 17.59% of separation along the F2 axes. 
The LDA plot was obtained with 100% jack-knife analysis. Interestingly, the previously 
discussed kinetic trends in Figure 3.21 were represented by the discriminating variables 
from this array. The corresponding loading plot (Figure 3.22B) indicated that the 
discriminating variables from SOX-Sub-D, SOX-MEF2A and SOX-Sub-F similarly 
contributed to the concentration trend, whereas variables from SOX-NFAT4 and SOX-
p38 peptides mainly contributed to concentration discrimination. The cross-reactive 
properties of this array demonstrated its capability to detect minor changes of the 
concentration of ERK1 in the presence of other MAPK groups. This sensing array 
presumably could be used for further quantitative determinations.      
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Figure 3.22: LDA score plot of the kinetic response pattern from the SOX-peptides 
showing in vitro differentiation of ERK1 concentration changes in the presence of JNK3 
and p38γ MAPKs. (A) LDA plot and (B) loading plot showing 100% jack-knife analysis. 
Final ERK1 concentrations:  0 nM, 0.05 nM, 0.1 nM, 0.2 nM, 0.4 nM, 0.8 nM, 1.6 nM 
and 3.2 nM. Final fixed concentrations of JNK3 (5 nM) and p38γ (2.5 nM). Sox-Sub-D, 
SOX-MEF2A, and SOX-Sub-F (2 µM). Sox-peptides (2 µM). SOX-p38 peptide (8 µM). 
Data collected with 96-well plate half area, plate reader with ex filter of 340  35 nm and 
em filter of 485  20 nm. Assay buffer:  (25mM HEPES, 50mM KCl, 0.1 mM EDTA, 
0.1 mM EGTA pH 7.4) with 2 mM DTT, 2.5 µg/mL BSA, 5mM MgCl2, 500 µM ATP at 
25 . 
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3.8.2 Detecting Increasing JNK3 Concentrations 
The aforementioned sensing ensemble was also followed to detect increasing 
concentrations of JNK3 in the presence of ERK1 and p38γ. The following final 
concentrations of JNK3 were used in each well as follows 0, 0.5, 1, 2, 4, 8, 16 and 32 nM 
JNK-3 in the presence of 0.5 nM ERK1 and 2.5 nM p38γ. Four replicates were also 
performed for each JNK3-catalyzed reaction at each different concentration. The 
fluorescence endpoint was similarly obtained by using the previously described 
procedure. The kinetic data in Figure 3.23 was acquired from this sensing array. 
Fluorescence changes of SOX-NFAT4 peptide were primarily observed by increasing 
JNK3 concentration. In contrast, the remaining SOX-peptides showed no fluorescence 
changes. SOX-MEF2A and SOX-Sub-D were efficiently phosphorylated by ERK1, 
showing saturation at 0 nM JNK3 concentration. Thus, no fluorescence changes were 
observed upon addition of JNK3 concentration. As expected no fluorescence increase of 
SOX-Sub-F was observed at high JNK3 concentration (supplementary information 
Figure 3.49B). This result strongly confirmed the lack of the F-recruitment site in the 
JNK group. In addition, SOX-p38 was initially phosphorylated by p38γ, showing no 
changes upon addition of JNK3.  
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Figure 3.23:  Kinetic plots showing emission changes as a function of phosphorylated 
SOX-NFAT4 and SOX-MEF2A at different JNK3 concentrations in the presence of fixed 
ERK1 and p38γ concentrations. (A) Fluorescence increase of SOX-NFAT4 peptide. (B) 
Fluorescence increase of SOX-MEF2A peptide. Final JNK3 concentrations:  0 nM, 0.5 
nM, 1 nM, 2 nM, 4 nM, 8 nM, 16 nM and 32 nM. Final fixed concentrations of ERK (0.5 
nM) and p38γ (2.5 nM). Sox-NFAT4 and SOX-MEF2A (2 µM). Data collected with 96-
well plate half area, plate reader with ex filter of 340  35 nm and em filter of 485  20 
nm. Assay buffer:  (25mM HEPES, 50mM KCl, 0.1 mM EDTA, 0.1 mM EGTA pH 7.4) 
with 2 mM DTT, 2.5 µg/mL BSA, 5mM MgCl2, 500 µM ATP at 25 . 
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Unfortunately, most of the SOX-peptides were initially phosphorylated by either 
ERK1 or p38γ. Therefore, no differentiation was obtained from the rates of 
phosphorylation and fluorescence values at 20 min. The LDA plot in Figure 3.24 showed 
that separation of each JNK3 concentration was only obtained along the F1 axes (100%). 
The use of additional cross-reactive peptides would be required to improve the 
discriminant properties of the array.  
 
Figure 3.24: LDA score plot of the kinetic response pattern from the SOX-peptides with 
increasing JNK3 concentrations in the presence of ERK1 and p38γ MAPKs. Final JNK3 
concentrations:  0 nM, 0.5 nM, 1 nM, 2 nM, 4 nM, 8 nM, 16 nM and 32 nM. Final fixed 
concentrations of ERK (0.5 nM) and p38γ (2.5 nM). Sox-peptides (2 µM) and SOX-p38 
peptide (8 µM). Data collected with 96-well plate half area, plate reader with ex filter of 
340  35 nm and em filter of 485  20 nm. Assay buffer:  (25mM HEPES, 50mM KCl, 
0.1 mM EDTA, 0.1 mM EGTA pH 7.4) with 2 mM DTT, 2.5 µg/mL BSA, 5mM MgCl2, 
500 µM ATP at 25 . 
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3.8.3 Detecting Increasing p38γ Concentrations 
The same sensing array was used to explore the semiquantitative detection of 
p38γ MAPK in the presence of ERK1 and JNK3. The p38γ kinase was used in each well 
at concentrations of 0 nM, 0.25 nM, 0.5 nM, 1 nM, 2 nM, 4 nM, 8 nM, and 16 nM in the 
presence of ERK1 (0.5 nM) and JNK3 (5 nM). Each p38γ-catalyzed reaction at each 
different kinase concentration was replicated four times. The fluorescence endpoint was 
obtained as previously described. The kinetic data in Figure 3.25 was acquired from this 
array. SOX-Sub-F was initially phosphorylated by ERK1, showing an initial fluorescence 
change at 0 nM p38γ. However, the fluorescence intensity was clearly enhanced by 
increasing concentrations of p38γ, showing saturation at 8 nM concentration (Figure 
3.25A). Interestingly, SOX-NFAT4 peptide presented a modest fluorescent enhancement 
after the addition of 0.5 nM concentration of p38γ (Figure 3.25B). This result suggested 
that SOX-NFAT4 was presumably recognized by the D-recruitment site of both JNK3 
and p38γ which present close structural similarities at the DRS. In contrast, the resulting 
kinetic assays showed that the phosphorylation reaction of SOX-p38 was efficiently 
catalyzed by p38γ MAPK, showing high specificity for this peptide substrate. The p38γ-
catalyzed reaction of SOX-p38 peptide showed continuous fluorescence changes with 
increasing p38γ concentrations (Figure 3.25C). 
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Figure 3.25:  Kinetic plots showing emission changes as a function of phosphorylated 
SOX-peptides at different p38γ concentrations in the presence of fixed ERK1 and JNK3 
concentrations. (A) Fluorescence increase of SOX-Sub-F peptide. (B) Fluorescence 
increase of SOX-NFAT4 peptide. (C) Fluorescence increase of SOX-p38 peptide. Final 
p38γ concentrations: 0 nM, 0.25 nM, 0.5 nM, 1 nM, 2 nM, 4 nM, 8 nM, and 16 nM. Final 
fixed concentrations: ERK (0.5 nM), and JNK3 (5 nM). SOX-Sub-F and Sox-NFAT4 (2 
µM); SOX-p38 peptide (8 µM). Data collected with 96-well plate half area, plate reader 
with ex filter of 340  35 nm and em filter of 485  20 nm. Assay buffer:  (25mM 
HEPES, 50mM KCl, 0.1 mM EDTA, 0.1 mM EGTA pH 7.4) with 2 mM DTT, 2.5 
µg/mL BSA, 5mM MgCl2, 500 µM ATP at 25 . 
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3.8.3.1 Semiquantitative Detection of  p38γ Using Pattern Recognition 
The rate constants and fluorescence values at 20 minutes were obtained from the 
previously discussed kinetic data. The LDA plot in Figure 3.26A was acquired from this 
sensing ensemble, showing a modest progression of the concentration changes in the 
array response. Most of the data was classified along the F1 axes with 96.75% of the 
variance, and 2.58% of the variance along the F2 axes. The rate of phosphorylation of the 
SOX-peptides was quite similar from 0 to 4 nM p38γ concentrations, showing overlap of 
the concentration sets on the left side of the LDA plot. The clusters were classified with 
59.38% jack-knife analysis due to the high similarity of the kinetic data at low 
concentrations. However, concentrations at 8 nM and 16 nM were differentiated from the 
other sets along the F1 axes, suggesting modest dependence of the kinetic response on 
increasing p38γ concentrations. The corresponding loading plot in Figure 3.26B was 
obtained. Most of the discriminating variables equally contributed to the modest 
concentration trend.  
These semiquantitative kinase assays showed that this sensing array best detected 
nanomolar concentration changes of ERK1 in the presence of JNK3 and p38γ using a 
pattern recognition approach. The semiquantitative detection of the progression of the 
concentration changes was effectively followed by using the kinetic response of the 
SOX-peptides with increasing ERK1 concentrations. Nevertheless, no differentiation of 
JNK3 concentration changes was achieved due to the immediate response from the SOX-
peptides to ERK1. A modest trend of p38γ concentration changes was also detected by 
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using this array. It should be pointed out, however, that this kinase assay could 
potentially be optimized to improve the differentiation patterns by adding more 
discriminating variables to the sensing ensemble.  
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Figure 3.26: LDA score plot of the kinetic response pattern from the SOX-peptides 
showing modest differentiation of p38γ concentration changes in the presence of ERK1 
and JNK3. (A) LDA plot with eight p38γ concentrations. (B) Corresponding loading plot 
for (A). Final p38γ concentrations: 0 nM, 0.25 nM, 0.5 nM, 1 nM, 2 nM, 4 nM, 8 nM, 
and 16 nM. Final fixed concentrations: ERK (0.5 nM), and JNK3 (5 nM). SOX-peptides 
(2 µM); SOX-p38 peptide (8 µM). Data collected with 96-well plate half area, plate 
reader with ex filter of 340  35 nm and em filter of 485  20 nm. Assay buffer:  (25mM 
HEPES, 50mM KCl, 0.1 mM EDTA, 0.1 mM EGTA pH 7.4) with 2 mM DTT, 2.5 
µg/mL BSA, 5mM MgCl2, 500 µM ATP at 25 . 
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3.9 DETECTION OF INHIBITION KINETICS OF ERK1 
A variety of small-molecule inhibitors have been developed to regulate the 
uncontrolled activity of the ERK pathway as described in Chapter 1. Pharmaceutical 
companies can screened over 2000 compounds involved in a cascade kinase assay to 
discover the initial efficiency of these inhibitors.
132
 However, few detection methods can 
be applied for high-throughput screening to rapidly investigate the in vitro activity of 
several kinases or mixtures of kinases. Herein, a semiquantitative kinase assay was 
investigated to explore the inhibition of ERK1 activity by using the previously described 
sensing array.  
3.9.1 VX-11e Inhibitor for ERKs 
Aronov et al. recently reported the synthesis of a potent pyrimidylpyrrole ERK 
inhibitor called VX-11e (3.20).
133
 The selectivity of 3.20 was assessed for kinases ERK2, 
Glycogen synthase kinase 3 (GSK3), cyclin-dependent kinase 2 (CDK2) and Aurora A. 
Compound 3.20 was found to present good selectivity for ERK2 with respect to the other 
kinases, showing a binding affinity of KI < 2 nM. This inhibitor was used to show the 
utility of this sensing ensemble to differentiate inhibition kinetics of ERK1 alone, and 
ERK1 in the presence of other MAPK sub-families. Thus, a preliminary semiquantitative 
assay was initially performed in vitro with ERK1 in the presence of VX-11e inhibitor at 
different nanomolar concentrations. Subsequently, a second assay was performed to 
186 
 
detect the reduced activity of ERK1 in the presence of JNK3 and p38γ with increasing 
VX-11e inhibitor concentrations.   
 
 
 
3.9.2 Sensing Array Using VX-11e Inhibitor 
A quick preliminary assay was performed with this sensing ensemble to 
investigate the performance of the inhibitor at the chosen concentrations. This array was 
first used to detect the decreased activity of ERK1 with increasing VX-11e 
concentrations. The same SOX-peptide concentrations were correspondingly used for this 
assay. The plate layout of the sensing ensemble for each SOX-peptide is shown in Figure 
3.27, presenting the corresponding inhibitor concentrations. For this kinase assay, stock 
solutions were prepared to obtain a final concentration of ERK1 (0.5 nM) in each well. 
Inhibitor stock solutions were separately prepared with increasing concentrations of 3.20 
as described in supplementary information to obtain a final concentration of 0 nM, 1 nM, 
8 nM, 16 nM, and 48 nM in each well. These concentrations were chosen based on the 
binding affinity KI < 2 nM of the inhibitor.  
3.20 
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Figure 3.27: Schematic representation of the sensing ensemble. Sensing array for the 
semi-quantitatively detection of decreasing ERK1 activity by inhibition of VX-11e. 
 
3.9.3 Differentiating Inhibition of ERK1 
The four experimental replicates of each inhibitor concentration were used to 
obtain the corresponding rate constants and fluorescence values at 20 minutes. The 
resulting kinetic data shown in Figure 3.28 was obtained from this sensing array, 
showing fluorescence changes that were dependent on inhibition concentrations. As 
expected, SOX-MEF2A and SOX-Sub-D peptides were efficiently phosphorylated by 
ERK1, showing saturation at the given concentration. The addition of increasing inhibitor 
concentrations decreased the rate of phosphorylation which was represented by a gradual 
drop of the fluorescence signal (Figure 3.28A and B). SOX-Sub-F showed an analogous 
diminution of the rate and a corresponding modest fluorescence drop (Figure 3.28C). 
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However, no fluorescence changes were observed for SOX-NFAT4 and SOX-p38 SOX-
NFAT4 and SOX-p38 (supporting information). The LDA plot in Figure 3.29A was 
obtained with this array. A modest progression of the inhibition changes was observed in 
the plot. The group without inhibition (0 nM) was located on the bottom right quadrant, 
whereas the remaining groups were gradually placed on the right side of the LDA plot. 
The data was differentiated with 83.83% of the variance along the F1 axes, and 16.17% 
of the variance along the F2 axes. Although, the LDA presented 100% jack-knife 
analysis, considerable scattering was found within the analyte replicates. The 
corresponding loading plot in Figure 3.29B indicated the contribution of the SOX-
peptides to the differentiation of the inhibitor concentrations. The discriminating 
variables obtained from SOX-Sub-D, SOX-MEF2A and SOX-Sub-F peptides mainly 
contributed to the concentration trend, whereas variables obtained from SOX-NFAT4 and 
SOX-p38 peptides contributed to the differentiation. The discriminating properties of this 
sensing ensemble enable the detection of inhibition changes in the catalytic activity of 
ERK1. This sensing array presumably could be used for the detection of ERK inhibition 
in the presence of other MAPK groups.  
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Figure 3.28: Kinetic data showing the average of 4 experimental replicates of ERK-
inhibitor concentrations. (A) Fluorescence changes of SOX-MEF2A peptide. (B) 
Fluorescence changes of SOX-Sub-D peptide. (C) Fluorescence changes of SOX-Sub-F 
peptide. Inhibitor concentrations: 0 nM, 1 nM, 8 nM, 16 nM, and 48 nM. Fixed 
concentration: ERK1 (0.5 nM). Sox-MEF2A, SOX-Sub-F and SOX-Sub-D (2 µM). Data 
collected with 96-well plate half area, plate reader with ex filter of 340  35 nm and em 
filter of 485  20 nm. Assay buffer:  (25mM HEPES, 50mM KCl, 0.1 mM EDTA, 0.1 
mM EGTA pH 7.4) with 2 mM DTT, 2.5 µg/mL BSA, 5mM MgCl2, 500 µM ATP at 
25 . 
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Figure 3.29: LDA score plots of the kinetic response pattern from the SOX-peptides 
showing inhibition of ERK1 activity. (A) LDA plot with ERK-inhibitor concentrations, 
showing 100% jack-knife analysis. (B) Corresponding loading plot for (A). Inhibitor 
concentrations: 0 nM, 1 nM, 8 nM, 16 nM, and 48 nM. Fixed concentration: ERK1 (0.5 
nM). Sox-peptides (2 µM) and SOX-p38 peptide (8 µM). Data collected with 96-well 
plate half area, plate reader with ex filter of 340  35 nm and em filter of 485  20 nm. 
Assay buffer:  (25mM HEPES, 50mM KCl, 0.1 mM EDTA, 0.1 mM EGTA pH 7.4) with 
2 mM DTT, 2.5 µg/mL BSA, 5mM MgCl2, 500 µM ATP at 25 . 
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3.9.4 Detecting ERK1 Inhibition in Kinase Mixtures 
In an effort to demonstrate the additional utility of this sensing array, the following 
kinase assay was performed to detect the inhibition of ERK1 activity in the presence of 
JNK3 and p38γ. The plate layout of the sensing ensemble for each SOX-peptide is shown 
in Figure 3.30, presenting the corresponding inhibitor concentrations with ERK1, JNK3 
and p38γ analyte concentrations. The stock solutions were prepared to obtain a final 
concentration of ERK1 (0.5 nM), JNK3 (5 nM) and p38γ (2.5 nM) in each well. 
Additional inhibitor stocks were separately prepared with increasing concentrations of 
3.20 as described in supplementary information to obtain a final concentration of 0 nM, 1 
nM, 2 nM, 3 nM, 4 nM, 8 nM, 16 nM, and 48 nM in each well.  
 
 
Figure 3.30: Schematic representation of the sensing ensemble. Sensing array for the 
semi-quantitatively detection of decreasing ERK1 activity by inhibition of VX-11e, in the 
presence of JNK3 and p38γ. 
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3.9.5 Inhibition Kinetics of ERK1 in Kinase Mixtures 
The previously described protocol was followed to obtain the rate constants and 
fluorescence values at 20 minutes. For this experiment, however, the rate constants were 
obtained by using the fluorescence endpoints ( ) from the previously obtained kinetic 
data with increasing kinase (ERK1, JNK3 and p38γ) concentrations. For instance, an 
average fluorescence endpoint of  = 7228 was obtained for SOX-Sub-D peptide with 
ERK1 at 1.6 nM concentration (Figure 3.21A). SOX-MEF2A (Figure 3.21B) and SOX-
Sub-F peptides (Figure 3.21C) yielded fluorescence endpoints of 16303 and 17903 with 
ERK1 at 3.2 nM concentration, respectively. In addition, a fluorescence endpoint of 8790 
was found from the assay of SOX-NFAT4 peptide with 32 nM JNK3 (Figure 3.23A). 
Finally, a fluorescence endpoint of 22819 was found from the assay of SOX-p38 peptide 
with 16 nM p38γ (Figure 3.25C). The rate constants were then obtained from each 
kinetic replicate using the same equation, constraining the aforementioned final 
fluorescence values for each corresponding SOX-peptide. The resulting kinetic data in 
Figure 3.31 was obtained from this array, showing emission changes that were dependent 
on increasing inhibitor concentration. SOX-MEF2A was mainly phosphorylated by 
ERK1, showing saturation at the given concentration in the presence of JNK3 and p38γ 
(Figure 3.31A). The rate of phosphorylation gradually decreased upon addition of 
increasing ERK-inhibitor concentrations. A comparable kinetic trend was observed with 
SOX-Sub-F, showing a modest fluorescence drop (Figure 3.31B). Interestingly, no 
fluorescence change was observed for SOX-Sub-D (Figure 3.31C). This result 
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corroborated with the reported high selectivity of the inhibitor which only affected the 
catalytic activity of ERK1, whereas no inhibition was observed for JNK3 even at high 48 
nM inhibitor concentration. As expected, no significant fluorescence changes were 
observed for SOX-NFAT4 and SOX-p38 (supporting information Figure 3.61). 
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Figure 3.31: Kinetic data showing the average of 4 experimental replicates of ERK-
inhibitor concentration in the presence of ERK1, JNK3 and p38γ. (A) Fluorescence 
changes of SOX-MEF2A peptide. (B) Fluorescence changes of SOX-Sub-F peptide. (C) 
Fluorescence changes of SOX-Sub-D peptide. Inhibitor concentrations: 0 nM, 1 nM, 2 
nM, 3 nM, 4 nM, 8 nM, 16 nM, and 48 nM. Fixed concentration: ERK1 (0.5 nM), JNK3 
(5 nM) and p38γ (2.5 nM). SOX-MEF2A, SOX-Sub-F and SOX-Sub-D (2 µM). Data 
collected with 96-well plate half area, plate reader with ex filter of 340  35 nm and em 
filter of 485  20 nm. Assay buffer:  (25mM HEPES, 50mM KCl, 0.1 mM EDTA, 0.1 
mM EGTA pH 7.4) with 2 mM DTT, 2.5 µg/mL BSA, 5mM MgCl2, 500 µM ATP at 
25 . 
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3.9.6 Differentiating Inhibition of ERK1 in the Presence of MAPK Groups  
This kinase assay encompassed the differential sensing of three MAPK groups (0.5 
nM ERK1, 5 nM JNK3 and 2.5 nM p38γ) with increasing ERK-inhibitor concentrations. 
The array enabled the semiquantitative detection of ERK inhibition using the 
aforementioned kinetic data. The LDA plot in Figure 3.32A was acquired from this 
sensing ensemble, showing progression of the inhibition changes in the array response. A 
control group was used in this LDA plot by including the kinetic data of SOX-peptides 
with 5 nM JNK3 and 2.5 nM p38γ (no ERK1 was added). This LDA presented a linear 
trend in the inhibition data, showing dependence of the kinetic response on the increasing 
inhibitor concentrations. The total catalytic activity of ERK1 in the presence of JNK3 and 
p38γ is represented by the analyte group at 0 nM inhibitor concentration which is located 
on the top right quadrant. The increasing inhibitor concentrations are diagonally placed 
on the left side of the LDA plot. The control group was expected to be located on the far 
bottom left side of the LDA plot. The ERK-inhibition patterns were classified with 
83.96% of the variance along the F1 axes, and 14.85% of the variance along the F2 axes. 
However, the groups were classified with 69.44% jack-knife analysis due to the 
analogous response of ERK1 to four inhibitor concentrations. The analyte groups in the 
range of 2 nM to 8 nM inhibitor concentrations presented considerable overlap. The 
corresponding loading plot shown in Figure 3.32B indicated the contribution of each 
SOX-peptide towards the differentiation of inhibitor concentrations in the array. The 
cross-reactive properties of this array demonstrated its utility to differentiate inhibition of 
196 
 
ERK1 activity in the presence of other MAPK groups. The semiquantitative detection of 
the progression of the inhibition changes was followed by using the kinetic response of 
the SOX-peptides in the array. 
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Figure 3.32: LDA score plots of the kinetic response pattern from the SOX-peptides 
showing inhibition of ERK1 activity in the presence of JNK3 and p38γ. (A) LDA plot 
with eight ERK-inhibitor concentrations and control, showing 69.44% jack-knife 
analysis. (B) LDA plot with five ERK-inhibitor concentrations and control, showing 
91.67% jack-knife analysis. (C) Corresponding loading plot for (B). Inhibitor 
concentrations: 0 nM, 1 nM, 2 nM, 3 nM, 4 nM, 8 nM, 16 nM, and 48 nM. Fixed 
concentration: ERK1 (0.5 nM), JNK3 (5 nM) and p38γ (2.5 nM). Sox-peptides (2 µM), 
and SOX-p38 peptide (8 µM). Data collected with 96-well plate half area, plate reader 
with ex filter of 340  35 nm and em filter of 485  20 nm. Assay buffer:  (25mM 
HEPES, 50mM KCl, 0.1 mM EDTA, 0.1 mM EGTA pH 7.4) with 2 mM DTT, 2.5 
µg/mL BSA, 5mM MgCl2, 500 µM ATP at 25 . 
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3.10 QUANTITATIVE ANALYSIS OF ERK1 ACTIVITY 
In the field of pattern recognition, machine learning approaches have emerged as 
powerful chemometric tools to analyze complex datasets. The machine learning 
technique has focused on the construction and study of models that can learn the structure 
from the dataset to predict the properties of analogous unknowns.
59
 Support vector 
machines (SVM) have been implemented for the classification and quantification of 
analytes as described in Chapter 1. For instance, this mathematical model has allowed for 
the simultaneous prediction of guest concentrations in complex mixtures.
134,135
 SVM is a 
supervised method that uses kernel functions to classify analyte groups with non-linear 
behavior by mapping the input data into a different dimensional space, obtaining linear 
correlations between the variables.
62
 The SVM functions can be additionally used to 
solve regression problems. SVM algorithms use training sets and prediction (test) models 
to generate a linear classification plot of the original dataset. The training set or 
calibration set uses input (x) and output (y) sets to tune the parameters of the predicting 
model. The classes of the input and output sets in the training set are known in advanced. 
The result of running the training set can be expressed as a function y(x) which considers 
the new data (x) as input and that produces an output vector. 
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3.10.1 Detecting Unknown ERK Concentrations  
In this study, SVM analysis was performed to improve the utility of this sensing 
array for the quantitative sensing of ERK1 activity. This SVM model was applied to the 
previously obtained response data from the sensing array. From the semiquantitative 
assay of increasing ERK1 concentrations in the presence of JNK3 (5 nM) and p38γ (2.5 
nM) shown in Figure 3.21, the obtained rate constants and fluorescence values at 20 min 
were used as input data. To assess the quantitative response of this array, the following 
concentrations 0 nM, 0.1nM, 0.4 nM, 1.6 nM and 3.2 nM of ERK1 were used as input 
data and the corresponding kinetic data were used as output data for the calibration and 
prediction model development (Table 3.1). In addition, the remaining ERK1 
concentrations 0.2 nM and 0.8 nM and the corresponding kinetic data were used as 
unknown samples for the cross-validation analysis (Table 3.2). Solo software was used to 
generate the SVM regression analysis.  
Different error values are generated to assess the confidence level of the SVM 
regression analysis. The training set produces a root mean square error of calibration 
(RMSEC) value. Once the SVM analysis is implemented, cross-validation analysis will 
be added along with the calibration and prediction results. This model validation is used 
to test the calibration and prediction models validity, producing a root mean square error 
of cross validation (RMSECV) value. The test model used to assess the utility and 
validation of the calibration model produces a root mean square error of prediction 
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(RMSEP) value, which gives a measure of the calibration model performance when 
presented with unknown data.  
ERK1 SOX-Sub-D SOX-MEF2A SOX-NFAT4 SOX-Sub-F SOX-p38 
(nM) k F k F k F k F k F 
0.0 0.02695 3082 0.00251 809 0.02119 3732 0.01187 4143 0.00841 3501 
0.0 0.02621 3121 0.00281 912 0.01857 3471 0.01408 4430 0.00633 2310 
0.0 0.02285 2797 0.00218 594 0.01482 2998 0.01372 4362 0.00367 1022 
0.0 0.02322 2830 0.00307 935 0.01819 3400 0.01330 4275 0.00393 1490 
0.1 0.03118 3543 0.00740 2286 0.02010 3464 0.01023 3539 0.00939 4340 
0.1 0.03209 3505 0.00808 2596 0.01672 3124 0.01683 5330 0.00310 1010 
0.1 0.02847 3219 0.00685 2006 0.01532 3201 0.01431 4550 0.00356 1303 
0.1 0.03142 3510 0.00433 1370 0.01160 2142 0.01243 3806 0.00247 2218 
0.4 0.12623 6954 0.03423 8329 0.01718 3103 0.01365 4431 0.00616 2288 
0.4 0.14153 7386 0.01005 2946 0.01655 2944 0.01422 4432 0.00506 2372 
0.4 0.12427 6923 0.03437 8297 0.00908 1752 0.01707 5104 0.00524 3268 
0.4 0.13120 7000 0.02622 6524 0.01144 1917 0.01611 4983 0.00363 2143 
1.6 0.20445 6967 0.10476 15243 0.02116 3794 0.03020 7931 0.00281 1435 
1.6 0.21434 6840 0.10928 15602 0.02084 3793 0.03004 8135 0.00280 510 
1.6 0.22317 6853 0.10012 15307 0.01454 3002 0.03314 8561 0.00458 1938 
1.6 0.30674 7605 0.09087 14459 0.01423 2863 0.02972 8104 0.00405 1857 
3.2 0.13687 5902 0.13607 16128 0.02454 4194 0.05340 11624 0.00765 3738 
3.2 0.15254 5912 0.12148 15529 0.01669 3267 0.05927 12193 0.00647 2388 
3.2 0.28457 6589 0.11248 15263 0.01788 3709 0.04932 11187 0.00476 2248 
3.2 0.26009 6659 0.11899 15417 0.01683 3312 0.04106 10328 0.00629 2792 
 
Table 3.1: ERK1 concentrations and kinetic data used as input data for the calibration 
set. 
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ERK1 SOX-Sub-D SOX-MEF2A SOX-NFAT4 SOX-Sub-F SOX-p38 
(nM) k F k F k F k F k F 
0.2 0.04540 4646 0.01519 4226 0.01634 2884 0.01162 3816 0.00866 3775 
0.2 0.04820 4717 0.01520 4325 0.01541 2860 0.01547 4493 0.00412 1594 
0.2 0.04607 4660 0.01394 3955 0.01151 2303 0.01434 4360 0.00709 4205 
0.2 0.04460 4618 0.01478 4169 0.01221 2498 0.01374 4329 0.00662 3191 
0.8 0.13508 6601 0.06279 12120 0.01768 3185 0.02591 7072 0.00577 2112 
0.8 0.14544 6702 0.05765 11668 0.01696 3234 0.02596 7297 0.00657 3073 
0.8 0.15627 6839 0.05682 11655 0.01377 2851 0.02231 6468 0.00500 1776 
0.8 0.14498 6666 0.05335 11228 0.01609 3267 0.02125 6078 0.00418 1210 
 
Table 3.2: ERK1 concentrations (0.2 nM and 0.8 nM) and kinetic data treated as 
unknown samples. 
  
This sensing array yielded a very accurate quantitative analysis of the mixtures of 
ERK1 in the presence of other MAPK groups at different concentrations. The result of 
the SVM regression method is shown in Figure 3.33. The nonlinear behavior of the 
original dataset from the sensing array was successfully detected and differentiated by the 
SVM functions, obtaining a linear relationship of the actual and predicted ERK1 
concentrations. The plot in Figure 3.33 additionally showed the correct quantification of 
two unknown samples (ERK1 at 0.2 and 0.8 nM) which are shown in red dots. The 
values of the root mean square errors of calibration RMSEC = 0.044, cross-validation 
RMSECV = 0.256, and prediction RMSEP = 0.151 showed good confidence levels of the 
generated calibration and test models. 
202 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.33: Quantitative analysis of the kinetic data of ERK1 in the presence of JNK3 (5 
nM) and p38γ (2.5 nM). Linear regression using a support vector machine (SVM) method 
allowed for the quantitative analysis of ERK1 activity. The plot of actual and predicted 
concentrations showed high confidence level of the prediction of two unknown samples 
(red dots). 
 
An additional SVM regression analysis was performed with different type of data 
to explore the application of the predicted dataset. From the same kinase assay with 
increasing concentrations of ERK1, the obtained score factors from the LDA in Figure 
3.22 were used as input and output datasets (Table 3.3 and Table 3.4) for the calibration 
and prediction models, respectively. The result of this SVM analysis is shown in Figure 
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3.34. An analogous linear relationship was found between the actual and predicted ERK1 
concentrations. The values of the root mean square errors of calibration RMSEC = 0.070, 
cross-validation RMSECV = 0.362, and prediction RMSEP = 0.130 showed similar 
confidence levels of the generated calibration and test models with respect to the 
previously described plot.  
ERK1 LDA Score factors 
(nM) F1 F2 F3 F4 F5 
0.0 -27.068 -10.266 0.046 -0.679 0.027 
0.0 -26.243 -10.019 0.357 -0.139 0.220 
0.0 -27.958 -12.774 0.081 -0.264 0.258 
0.0 -27.952 -12.104 -0.250 -0.182 0.219 
0.1 -24.912 -5.334 -0.765 -0.602 -0.348 
0.1 -23.210 -6.047 -0.147 1.081 0.423 
0.1 -25.305 -8.577 -0.415 0.287 0.181 
0.1 -24.556 -6.679 0.329 -0.512 -0.066 
0.4 -0.400 17.490 -0.099 -0.446 -0.354 
0.4 -0.760 16.865 5.044 -2.125 0.553 
0.4 0.486 16.921 0.423 0.299 -0.047 
0.4 -0.313 16.207 1.803 -0.472 0.238 
1.6 26.249 0.095 -1.341 -1.713 -1.192 
1.6 27.203 -2.510 -1.772 -2.141 -1.194 
1.6 25.278 -1.110 -1.623 -0.396 0.131 
1.6 28.052 -0.297 -1.168 -1.646 2.116 
3.2 36.699 -13.822 1.904 0.556 -2.539 
3.2 34.052 -12.171 2.394 3.408 -0.318 
3.2 35.464 -14.271 0.709 0.802 2.432 
3.2 34.930 -12.537 0.039 -1.714 0.309 
 
Table 3.3: Input data used for the calibration dataset of the SVM model. LDA score 
factors obtained from the sensing array of five SOX-peptides in the presence of different 
ERK1 concentrations with JNK3 (5 nM) and p38γ (2.5 nM) kinases. 
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ERK1 LDA Score factors 
(nM) F1 F2 F3 F4 F5 
0.2 -17.742 3.663 -0.415 -0.210 -0.672 
0.2 -16.267 3.782 0.155 0.692 -0.207 
0.2 -17.016 3.297 0.235 0.318 -0.336 
0.2 -17.373 3.291 -0.101 0.293 -0.429 
0.8 8.402 10.783 -1.308 1.616 -0.195 
0.8 7.787 11.498 -1.040 1.847 0.371 
0.8 7.425 12.350 -1.479 0.988 0.259 
0.8 5.044 12.276 -1.597 1.052 0.159 
 
Table 3.4: Input data treated as unknown samples for the prediction dataset of the SVM 
model. LDA score factors obtained from the sensing array of five SOX-peptides in the 
presence of different ERK1 concentrations with JNK3 (5 nM) and p38γ (2.5 nM) kinases. 
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Figure 3.34: Quantitative analysis of the LDA score data from the kinetic response of 
five SOX-peptides in the presence of increasing ERK1 concentrations in the presence of 
JNK3 (5 nM) and p38γ (2.5 nM). Linear regression using a support vector machine 
(SVM) method allowed for the quantitative analysis of ERK1 concentrations. The plot of 
actual and predicted concentrations showed high confidence level of the prediction of two 
unknown samples at 0.2 and 0.8 nM (red dots). 
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3.10.2 Detecting Unknown ERK-Inhibitor Concentrations  
The successful SVM analysis of either the raw kinetic dataset or the LDA score 
factors allowed for the simultaneous prediction of two unknown concentrations of ERK1 
in the presence of other MAP kinases. After the quantification of ERK1 concentrations in 
the presence of other MAPK groups was accomplished, the following study involved the 
quantification of ERK1-inhibitor concentrations. From the semiquantitative assay of 
inhibition of ERK1 (0.5 nM) in the presence of JNK3 (5 nM) and p38γ (2.5 nM) shown 
in Figure 3.32, the obtained LDA score factors from the response data of the array were 
used as input/output datasets. The following inhibitor concentrations 0 nM, 1 nM, 4 nM, 
8 nM, 16 nM and 48 nM of ERK1 were chosen as input data and the corresponding score 
factors were used as output data for the calibration and prediction model development 
(Table 3.5). The inhibitor concentration at 2 nM and the corresponding LDA score data 
were used as unknown samples for the cross-validation analysis (Table 3.6).   
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Inhibitor LDA Score factors 
(nM) F1 F2 F3 F4 
0 17.083 5.996 -0.783 0.896 
0 17.686 4.943 -1.727 0.466 
0 16.995 5.193 -1.336 -0.703 
0 15.554 5.954 -0.017 -0.613 
1 6.571 1.124 1.579 0.043 
1 5.315 0.279 1.878 0.201 
1 6.866 1.731 0.395 -0.267 
1 4.021 0.707 0.458 -0.874 
4 2.798 0.204 -1.434 0.063 
4 0.898 -2.281 0.202 0.518 
4 0.911 -1.575 0.148 -0.776 
4 0.878 -2.189 1.489 -0.947 
8 1.296 -1.752 1.228 -0.434 
8 1.174 -1.066 0.822 -0.339 
8 -0.127 -2.199 0.959 -0.497 
8 -0.776 -1.885 0.302 -1.237 
16 -2.882 -2.635 -0.349 1.367 
16 -4.603 -3.904 -2.608 1.801 
16 -3.998 -3.137 -0.595 -0.274 
16 -3.214 -2.862 -0.529 -1.507 
48 -5.825 -2.647 -1.361 0.519 
48 -5.855 -2.680 -1.202 -0.659 
48 -7.300 -3.647 -1.665 -0.291 
48 -5.833 -3.439 -0.752 -1.574 
 
Table 3.5: Input data used for the calibration dataset of the SVM model. LDA score 
factors obtained from the sensing array of five SOX-peptides in the presence of different 
ERK1-inhibitor concentrations with ERK1 (0.5 nM), JNK3 (5 nM) and p38γ (2.5 nM) 
kinases. 
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Inhibitor LDA Score factors 
(nM) F1 F2 F3 F4 
2 1.327 -1.597 0.217 1.654 
2 0.541 -3.192 -1.638 2.173 
2 1.604 -1.535 -0.719 -0.214 
2 1.568 -1.510 0.439 -1.020 
 
Table 3.6: Input data treated as unknown sample for the prediction dataset of the SVM 
model. LDA score factors obtained from the sensing array of five SOX-peptides in the 
presence of different ERK1-inhibitor concentrations with ERK1 (0.5 nM), JNK3 (5 nM) 
and p38γ (2.5 nM) kinases. 
 
This sensing array additionally generated a correct quantitative analysis of ERK1-
inhibitor in the presence of ERK1 (0.5 nM), JNK3 (5 nM) and p38γ (2.5 nM) kinases at 
different concentrations. The result of the SVM analysis is shown in Figure 3.35. The 
kinetic response of ERK1 with different inhibitor concentrations produced from this array 
was quantified by the SVM functions, obtaining a linear relationship of the actual and 
predicted ERK1-inhibitor concentrations. The plot in Figure 3.35 showed the correct 
quantification of the unknown sample (ERK1-inhibitor at 2 nM) which is shown as a red 
dot. The values of the root mean square errors of calibration RMSEC = 4.48, cross-
validation RMSECV = 7.25, and prediction RMSEP = 2.06 were also obtained from this 
SVM analysis. Although the accuracy was diminished, the obtained calibration curve was 
still useful for the correct identification of the unknown sample.  
This sensing array along with a SVM model demonstrated its utility to construct a 
calibration model for the quantitative detection of ERK1 and ERK-inhibitor 
concentrations in the presence of other MAPK groups. This study demonstrated the 
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applicability of LDA score factors from the kinetic response of five SOX-peptides to be 
used as input dataset. The SVM analysis of the LDA score factors allowed for the 
construction of a calibration and prediction model, allowing for the detection of unknown 
concentrations of either ERK1 or inhibitor in the presence of other MAP kinases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.35: Quantitative analysis of the LDA score data from the kinetic response of 
five SOX-peptides in the presence of ERK1-inhibitor with ERK1 (0.5 nM), JNK3 (5 nM) 
and p38γ (2.5 nM). Linear regression using a support vector machine (SVM) method 
allowed for the quantitative analysis of inhibitor concentrations. The plot of actual and 
predicted concentrations showed correct prediction of the unknown sample at 2 nM (red 
dot). 
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3.11 CONCLUSIONS 
From these kinase assays the following has been determined: (1) MAPK sub-families 
and isoforms can be differentiated using cross-reactive SOX-peptides with docking sites 
that present different selectivity and affinity towards this class of analytes. (2) This 
sensing array can be further applied to the semiquantitative detection of concentration 
changes of ERKs in a mixture of MAPKs at different nanomolar concentrations. (3) 
Inhibition of the catalytic activity of ERKs can be additionally detected in the presence of 
other MAPK groups using this array sensing approach. (4) This sensing array further 
allowed for the quantitative analysis of ERK1 and inhibition concentrations using a 
calibration and prediction model. 
In summary, this study showed that the discriminating properties of the docking sites 
on MAPK substrates can be used to develop a pattern recognition approach for this class 
of analytes. The enzymatic activity of nine different MAPK isoforms was detected and 
differentiated by using a high-throughput screening protocol in parallel with a differential 
sensing approach. The fluorescence changes of the chosen SOX-peptide substrates were 
consistent with previous studies, showing similar specificity for corresponding MAPKs. 
From these results, SOX-peptides proved to be not very selective or specific when used 
in a sensing array.  
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3.12  FUTURE WORK 
The developed kinase protocols in this project have contributed to the rapid detection 
of MAPK activity which may assist in developing diagnostic techniques associated with 
kinase malfunction and early-onset cancer. The ability of this sensing array to detect and 
differentiate semiquantitative changes in kinase concentration and inhibition of catalytic 
activity has opened the possibility to extrapolate this assay to the quantitative detection of 
MAP kinases. Additional assays are still left on this project. Important future experiments 
consist of exploring the quantitative detection of MAPK concentration changes in real-
life biological mixtures, detecting cell lysates with differing kinase expression, and 
testing how cells from healthy, metastatic and carcinoma tissues respond to the sensing 
ensemble.  
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3.13.1 Materials and Methods 
Starting materials were purchased from Aldrich Chemical Co., Acros Organics, 
EM, or TCI, and used without further purification.  All solvents were of reagent grade 
quality and purchased commercially. All compounds were prepared according to 
previous literature Imperiali et al.
128
 All reactions were performed in standard glassware. 
Evaporation was done by rotatory evaporation using a standard rotovap equipped with 
dry ice condenser. TLC analyses were carried out using Silica TLC Plates Aluminum 
Backing 20 by 20 cm sheet UV active.  Column chromatography (CC) was performed 
using silica gel 60 (230 ± 400 mesh, 0.040 ± 0.063 mm) from Dynamic Adsorbents. 
1
H 
and 
13
C spectra were recorded on Varian DirectDrive or Varian INOVA NMR 
spectrometers.  The NMR spectra were referenced to solvent and the spectroscopic 
solvents were purchased from Cambridge Isotope Laboratories. Finnigan MAT-VSQ 700 
and DSQ spectrometers were used to obtain mass spectra. HR electrospray ionization 
(ESI) mass spectra were recorded on Agilent 6530 Accurate-Mass Q-TOF LC/MS. 
3.13.2 Peptide Synthesis 
Peptides were synthesized using standard SPPS protocol. Peptide Sub-D and 
MEF2A were synthesized on rink resin (NovaSyn TGR resin) using a peptide synthesizer 
(CEM Liberty Automated Microwave). Peptides Sub-F and p38 were synthesized on 
NovaSyn Wang resin with a different peptide synthesizer (Prelude by Protein 
Technology, Inc). NFAT4 peptide was purchased from Bio-Synthesis. Coupling reactions 
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used Fmoc-L-amino acid/ HBTU/DIPEA (5:5:10 eq) relative to 1 eq. of pre-loaded resin. 
The N-terminus of each peptide was acetylated using a solution of 1.2 M of NMM in 
DMF (2 mL), acetic acid (1 mL) and CH2Cl2 (1 mL). Few beads were taken to 
corroborate the presence of the desired peptide. Crude peptide was cleaved from the resin 
using a solution of 5 mL TFA/ H2O/TIS (95/2.5/2.5 % v/v) for 2 h. Crude peptides were 
characterized by mass spectrometry using a either MALDI-TOF (Vogayer, PerSeptive 
Biosystem) or ESI (LCQ, Thermo Finnigan).  
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Peptide Peptide Sequence Molecular  Formula 
MALDI-TOF 
[M]
+
 Calcd. 
MALDI-TOF 
[M]
+
 Found 
3.2 
 
FQRKTLQRRNLKGLNLNL
XXXTGPLSPCPF 
 
C157H267N47O38S 3451.01 3451.6 
   
MALDI-TOF 
[M]
+
 Calcd. 
MALDI-TOF 
[M]
+
 Found 
3.3 
NLGMNSRKPDLRVVIPPGX
XXTGPLSPCPF 
 
C147H246N40O38S2 
[M+2H]
2+
 
1622.4 
 
[M+3H]
3+
 
1081.9 
[M+2H]
2+
 
1691.4 
 
[M+3H]
3+
 
1043.4 
   
MALDI-TOF 
[M]
+
 Calcd. 
MALDI-TOF 
[M]
+
 found 
3.4 
LERPSRDHLYLPLSGRYRE
SCLSPSPA 
 
C137H217N41O42S 3141.57 3141.92 
   
ESI [M+H]
+
 
Calcd. 
ESI [M+H]
+
 
found 
3.5 
YAECLTPRILAK 
WEWPA 
 
 
C99H145N23O25S 
 
[M+1H]
1+ 
2089.1 
 
[M+2H]
2+
 
1045.0 
[M+1H]
1+ 
2088.6 
 
[M+2H]
2+
 
1044.6 
3.6 
ICTTPITTTYFFFKKK 
 
C101H147N23O25 
[M+1H]
1+
 
1981.05 
 
[M+2H]
2+
 
991.53 
 
[M+3H]
3+
 
661.02 
[M+1H]
1+
 
1980.8 
 
[M+2H]
2+
 
990.6 
 
[M+3H]
3+
 
661.0 
 
Table 3.7:  LCMS characterization data of the crude peptides. 
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3.13.3 Synthesis of SOX-Br Fluorophore 
8-hydroxy-N,N,2-trimethylquinoline-5-sulfonamide (3.9) 
 
A solution of chlorosulfonic acid (50 mL, 0.751 moles, 11.9 eq) was cooled to 0 
°C in a round bottom flask and 3.8 (10 g, 63 mmol, 1 eq) was added in portions while 
keeping the temperature between 0 °C – 5 °C. The reaction was stirred at 0 °C for 2 h. 
The reaction mixture was then extracted several times with CH2Cl2 (200 mL). The 
organic layers were joined and washed with NaHCO3, brine and dried over Na2SO4. The 
solution was filtered and the solvent evaporated to dryness. Crude product 3.9 (3.51 g, 
13.6 mmol, 21.6%) was obtained as a yellow solid, and it was used in the next reaction 
without further purification. 
1
H NMR (400 MHz, CDCl3) δ 8.99 (d, J = 8.9 Hz, 1H), 8.29 
(d, J = 8.5 Hz, 1H), 7.63 (d, J = 8.9 Hz, 1H), 7.23 (d, J = 9.7 Hz, 1H), 2.83 (s, 3H). 
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8-hydroxy-N,N,2-trimethylquinoline-5-sulfonamide (3.10) 
 
A solution of 3.9 (3 g, 12 mmol, 1 eq) in dry THF (45 mL) was stirred at room 
temperature. N,N-dimethylamine (30 mL, 2 M in THF, 60 mmol, 4.57 eq) was carefully 
added drop wise over a period of 15 minutes. The reaction was then stirred at room 
temperature overnight. The crude product after evaporation was purified by normal phase 
column chromatography (hexane:ethylacetate, 1:1 v/v) to yield compound 3.10 (1.33 g, 5 
mmol, 41.6%) as a pale yellow solid. 
1
H NMR (499 MHz, CDCl3) δ 8.95 (d, J = 8.9 Hz, 
1H), 8.07 (d, J = 8.3 Hz, 1H), 7.44 (d, J = 8.9 Hz, 1H), 7.15 (d, J = 8.3 Hz, 1H), 2.73 (d, J 
= 3.6 Hz, 9H); 
13
C NMR (126 MHz, CDCl3) δ 157.86 (s), 156.27 (s), 137.51 (s), 134.47 
(s), 132.11 (s), 124.41 (s), 123.63 (s), 121.69 (s), 108.02 (s), 37.40 (s), 24.70 (s). HRMS 
(m/z): [M+H]
+
 calcd. for C12H15N2O3S 267.0797; Found 267.07977.
 
[M+Na]
+
 calcd. for 
C12H14N2O3SNa [M+Na]
+
 289.06173; Found 289.06172. 
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8-((tert-butyldiphenylsilyl)oxy)-N,N,2-trimethylquinoline-5-sulfonamide (3.11) 
 
Compound 3.10 (1.33 g, 5 mmol, 1 eq) and imidazole (0.83 g, 12.2 mmol, 2.44 
eq) were added in dry DMF (15 mL) and stirred at 25 °C for 10 minutes. A solution of 
TBDPSCl (2.17 mL, 8.33 mmol, 1.66 eq) was added drop wise to the reaction mixture 
and stirred for 24 h at 25 °C. The reaction mixture was neutralized with water and a 
saturated ammonium chloride solution. The reaction mixture was extracted with ethyl 
acetate. The organic layer was washed with brine and dried over Na2SO4. The filtrate was 
evaporated under reduced pressure at 25 °C. The crude product after evaporation was 
dissolved in solution (2 mL) of MeOH:CH2Cl2 1:1 v/v. This solution was slowly 
evaporated to approximately half of its volume. The precipitate was filtered and the 
solvent evaporated to dryness. Product 3.11 (1.83 g, 3.62 mmol, 72.7%) was obtained as 
a white crystalline solid. 
1
H NMR (499 MHz, CDCl3) δ 8.79 (d, J = 8.8 Hz, 1H), 7.95 (d, 
J = 8.3 Hz, 1H), 7.73 (d, J = 6.7 Hz, 4H), 7.34 (t, J = 7.4 Hz, 2H), 7.30 – 7.25 (m, 5H), 
7.17 (d, J = 8.9 Hz, 1H), 7.13 (d, J = 8.3 Hz, 1H), 2.70 (s, 6H), 2.18 (s, 3H), 1.15 (s, 9H). 
13
C NMR (126 MHz, CDCl3) δ 157.54 (s), 156.82 (s), 140.61 (s), 134.83 (s), 133.98 (s), 
133.13 (s), 131.04 (s), 129.35 (s), 127.35 (s), 124.53 (s), 123.47 (s), 115.04 (s), 37.35 (s), 
26.65 (s), 23.67 (s), 20.22 (s). LRMS (m/z): [M+H]
+
 calcd. for C28H33N2O3SSi 505.19; 
Found 505.2. [M+Na]
+
 calcd. for C28H32N2O3SSiNa 527.71; Found 527.2.   
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8-((tert-butyldiphenylsilyl)oxy)-2-formyl-N,N-dimethylquinoline-5-sulfonamide (3.12) 
 
 
SeO2 (0.23 g, 2.10 mmol, 1.02 eq) was dissolved in 1,4-dioxane (10 mL) and the 
reaction mixture was heated to 60 °C.  A solution of 3.11 (1.04 g, 2.06 mmol, 1 eq) was 
added to the SeO2 solution. After the solution became homogenous, it was stirred at 75 
°C for 24 h. The reaction mixture was then allowed to cool to room temperature. The 
mixture was filtered through celite to remove a dark brown residue. The solvent was 
evaporated by rotary evaporation, covering the flask to avoid direct light to yield a pale 
yellow solid 3.12 (1.57 g). This crude material was used in the next step without further 
purification.  
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8-((tert-butyldiphenylsilyl)oxy)-2-(hydroxymethyl)-N,N-dimethylquinoline-5-
sulfonamide (3.13) 
 
Crude product 3.12 (1.5 g) was dissolved in dry CH2Cl2 (10 mL) and the reaction 
was cooled to 0 °C. NaBH4 (1.09 g, 28.92 mmol) was dissolved in EtOH and was slowly 
added to the reaction mixture containing 5. The reaction mixture was stirred at 0 °C for 
0.5 h. Diethyl ether (30 mL) was added to the reaction mixture and the organic layer was 
extracted with saturated ammonium chloride, H2O, and brine. The organic layer was 
dried over Na2SO4. The solution was filtered and the solvent was evaporated to dryness. 
Crude material 3.13 (0.51 g) was obtained as a pale yellow thick oil. This crude product 
was used in the subsequent reaction without further purification.
 1
H NMR (400 MHz, 
CDCl3) δ 8.96 (d, J = 8.9 Hz, 1H), 7.93 (d, J = 8.3 Hz, 1H), 7.73 (dd, J = 8.1, 1.4 Hz, 
4H), 7.40 – 7.30 (m, 7H), 7.03 (d, J = 8.3 Hz, 1H), 4.64 (s, 2H), 2.70 (s, 6H), 1.17 (s, 
9H).
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2-(bromomethyl)-8-((tert-butyldiphenylsilyl)oxy)-N,N-dimethylquinoline-5-sulfonamide 
(3.14) 
 
All glassware and syringes were oven-dried before use. CBr4 (0.71 g, 2.14 mmol) 
and 3.13 (0.99 g, 1.90 mmol) were added to a round bottom flask, and the flask was 
purged with nitrogen. Fresh ether (20 mL) was added and the reaction mixture was 
cooled to 0 °C. PPh3 (0.55 g, 2.09 mmol) was dissolved in ether (5 mL) and slowly added 
to the reaction mixture. The reaction was stirred at room temperature overnight under 
nitrogen. A yellow precipitate was filtered and the solvent was evaporated. The crude 
product was purified by flash chromatography (hexane:ethylacetate, 9:1 v/v). Product 
3.14 (1.20 g, 2.05 mmol, 34.7% over three steps) was obtained as a pale yellow sticky oil. 
1
H NMR (400 MHz, CDCl3) δ 8.91 (d, J = 9.0 Hz, 1H), 8.00 (d, J = 8.3 Hz, 1H), 7.72 (d, 
J = 1.4 Hz, 2H), 7.70 (d, J = 1.5 Hz, 2H), 7.49 (d, J = 9.0 Hz, 1H), 7.33 (t, J = 1.6 Hz, 
1H), 7.31 – 7.29 (m, 2H), 7.28 (t, J = 1.5 Hz, 2H), 7.26 – 7.25 (m, 1H), 7.13 (d, J = 8.3 
Hz, 1H), 4.10 (s, 2H), 2.70 (s, 6H), 1.15 (s, 9H). HRMS (m/z): [M+H]
+
 calcd. for 
C28H32BrN2O3SSi 585.10639; Found 585.10677. [M+Na]
+
 calcd. for 
C28H31BrN2NaO3SSi  607.08834; Found 607.08913.   
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3.13.4 Alkylation Reaction of Peptides with SOX-Br 
The resin-bound peptides were dried for at least 4 h under vaccum prior to the 
alkylation reaction. The resin-bound peptide (0.077 g, 0.0084 mmol, 1 eq) was swelled 
with dry DMF for 30 min. The Mmt protecting group was cleaved by exposing the resin 
to a solution of 1% TFA and 5% TIS in CH2Cl2 for 30 min. This previous step was 
repeated until the yellowish solution changed to a transparent color. The resin was 
thoroughly washed with CH2Cl2 and DMF. A solution of SOX-Br (0.010 g, 0.0184 mmol, 
2 eq) and tetramethylguanidine (5 µL, 0.042 mmol, 5 eq) in dried DMF (6 mL) was 
stirred at room temperature. The solution was then added to the resin-bound peptide. The 
reaction mixture was allowed to shake for 24 h under argon. The reagents were filtered 
and the resin was thoroughly washed with DMF, CH2Cl2 and MeOH. The resin was then 
dried under vacuum for 4 h. A cleaving solution of 5 mL of TFA/ H2O/TIS (95/2.5/2.5 % 
v/v) was added to the resin. The crude SOX-peptides were purified using preparative 
HPLC. Pure SOX-peptides were analyzed by analytical HPLC (Shimadzu HPLC) 
equipped with Gemini C18 column (250 X 10 mm, 5 µm) or Vydac 218MS C18 (250 
mm X 4.6 mm ) with UV detection at 220 and 316 nm. Solvent A: H2O with 0.1% v/v 
TFA; solvent B: CH3CN with 0.1% v/v TFA. Rate flow: 4 mL/min or 1 mL/min. Purified 
peptides were characterized by mass spectrometry using a either MALDI-TOF (Vogayer, 
PerSeptive Biosystem) or ESI (LCQ, Thermo Finnigan).  
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Table 3.8:  LCMS characterization data of the purified SOX-peptides. 
 
 
 
 
SOX- 
Peptide 
Peptide sequence 
Molecular 
Formula 
HPLC  
tR  
(min) 
ESI [M+H]
+
 
Calcd. 
ESI [M+H]
+
 
Found 
 
3.15 
 
FQRKTLQRRNL 
KGLNLNLXXXTGPL
SPCSOXPF 
 
C171H279N49O42S2 13.56 
[M+6H]
6+
 
627.0 
 
[M+5H]
5+
 
752.2 
 
[M+4H]
4+
 
940.0 
[M+6H]
6+
 
627.1 
 
[M+5H]
5+
 
752.6 
 
[M+4H]
4+
 
940.5 
    
MALDI-
TOF [M]
+
 
Calcd. 
MALDI-
TOF [M]
+
 
Found 
3.16 
NLGMNSRKPDL 
RVVIPPGXXXTGPLS
PCSOXPF 
 
C159H256N42O41S3 10.58 3505.84 3505.85 
3.17 
LERPSRDHLYL 
PLSGRYRESCSOXLS
PSPA 
 
C149H233N43O45S2 26.28 3408.67 3408.54 
    
ESI [M+H]
+
 
Calcd. 
ESI [M+H]
+
 
found 
 
3.18 
YAECSOXLTPRILAK
WEWPA 
 
 
C111H157N25O28S2 26.6 
[M+2H]
2+
 
1177.6 
 
[M+3H]
3+
 
785.37 
[M+2H]
2+
 
1177.6 
 
[M+3H]
3+
 
785.4 
3.19 
ICSOXTTPITTTYFFF
KKK 
 
C108H157N21O27S2 31.56 
[M+2H]
2+
 
1123.6 
 
[M+3H]
3+
 
749.4 
[M+2H]
2+
 
1123.9 
 
[M+3H]
3+
 
749.4 
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3.13.5 Experimental Information 
The fluorescence measurements were taken with a Biotek Synergy 2 Multi-Mode 
Microplate Reader or a Tecan Infinite 500 Microplate Reader at 25°C with assay buffer: 
25 mM HEPES, 50 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA pH 7.4 with 2 mM DTT, 
2.5 µg/mL BSA, 5 mM MgCl2. The phosphorylation reaction was initiated upon addition 
of 5µL of 5 mM ATP stock to 45 µL well assay, obtaining a final concentration of 500 
µM ATP. The kinetic assays were measured with a 96-well half area flat bottom, non-
binding surface, and black polystyrene. A final reaction volume of 50 µL was used in 
each well for all assays. Four experimental replicates were measured for each kinase-
peptide in well assay. The well plate reader was blanked with HEPES buffer. The 96-well 
plates half area were read with ex filter of 340  35 nm and em filter of 485  20 nm, 
using a top 400 mirror. Speed 300 µL/sec. The collected kinetic data was analyzed by 
using IgorPro 6.04 or OriginPro 8.5.1. The rate constants and fluorescence values at 20 
min were analyzed by linear discriminant analysis using XLSTAT 2011 software 
package. SOX-peptide concentrations were determined by UV-Vis (DU 800 
Spectrophotometer) based on the extinction coefficient of the fluorophore ε355 = 8247 
M
-1
 cm
-1
 in 0.1 M NaOH with 1 mM Na2EDTA as previously reported. Stock kinase 
solutions were prepared to obtain a final concentration of 1 µM MAPK. Kinase solutions 
were prepared by adding the corresponding aliquot (µL) of 1 µM MAPK stock to the 
corresponding volume of assay buffer according to each kinase assay.   
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Preliminary sensing array experiment. Nine individual kinase solutions with the 
following final concentrations 2.5 nM ERK1/2, 25 nM JNK1/2/3 and 12.5 nM p38α/β/γ/δ 
(final volume 880 µL) were prepared in buffer assay. Kinase aliquots of 40 µL were then 
added to obtain the following final concentration 2 nM ERK1/2, 20 nM JNK1/2/3 and 10 
nM p38α/β/γ/δ in the sensing ensemble. Stock peptide aliquots of 5 µL (20 µM) were 
added to obtain a final concentration of 2 µM SOX-peptide in the array. 
Optimizing sensing array experiment. Three different kinase solutions with the 
following final concentrations 0.6 nM ERK1, 6.4 nM JNK3 and 3.1 nM p38γ (final 
volume 588 µL) were prepared in buffer assay. Kinase aliquots of 40 µL were then added 
to obtain the following final concentrations 0.5 nM ERK1, 5 nM JNK3 and 2.5 nM p38γ 
in the sensing ensemble. Stock peptide solutions of 5 µL (20 µM) were added to obtain a 
final concentration of 2 µM SOX-peptide. 
Optimizing SOX-p38 peptide concentration assay. A kinase solution with the 
following final concentration 27 nM p38γ (final volume 300 µL) was prepared in buffer 
assay. Kinase aliquots of 15 µL were then added to obtain the following final 
concentration 8 nM p38γ in the sensing ensemble. Different SOX-p38 peptide solutions 
(final volume 40 µL) were prepared to obtain the following final concentrations 3.5 nM, 
8.3 nM, 16.6 nM, 25 nM, 50 nM and 83 nM in buffer assay. Peptide aliquots of 30 µL 
were then added to obtain the following final concentrations 2 µM, 5 µM, 10 µM, 15 µM, 
30 µM and 50 µM in the sensing ensemble, respectively. 
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Array reproducibility for nine MAPKs experiment. Nine individual kinase 
solutions with the following final concentrations 1 nM ERK1/2, 10 nM JNK1/2/3 and 5 
nM p38α/β/γ/δ (final volume 460 µL) were prepared in buffer assay. Kinase aliquots of 
25 µL were then added to obtain the following final concentration 0.5 nM ERK1/2, 5 nM 
JNK1/2/3 and 2.5 nM p38α/β/γ/δ in the sensing ensemble. Peptide aliquots of 20 µL (5 
µM) were added to obtain a final concentration of 2 µM SOX-peptide in the array. SOX-
p38 peptide aliquots of 20 µL (20 µM) were added into the corresponding wells to obtain 
a final concentration of 8 µM. 
Increasing ERK1 concentration assay. ERK1 stock solution (1 µM) was diluted 
to obtain a final concentration of 0.1 µM. Eight different kinase solutions (final volume 
550 µL) were prepared to obtain the following final concentrations 10 nM JNK3 and 5 
nM p38γ with 0 nM, 0.1 nM, 0.2 nM, 0.4 nM, 0.8 nM 1.6 nM, 3.2 nM and 6.4 nM ERK1 
in buffer assay, respectively. Kinase aliquots of 25 µL were then added to obtain the 
following final concentrations 5 nM JNK3, 2.5 nM p38γ and 0 nM, 0.05 nM, 0.1 nM, 0.2 
nM, 0.4 nM, 0.8 nM, 1.6 nM and 3.2 nM ERK1 in the sensing ensemble, respectively. 
Peptide aliquots of 20 µL (5 µM) were added to obtain a final concentration of 2 µM 
SOX-peptide in the array. SOX-p38 peptide aliquots of 20 µL (20 µM) were added into 
the corresponding wells to obtain a final concentration of 8 µM. 
Increasing JNK3 concentration assay. Eight different kinase solutions (final 
volume 550 µL) were prepared to obtain the following final concentrations 1 nM ERK1 
and 5 nM p38γ with 0 nM, 1 nM, 2 nM, 4 nM, 8 nM 16 nM, 32 nM and 64 nM JNK3 in 
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buffer assay, respectively. Kinase aliquots of 25 µL were then added to obtain the 
following final concentrations 0.5 nM ERK1, 2.5 nM p38γ and 0 nM, 0.5 nM, 1 nM, 2 
nM, 4 nM, 8 nM, 16 nM and 32 nM JNK3 in the sensing ensemble, respectively. Peptide 
aliquots of 20 µL (5 µM) were added to obtain a final concentration of 2 µM SOX-
peptide in the array. SOX-p38 peptide aliquots of 20 µL (20 µM) were added into the 
corresponding wells to obtain a final concentration of 8 µM. 
Increasing p38γ concentration assay. Eight different kinase solutions (final 
volume 575 µL) were prepared to obtain the following final concentrations 1 nM ERK1 
and 10 nM JNK3 with 0 nM, 0.5 nM, 1 nM, 2 nM, 4 nM, 8 nM 16 nM, and 32 nM p38γ 
in buffer assay, respectively. Kinase aliquots of 25 µL were then added to obtain the 
following final concentrations 0.5 nM ERK1, 5 nM JNK3 and 0 nM, 0.25 nM, 0.5 nM, 1 
nM, 2 nM, 4 nM, 8 nM, and 16 nM p38γ in the sensing ensemble, respectively. Peptide 
aliquots of 20 µL (5 µM) were added to obtain a final concentration of 2 µM SOX-
peptide in the array. SOX-p38 peptide aliquots of 20 µL (20 µM) were added into the 
corresponding wells to obtain a final concentration of 8 µM. 
ERK1 inhibitor experiment. A kinase solution with the following final 
concentration 1.65 nM ERK1 (final volume 2760 µL) was prepared in buffer assay. 
Kinase aliquots of 15 µL were then added to obtain the following final concentration 0.5 
nM ERK1 in the sensing ensemble. Different inhibitor solutions (final volume 300 µL) 
were prepared to obtain the following final concentrations 0 nM, 5 nM, 40 nM, 80 nM 
and 240 nM with 25% DMSO in buffer assay. Inhibitor aliquots of 10 µL were then 
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added to obtain the following final concentrations 0 nM, 1 nM, 8 nM, 16 nM, and 48 nM 
in the sensing ensemble, respectively. Peptide aliquots of 20 µL (5 µM) were added to 
obtain a final concentration of 2 µM SOX-peptide. SOX-p38 peptide aliquots of 20 µL 
(20 µM) were added into the corresponding wells to obtain a final concentration of 8 µM. 
ERK1 inhibition in kinase mixtures experiment. A kinase solution with the 
following final concentrations 1.65 nM ERK1, 16.7 nM JNK3 and 8.4 nM p38γ (final 
volume 2760 µL) was prepared in buffer assay. Kinase aliquots of 15 µL were then added 
to obtain the following final concentration 0.5 nM ERK1, 5 nM JNK3 and 2.5 nM p38γ 
in the sensing ensemble. Different inhibitor solutions (final volume 450 µL) were 
prepared to obtain the following final concentrations 0 nM, 5 nM, 10 nM, 15 nM, 20 nM 
40 nM, 80 nM and 240 nM with 25% DMSO in buffer assay. Inhibitor aliquots of 10 µL 
were then added to obtain the following final concentrations 0 nM, 1 nM, 2 nM, 3 nM, 4 
nM, 8 nM, 16 nM, and 48 nM in the sensing ensemble, respectively. Peptide aliquots of 
20 µL (5 µM) were added to obtain a final concentration of 2 µM SOX-peptide. SOX-
p38 peptide aliquots of 20 µL (20 µM) were added into the corresponding wells to obtain 
a final concentration of 8 µM. 
Expression, Purification and Activation of Tagless MAP Kinases – Tagless N-
terminal truncated human JNK3α2 (amino acids 39-422 with alanine inserted between 
amino acids 39 and 40, GenBank accession number NM_138982) was expressed, 
purified and activated as described previously.
112,113
 Activated tagless ERK2 (Rattus 
norvegicus mitogen activated protein kinase 1, GenBank accession number NM_053842) 
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was expressed, purified and activated as described in Kaoud et al.
114
 Activated ERK1 
were expressed, purified and activated as described in Callaway et al.
115
 p38MAPKγ was 
expressed, purified and activated as described previously.
116,117
 The activated kinases 
were all stored in buffer S [25 mM HEPES (pH 7.5), 50 mM KCl, 0.1 mM EDTA, 0.1 
mM EGTA, 2 mM DTT and 10-20% (v/v) glycerol] at -80 ºC. 
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3.13.6 Supplementary Figures 
 
3.13.6.1 Preliminary Assay 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.36: Fit curves of the fluorescence changes of SOX-Sub-D peptide upon 
phosphorylation with three different MAPKs, showing 4 experimental replicates. Kinase 
concentrations: ERK1/2 (2 nM), JNK1/2/3 (20 nM) and p38α/β/γ/δ (10 nM) with SOX-
peptide (2 µM).Data collected with 96-well plate half volume, plate reader with ex filter 
of 360  10 nm and em filter of 485  10 nm, using a top 400 mirror. Assay buffer:  
(25mM HEPES, 50mM KCl, 0.1 mM EDTA, 0.1 mM EGTA pH 7.4) with 2 mM DTT, 
2.5 µg/mL BSA, 5mM MgCl2, 500 µM ATP at 25 . 
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Figure 3.37: Fit curves of the fluorescence changes of SOX-NFAT4 peptide upon 
phosphorylation with three different MAPKs, showing 4 experimental replicates. Kinase 
concentrations: ERK1/2 (2 nM), JNK1/2/3 (20 nM) and p38α/β/γ/δ (10 nM) with SOX-
peptide (2 µM). Data collected with 96-well plate half area, plate reader with ex filter of 
360  10 nm and em filter of 485  10 nm, using a top 400 mirror. Assay buffer:  (25mM 
HEPES, 50mM KCl, 0.1 mM EDTA, 0.1 mM EGTA pH 7.4) with 2 mM DTT, 2.5 
µg/mL BSA, 5mM MgCl2, 500 µM ATP at 25 . 
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Figure 3.38: Fit curves of the fluorescence changes of SOX-MEF2A peptide upon 
phosphorylation with different MAPKs, showing 4 experimental replicates. Kinase 
concentrations: ERK1/2 (2 nM), JNK/2/3 (20 nM) with SOX-peptide (2 µM). Data 
collected with 96-well plate half area, plate reader with ex filter of 360  10 nm and em 
filter of 485  10 nm, using a top 400 mirror. Assay buffer:  (25mM HEPES, 50mM KCl, 
0.1 mM EDTA, 0.1 mM EGTA pH 7.4) with 2 mM DTT, 2.5 µg/mL BSA, 5mM MgCl2, 
500 µM ATP at 25 . 
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Figure 3.39: Fit curves of the fluorescence changes of SOX-MEF2A peptide upon 
phosphorylation with different MAPKs, showing 4 experimental replicates. Kinase 
concentrations: JNK1 (20 nM) and p38α/β/δ (10 nM) with SOX-peptide (2 µM). Data 
collected with 96-well plate half area, plate reader with ex filter of 360  10 nm and em 
filter of 485  10 nm, using a top 400 mirror. Assay buffer:  (25mM HEPES, 50mM KCl, 
0.1 mM EDTA, 0.1 mM EGTA pH 7.4) with 2 mM DTT, 2.5 µg/mL BSA, 5mM MgCl2, 
500 µM ATP at 25 . 
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Figure 3.40: Fit curves of the fluorescence changes of SOX-Sub-F peptide upon 
phosphorylation with different MAPKs, showing 4 experimental replicates. Kinase 
concentrations: ERK1/2 (2 nM) and JNK1/2/3 (20 nM) with SOX-peptide (2 µM). Data 
collected with 96-well plate half area, plate reader with ex filter of 360  10 nm and em 
filter of 485  10 nm, using a top 400 mirror. Assay buffer:  (25mM HEPES, 50mM KCl, 
0.1 mM EDTA, 0.1 mM EGTA pH 7.4) with 2 mM DTT, 2.5 µg/mL BSA, 5mM MgCl2, 
500 µM ATP at 25 . 
JNK3 
ERK2 ERK1 
JNK2 JNK1 
234 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.41: Fit curves of the fluorescence changes of SOX-Sub-F peptide upon 
phosphorylation with different MAPKs, showing 4 experimental replicates. Kinase 
concentrations: p38α/β/γ/δ (10 nM) with SOX-peptide (2 µM). Data collected with 96-
well plate half area, plate reader with ex filter of 360  10 nm and em filter of 485  10 
nm, using a top 400 mirror. Assay buffer:  (25mM HEPES, 50mM KCl, 0.1 mM EDTA, 
0.1 mM EGTA pH 7.4) with 2 mM DTT, 2.5 µg/mL BSA, 5mM MgCl2, 500 µM ATP at 
25 . 
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Figure 3.42: Fit curves of the fluorescence changes of SOX-p38 peptide upon 
phosphorylation with different MAPKs, showing 4 experimental replicates. Kinase 
concentrations: ERK1/2 (2 nM) and JNK1/2/3 (20 nM) with SOX-peptide (2 µM). Data 
collected with 96-well plate half area, plate reader with ex filter of 360  10 nm and em 
filter of 485  10 nm, using a top 400 mirror. Assay buffer:  (25mM HEPES, 50mM KCl, 
0.1 mM EDTA, 0.1 mM EGTA pH 7.4) with 2 mM DTT, 2.5 µg/mL BSA, 5mM MgCl2, 
500 µM ATP at 25 . 
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Figure 3.43: Fit curves of the fluorescence changes of SOX-p38 peptide upon 
phosphorylation with different MAPKs, showing 4 experimental replicates. Kinase 
concentrations: p38α/β/γ/δ (10 nM) with SOX-peptide (2 µM). Data collected with 96-
well plate half area, plate reader with ex filter of 360  10 nm and em filter of 485  10 
nm, using a top 400 mirror. Assay buffer:  (25mM HEPES, 50mM KCl, 0.1 mM EDTA, 
0.1 mM EGTA pH 7.4) with 2 mM DTT, 2.5 µg/mL BSA, 5mM MgCl2, 500 µM ATP at 
25 . 
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3.13.6.2 Fluorescence Changes o of Three MAPK Groups 
 
 
Figure 3.44: Fluorescence changes of SOX-peptides upon phosphorylation with ERK1, 
showing 4 experimental replicates. A) SOX-Sub-D. (B) SOX-MEF2A. (C) SOX-NFAT4. 
(D) SOX-Sub-F. (E) SOX-p38. Concentrations: ERK1 (0.5 nM); SOX-peptides (2 µM). 
Data collected with 96-well plate half area, plate reader with ex filter of 340  35 nm and 
em filter of 485  20 nm. Assay buffer:  (25mM HEPES, 50mM KCl, 0.1 mM EDTA, 
0.1 mM EGTA pH 7.4) with 2 mM DTT, 2.5 µg/mL BSA, 5mM MgCl2, 500 µM ATP at 
25 . 
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Figure 3.45: Fluorescence changes of SOX-peptides upon phosphorylation with JNK3, 
showing 4 experimental replicates. A) SOX-Sub-D. (B) SOX-MEF2A. (C) SOX-NFAT4. 
(D) SOX-Sub-F. (E) SOX-p38. Concentrations: JNK3 (5 nM); SOX-peptides (2 µM). 
Data collected with 96-well plate half area, plate reader with ex filter of 340  35 nm and 
em filter of 485  20 nm. Assay buffer:  (25mM HEPES, 50mM KCl, 0.1 mM EDTA, 
0.1 mM EGTA pH 7.4) with 2 mM DTT, 2.5 µg/mL BSA, 5mM MgCl2, 500 µM ATP at 
25 . 
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Figure 3.46: Fluorescence changes of SOX-peptides upon phosphorylation with p38γ, 
showing 4 experimental replicates. A) SOX-Sub-D. (B) SOX-MEF2A. (C) SOX-NFAT4. 
(D) SOX-Sub-F. (E) SOX-p38. Concentrations: p38γ (2.5 nM); SOX-peptides (2 µM). 
Data collected with 96-well plate half area, plate reader with ex filter of 340  35 nm and 
em filter of 485  20 nm. Assay buffer:  (25mM HEPES, 50mM KCl, 0.1 mM EDTA, 
0.1 mM EGTA pH 7.4) with 2 mM DTT, 2.5 µg/mL BSA, 5mM MgCl2, 500 µM ATP at 
25 . 
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3.13.6.3 Reproducible Fluorescence Changes of MAPKs  
  
Figure 3.47: Fluorescence changes of SOX-Sub-D peptide upon phosphorylation with 
different MAPKs, showing 4 experimental replicates. Kinase concentrations: ERK1/2 (0.5 
nM), JNK1/2/3 (5 nM) with SOX-Sub-D peptide (2 µM).  
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Figure 3.48: Fluorescence changes of SOX-Sub-D peptide upon phosphorylation with 
different MAPKs, showing 4 experimental replicates. Kinase concentrations: p38α/β/γ/δ 
(2.5 nM) with SOX-Sub-D peptide (2 µM). Data collected with 96-well plate half area, 
plate reader with ex filter of 360  10 nm and em filter of 485  10 nm, using a top 400 
mirror. Assay buffer:  (25mM HEPES, 50mM KCl, 0.1 mM EDTA, 0.1 mM EGTA pH 
7.4) with 2 mM DTT, 2.5 µg/mL BSA, 5mM MgCl2, 500 µM ATP at 25 . 
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Figure 3.49: Fluorescence changes of SOX-MEF2A peptide upon phosphorylation with 
different MAPKs, showing 4 experimental replicates. Kinase concentrations: ERK1/2 (0.5 
nM), and JNK1/2/3 (5 nM) with SOX-MEF2A peptide (2 µM).  
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Figure 3.50: Fluorescence changes of SOX-MEF2A peptide upon phosphorylation with 
different MAPKs, showing 4 experimental replicates. Kinase concentrations: p38α/β/γ/δ 
(2.5 nM) with SOX-MEF2A peptide (2 µM). Data collected with 96-well plate half area, 
plate reader with ex filter of 360  10 nm and em filter of 485  10 nm, using a top 400 
mirror. Assay buffer:  (25mM HEPES, 50mM KCl, 0.1 mM EDTA, 0.1 mM EGTA pH 
7.4) with 2 mM DTT, 2.5 µg/mL BSA, 5mM MgCl2, 500 µM ATP at 25 . 
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Figure 3.51: Fluorescence changes of SOX-NFAT4 peptide upon phosphorylation with 
different MAPKs, showing 4 experimental replicates. Kinase concentrations: ERK1/2 (0.5 
nM), and JNK1/2/3 (5 nM) with SOX-NFAT4 peptide (2 µM). 
245 
 
 
 
 
 
Figure 3.52: Fluorescence changes of SOX-NFAT4 peptide upon phosphorylation with 
different MAPKs, showing 4 experimental replicates. Kinase concentrations: p38α/β/γ/δ 
(2.5 nM) with SOX-NFAT4 peptide (2 µM). Data collected with 96-well plate half area, 
plate reader with ex filter of 360  10 nm and em filter of 485  10 nm, using a top 400 
mirror. Assay buffer:  (25mM HEPES, 50mM KCl, 0.1 mM EDTA, 0.1 mM EGTA pH 
7.4) with 2 mM DTT, 2.5 µg/mL BSA, 5mM MgCl2, 500 µM ATP at 25 . 
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Figure 3.53: Fluorescence changes of SOX-Sub-F peptide upon phosphorylation with 
different MAPKs, showing 4 experimental replicates. Kinase concentrations: ERK1/2 (0.5 
nM), and JNK1/2/3 (5 nM) with SOX-Sub-F peptide (2 µM). 
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Figure 3.54: Fluorescence changes of SOX-Sub-F peptide upon phosphorylation with 
different MAPKs, showing 4 experimental replicates. Kinase concentrations: p38α/β/γ/δ 
(2.5 nM) with SOX-Sub-F peptide (2 µM). Data collected with 96-well plate half area, 
plate reader with ex filter of 360  10 nm and em filter of 485  10 nm, using a top 400 
mirror. Assay buffer:  (25mM HEPES, 50mM KCl, 0.1 mM EDTA, 0.1 mM EGTA pH 
7.4) with 2 mM DTT, 2.5 µg/mL BSA, 5mM MgCl2, 500 µM ATP at 25 . 
248 
 
 
 
Figure 3.55: Fluorescence changes of SOX-p38 peptide upon phosphorylation with 
different MAPKs, showing 4 experimental replicates. Kinase concentrations: ERK1/2 (0.5 
nM), and JNK1/2/3 (5 nM) with SOX-p38 peptide (8 µM). 
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Figure 3.56: Fluorescence changes of SOX-p38 peptide upon phosphorylation with 
different MAPKs, showing 4 experimental replicates. Kinase concentrations: p38α/β/γ/δ 
(2.5 nM) with SOX-p38 peptide (8 µM). Data collected with 96-well plate half area, plate 
reader with ex filter of 360  10 nm and em filter of 485  10 nm, using a top 400 
mirror. Assay buffer:  (25mM HEPES, 50mM KCl, 0.1 mM EDTA, 0.1 mM EGTA pH 
7.4) with 2 mM DTT, 2.5 µg/mL BSA, 5mM MgCl2, 500 µM ATP at 25 . 
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MAPK SOX-Sub-D SOX-MEF2A SOX-NFAT4 SOX-Sub-F SOX-p38 
Kinetic 
Param. 
k F k F k F k F k F 
ERK-1 0.06342 7958 0.04593 9109 0.00381 1190 0.00630 2222 0.00093 804 
ERK-1 0.06345 7869 0.03598 7951 0.00218 666 0.00603 2177 0.00301 2337 
ERK-1 0.06172 7791 0.03107 7404 0.00204 622 0.00538 1917 0.00175 1196 
ERK-1 0.05399 7300 0.03110 7422 0.00244 689 0.00566 2127 0.00171 1528 
ERK-2 0.05517 7577 0.04626 9997 0.00155 577 0.00416 1803 0.00117 1086 
ERK-2 0.05899 7736 0.04222 9519 0.00185 700 0.00379 1487 0.00163 1407 
ERK-2 0.05349 7309 0.03680 8862 0.00205 777 0.00390 1629 0.00112 963 
ERK-2 0.04153 6690 0.03142 8253 0.00229 868 0.00349 1354 0.00115 1272 
JNK-1 0.07438 8415 0.00827 2628 0.01401 2570 0.00218 1146 0.00181 1456 
JNK-1 0.06794 8220 0.00743 2396 0.01404 2598 0.00185 805 0.00168 1243 
JNK-1 0.05223 7283 0.00730 2363 0.01194 2230 0.00223 1107 0.00260 2085 
JNK-1 0.04603 6745 0.00650 2140 0.01245 2609 0.00191 860 0.00168 1307 
JNK-2 0.14811 10132 0.01121 3259 0.03953 5336 0.00268 1122 0.00237 1587 
JNK-2 0.11530 9614 0.01070 3121 0.03880 5394 0.00295 1277 0.00883 4080 
JNK-2 0.11312 9598 0.01005 3031 0.03884 5364 0.00267 1091 0.00159 1063 
JNK-2 0.07529 8430 0.00938 2822 0.03272 4885 0.00199 930 0.00135 866 
JNK-3 0.11423 9550 0.01424 4126 0.02902 4362 0.00399 1684 0.00211 1554 
JNK-3 0.10671 9466 0.01444 4199 0.03055 4635 0.00338 1347 0.00236 1539 
JNK-3 0.08365 8849 0.01416 4210 0.02779 4299 0.00326 1318 0.00236 1349 
JNK-3 0.06233 8100 0.01325 3866 0.01985 3443 0.00387 1652 0.00254 1431 
p38α 0.08633 9152 0.07057 12244 0.00365 925 0.01185 3838 0.00178 1421 
p38α 0.08202 8984 0.06110 11740 0.00400 1021 0.01081 3583 0.00267 2240 
p38α 0.07584 8619 0.05007 10734 0.00371 994 0.01033 3521 0.00161 1157 
p38α 0.05471 7759 0.02427 7048 0.00425 1142 0.01011 3515 0.00170 1151 
p38β 0.10025 9420 0.01946 4991 0.03635 4883 0.00379 1519 0.00264 2081 
p38β 0.07974 8784 0.01882 4752 0.04315 5533 0.00426 1819 0.00274 1906 
p38β 0.07895 8862 0.01728 4561 0.03396 4716 0.00400 1615 0.00250 1659 
p38β 0.04437 7145 0.01636 4441 0.03260 4674 0.00346 1394 0.00297 2062 
p38γ 0.01683 3033 0.00883 2741 0.00311 968 0.01401 4388 0.00231 1184 
p38γ 0.01606 3080 0.00881 2789 0.00306 937 0.01302 4342 0.00390 2288 
p38γ 0.01559 3024 0.00794 2545 0.00255 691 0.01209 4057 0.00285 1425 
p38γ 0.01362 2660 0.00754 2391 0.00378 1164 0.01092 3750 0.00409 2317 
p38δ 0.06713 8001 0.04565 9506 0.00438 1039 0.03229 8436 0.00388 2422 
p38δ 0.06994 8186 0.04199 9248 0.00492 1180 0.02962 8078 0.00271 1502 
p38δ 0.05931 7733 0.03526 8392 0.00574 1479 0.02561 7493 0.00353 2223 
p38δ 0.04772 7060 0.02690 7289 0.00496 1242 0.02249 6938 0.00279 1280 
 
Table 3.9: Rate constants (k) corresponding to delta fluorescence of SOX-peptides and 
fluorescence values (F) at 20 min. 
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3.13.6.4 Increasing ERK1 Concentrations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.57: Kinetic data showing the average of 4 experimental replicates of each ERK 
concentration in the presence of JNK3 and p38γ. (A) Fluorescence increase of SOX-
NFAT4 peptide. (B) Fluorescence increase of SOX-p38 peptide. (C) Control experiment 
showing the fluorescence background from kinase solutions and buffer. Final ERK1 
concentrations:  0 nM, 0.05 nM, 0.1 nM, 0.2 nM, 0.4 nM, 0.8 nM, 1.6 nM and 3.2 nM. 
Fixed concentrations of JNK3 (5 nM) and p38γ (2.5 nM). Sox-NFAT4 (2 µM) and SOX-
p38 (8 µM). Data collected with 96-well plate half area, plate reader with ex filter of 340 
 35 nm and em filter of 485  20 nm. Assay buffer:  (25mM HEPES, 50mM KCl, 0.1 
mM EDTA, 0.1 mM EGTA pH 7.4) with 2 mM DTT, 2.5 µg/mL BSA, 5mM MgCl2, 500 
µM ATP at 25 . 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
 
C 
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3.13.6.5 Increasing JNK3 Concentrations 
 
 
 
  
 
 
Figure 3.58: Kinetic data showing the average of 4 experimental replicates of each JNK3 
concentration in the presence of ERK and p38γ. (A) Fluorescence increase of SOX-Sub-
D peptide. (B) Fluorescence increase of SOX-Sub-F peptide. (C) Fluorescence increase 
of SOX-p38 peptide. (D) Control experiment showing the fluorescence background from 
kinase solutions and buffer. Final JNK3 concentrations:  0 nM, 0.5 nM, 1 nM, 2 nM, 4 
nM, 8 nM, 16 nM and 32 nM. Final fixed concentrations of ERK (0.5 nM) and p38γ (2.5 
nM). Sox-Sub-D and SOX-Sub-F (2 µM); SOX-p38 peptide (8 µM). Data collected with 
96-well plate half area, plate reader with ex filter of 340  35 nm and em filter of 485  
20 nm. Assay buffer:  (25mM HEPES, 50mM KCl, 0.1 mM EDTA, 0.1 mM EGTA pH 
7.4) with 2 mM DTT, 2.5 µg/mL BSA, 5mM MgCl2, 500 µM ATP at 25 . 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
 
C 
 
D 
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3.13.6.6 Increasing p38γ Concentrations 
 
 
 
Figure 3.59: Kinetic data showing the average of 4 experimental replicates of each p38γ 
concentration in the presence of ERK and JNK3. (A) Fluorescence increase of SOX-Sub-
D peptide. (B) Fluorescence increase of SOX-MEF2A peptide. (C) Control experiment 
showing the fluorescence background from kinase solutions and buffer. Final p38γ 
concentrations: 0 nM, 0.25 nM, 0.5 nM, 1 nM, 2 nM, 4 nM, 8 nM, and 16 nM. Final 
fixed concentrations: ERK (0.5 nM), and JNK3 (5 nM). SOX-Sub-D and Sox-MEF2A (2 
µM). Data collected with 96-well plate half area, plate reader with ex filter of 340  35 
nm and em filter of 485  20 nm. Assay buffer:  (25mM HEPES, 50mM KCl, 0.1 mM 
EDTA, 0.1 mM EGTA pH 7.4) with 2 mM DTT, 2.5 µg/mL BSA, 5mM MgCl2, 500 µM 
ATP at 25 . 
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3.13.6.7 ERK-Inhibitor Concentrations  
 
Figure 3.60: Kinetic data showing the average of 4 experimental replicates of ERK-
inhibitor concentration. (A) Fluorescence changes of SOX-NFAT4 peptide. (B) 
Fluorescence changes of SOX-p38 peptide. Inhibitor concentrations: 0 nM, 1 nM, 8 nM, 
16 nM, and 48 nM. Fixed concentration: ERK1 (0.5 nM). Sox-NFAT4 (2 µM) and SOX-
p38 peptide (8 µM). Data collected with 96-well plate half area, plate reader with ex 
filter of 340  35 nm and em filter of 485  20 nm. Assay buffer:  (25mM HEPES, 
50mM KCl, 0.1 mM EDTA, 0.1 mM EGTA pH 7.4) with 2 mM DTT, 2.5 µg/mL BSA, 
5mM MgCl2, 500 µM ATP at 25 . 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
B 
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3.13.6.8 ERK-Inhibitor Concentrations with MAPK groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.61: Kinetic data showing the average of 4 experimental replicates of ERK-
inhibitor concentration in the presence of ERK1, JNK3 and p38γ. (A) Fluorescence 
changes of SOX-NFAT4 peptide. (B) Fluorescence changes of SOX-p38 peptide. (C) 
Control experiment showing the fluorescence background from kinase solutions. 
Inhibitor concentrations: 0 nM, 1 nM, 2 nM, 3 nM, 4 nM, 8 nM, 16 nM, and 48 nM. 
Fixed concentration: ERK1 (0.5 nM), JNK3 (5 nM) and p38γ (2.5 nM). SOX-NFAT4 (2 
µM) and SOX-p38 peptide (8 µM). Data collected with 96-well plate half area, plate 
reader with ex filter of 340  35 nm and em filter of 485  20 nm. Assay buffer:  (25mM 
HEPES, 50mM KCl, 0.1 mM EDTA, 0.1 mM EGTA pH 7.4) with 2 mM DTT, 2.5 
µg/mL BSA, 5mM MgCl2, 500 µM ATP at 25 . 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
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3.13.6.9 Control Experiments 
 
Figure 3.62:  Control experiments without MAP kinases. Fluorescence changes during 
the presence of SOX-peptides with ATP. Concentrations: SOX-Sub-D (2 µM); SOX-
MEF2A (2 µM), SOX-NFAT4 (2 µM), SOX-Sub-F (2 µM), SOX-p38 peptide (8 µM). 
Data collected with 96-well plate half area, plate reader with ex filter of 360  10 nm and 
em filter of 485  10 nm, using a top 400 mirror. Assay buffer:  (25mM HEPES, 50mM 
KCl, 0.1 mM EDTA, 0.1 mM EGTA pH 7.4) with 2 mM DTT, 2.5 µg/mL BSA, 5mM 
MgCl2, 500 µM ATP at 25 . 
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Figure 3.63:  Control experiments without ATP. (A) Fluorescence changes of SOX-Sub-
F peptide (2 µM) with ERK1 (1.6 nM) with and without ATP. (B) Fluorescence changes 
of SOX-NFAT4 peptide (2 µM) with ERK1 (0.4 nM) with and without ATP. Data 
collected with 96-well plate half area, plate reader with ex filter of 360  10 nm and em 
filter of 485  10 nm, using a top 400 mirror. Assay buffer:  (25mM HEPES, 50mM KCl, 
0.1 mM EDTA, 0.1 mM EGTA pH 7.4) with 2 mM DTT, 2.5 µg/mL BSA, 5mM MgCl2, 
500 µM ATP at 25 . 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
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Appendix A: 
1
H NMR Spectra of New Compounds 
 
 
 
Figure A.1: 400 MHz 
1
H NMR spectrum of compound 2.19 in D2O (D, 99.9%). 
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Figure A.2: 500 MHz 
1
H NMR spectrum of compound R-9 in CD3CN (D, 99.8%).
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Figure A.3: 600 MHz 
1
H NMR spectrum of compound R-10 in D2O, 30% 
CD3CN (D, 99.8%).
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Figure A.4. 500 MHz 
1
H NMR spectrum of compound R-11 in CDCl3 (D, 99.8%). 
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Appendix B: Characterization data of SOX-peptides 
 
SOX-Sub-D peptide  
 
 
 
 
Figure B.1: HPLC and MS analysis of SOX-Sub-D peptide (A) HPLC tR (gradient: 5 to 
90% B over 20 min) = 13.56 min. (B) ESI obsd m/z = [M+6H]
6+ 
627.1; [M+5H]
5+ 
752.6; 
[M+4H]
4+ 
940.5. Calculated [M+6H]
6+ 
627.0; [M+5H]
5+ 
752.2; [M+4H]
4+ 
940.0. 
A 
 
 
 
 
 
 
 
 
 
B 
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SOX-MEF2A peptide  
 
 
Figure B.2: MS analysis of SOX-MEF2A peptide. MALDI-TOF [M]
+
 obsd m/z = 
3505.85, calculated 3505.84. 
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SOX-NFAT4 peptide  
 
 
 
 
 
 
 
Figure B.3: HPLC and MS analysis of SOX-NFAT4 peptide (A) HPLC tR (gradient: 5 
to15% B over 5 min, 15 to 40% B over 35 min, 40 to 95% over 5 min) = 26.28 min. (B) 
MALDI-TOF [M]
+
 obsd m/z = 3408.54, calculated 3408.67. 
 
A 
 
 
B 
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SOX-Sub-F peptide  
 
 
 
 
Figure B.4: HPLC and MS analysis of SOX-Sub-F peptide.  (A) HPLC tR (gradient: 5 
to15% B over 5 min, 15 to 55% B over 25 min, 55 to 95% over 5 min) = 26.6 min. (B) 
ESI obsd m/z [M+2H]
2+ 
= 1177.6; [M+3H]
3+ 
785.37, calculated [M+2H]
2+
1177.8; 
[M+3H]
3+ 
785.4. 
 
A 
 
 
 
 
 
 
 
 
 
 
B 
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SOX-p38 peptide  
 
 
 
 
 
 
 
Figure B.5: HPLC and MS analysis of SOX-p38 peptide. (A) HPLC tR (gradient: 5 to 
20% B over 5 min, 20 to 70% B over 45 min) = 31.56 min. (B) ESI obsd m/z [M+2H]
2+ 
=1123.9; [M+3H]
3+ 
749.4, calculated [M+2H]
2+
1123.6; [M+3H]
3+ 
749.4.  
A 
 
 
B 
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